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Abstract
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and
survival. Melanoma and squamous cell carcinoma (SCC) are high risk skin cancers which have the potential to metastasise
and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage
surrounding tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate referral and
unnecessary excision of benign lesions. Teledermatology provides a way for generalist clinicians to access the opinion of a
specialist dermatologist for skin lesions that they consider to be suspicious without referring the patients concerned through
the normal referral pathway. Teledermatology consultations can be ‘store-and-forward’ with electronic digital images of a
lesion sent to a dermatologist for review at a later time, or can be live and interactive consultations using video conferencing
to connect the patient, referrer and dermatologist in real time.
Objectives
To determine the diagnostic accuracy of teledermatology for the detection of any skin cancer (melanoma, BCC or cSCC) in
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adults, and to compare its accuracy with that of in-person diagnosis.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; EMBASE; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies evaluating skin cancer diagnosis for teledermatology alone, or in comparison with face-to-face diagnosis by a
specialist clinician, compared with a reference standard of histological confirmation or clinical follow-up and expert opinion.
Studies evaluating the referral accuracy of teledermatology compared with a reference standard of face-to-face diagnosis by
a specialist clinician were also included.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). We contacted authors of included studies where information related to the target condition of any
skin cancer was missing. Data permitting, we estimated summary sensitivities and specificities using the bivariate
hierarchical model. Due to scarcity of data, no covariate investigations were undertaken for this review. For illustrative
purposes, estimates of sensitivity and specificity were plotted on coupled forest plots for diagnostic threshold and target
condition under consideration.
Main results
Twenty-two studies were included reporting diagnostic accuracy data for 4057 lesions and 879 malignant cases (16 studies)
and referral accuracy data for reported data for 1449 lesions and 270 ‘positive’ cases as determined by the reference
standard face-to-face decision (six studies). Methodological quality was variable with poor reporting hindering assessment.
The overall risk of bias was rated as high or unclear for participant selection, reference standard and participant flow and
timing in at least half of all studies; the majority were considered at low risk of bias for the index test. The applicability of
study findings were of high or unclear concern for the majority of studies in all domains assessed due to the recruitment of
study participants from secondary care settings or specialist clinics rather than from the primary or community-based settings
in which teledermatology is more likely to be used and due to the acquisition of lesion images by dermatologists or in
specialist imaging units rather than by primary care clinicians.
Seven studies provided data for the primary target condition of any skin cancer (1588 lesions and 638 malignancies). For the
correct diagnosis of lesions as malignant using photographic images, summary sensitivity was 94.9% (95% CI 90.1 to
97.4%) and summary specificity 84.3% (95% CI 48.5 to 96.8%) (from four studies). Individual study estimates using
dermoscopic images or a combination of photographic and dermoscopic images generally suggested similarly high
sensitivities with highly variable specificities. Limited comparative data suggested similar diagnostic accuracy between
teledermatology assessment and in-person diagnosis by a dermatologist; however, data were too scarce to draw firm
conclusions. For the detection of invasive melanoma or atypical intraepidermal melanocytic variants both sensitivities and
specificities were more variable. Sensitivities ranged from 59% (95% CI 42% to 74%) to 100% (95% CI 54% to 100%) and
specificities from 30% (95% CI 22% to 40%) to 100% (95% CI 93% to 100%), with reported diagnostic thresholds including
the correct diagnosis of melanoma, classification of lesions as ‘atypical’ or ‘typical as well as the decision to refer or to excise
a lesion.
Referral accuracy data comparing teledermatology against a face-to-face reference standard suggested good agreement for
lesions considered to require some positive action by face to face assessment (sensitivities of over 90%). For lesions
considered of less concern when assessed face-to-face (e.g. for those not recommended for excision or referral), agreement
was more variable with teledermatology specificities ranging from 57% (95% CI 39 to 73%) to 100% (95% CI 86% to 100%),
suggesting that remote assessment is more likely recommend excision, referral or follow-up compared to in-person
decisions.
Authors' conclusions
Studies were generally small and heterogeneous and methodological quality was difficult to judge due to poor reporting.
Bearing in mind concerns regarding the applicability of study participants and of lesion image acquisition in specialist
settings, our results suggest that teledermatology can correctly identify the majority of malignant lesions. Using a more widely
defined threshold to identify ‘possibly’ malignant cases or lesions that should be considered for excision is likely to
appropriately triage those lesions requiring face-to-face assessment by a specialist. Despite the increasing use of
teledermatology on an international level, the evidence base to support its ability to accurately diagnose lesions and to triage
lesions from primary to secondary care is lacking and further prospective and pragmatic evaluation is needed.
Plain language summary
What is the diagnostic accuracy of teledermatology for the diagnosis of skin cancer in adults?
Why is improving the diagnosis of skin cancer important?
There are different types of skin cancer. Melanoma is one of the most dangerous forms and it is important to identify it early
so that it can be removed. If it is not recognised when first brought to the attention of doctors (also known as a false negative
test result) treatment can be delayed resulting in the melanoma spreading to other organs in the body and possibly causing
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early death. Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are usually localised skin cancers,
although cSCC can spread to other parts of the body and BCC can cause disfigurement if not recognised early. Calling
something a skin cancer when it is not really a skin cancer (a false positive result) may result in unnecessary surgery and
other investigations that can cause stress and worry to the patient. Making the correct diagnosis is important. Mistaking one
skin cancer for another can lead to the wrong treatment being used or lead to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane review was to find out whether teledermatology is accurate enough to identify which people with
skin lesions need to be referred to see a specialist dermatologist and who can be safely reassured that their lesion is not
malignant. Researchers in Cochrane included 22 studies to answer this question.
What was studied in the review?
Teledermatology means sending pictures of skin lesions or rashes to a specialist for advice on diagnosis or management. It
is a way for primary care clinicians (GPs) to get an opinion from a specialist dermatologist without having to refer patients
through the normal referral pathway. Teledermatology can involve sending photographs or magnified images of a skin lesion
taken with a special camera (dermatoscope) to a skin specialist to look at or it might involve immediate discussion about a
skin lesion between a GP and a skin specialist using video conferencing.
What are the main results of the review?
The review included 22 studies, 16 studies comparing teledermatology diagnoses to the final lesion diagnoses (diagnostic
accuracy) 4057 lesions and 879 malignant cases and five studies comparing teledermatology decisions to the decisions that
would be made with the patient present (referral accuracy) for 1449 lesions and 270 ‘positive’ cases.
The studies were very different from each other in terms of the types of individuals with suspicious skin cancer lesions
included and the type of teledermatology used. A single reliable estimate of the accuracy of teledermatology could not be
made. For the correct diagnosis of a lesion to be a skin cancer, data suggested that less than 7% of malignant skin lesions
were missed by teledermatology. Study results were too variable to tell us how many people would be referred unnecessarily
for a specialist dermatology appointment following a teledermatology consultation. Without access to teledermatology
services however, most of the lesions included in these studies would likely be referred to a dermatologist.
How reliable are the results of the studies of this review?
In the included studies, the final diagnosis of skin cancer was made by lesion biopsy and the absence of skin cancer was
confirmed by biopsy or by follow up over time to make sure the skin lesion remained negative for melanoma. This is likely to
have been a reliable method for deciding whether patients really had skin cancer. In a few studies, a diagnosis of no skin
cancer was made by a skin specialist rather than biopsy. This is less likely to have been a reliable method for deciding
whether patients really had skin cancer. Poor reporting of what was done in the study made it difficult for us to say how
reliable the study results are. Selecting some patients from specialist clinics instead of primary care along with different ways
of doing teledermatology were common problems.
Who do the results of this review apply to?
Studies were conducted in: Europe (n=14; 64%), North America (n=4; 18%), South America (n=2; 9%) or Oceania (n=2; 9%).
The average age of people who were studied was 52 years; however, the majority of studies included at least some people
under the age of 16 years. The percentage of people with skin cancer ranged between 2% and 88% with an average of 30%,
which is much higher than would be observed in a primary care setting in the UK.
What are the implications of this review?
Teledermatology is likely to be a good way of helping GPs to decide which skin lesions need to be seen by a skin specialist.
Our review suggests that using magnified images in addition to photographs of the lesion improves accuracy. More research
is needed to establish the best way of providing teledermatology services.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow up, or specialist clinician diagnosis were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers conducted for the National Institute for Health Research (NIHR) Cochrane
Systematic Reviews Programme. For the purposes of these reviews, diagnostic accuracy is assessed by the sensitivity and
specificity of a test. Appendix 1 shows the content and structure of the programme and Appendix 2 provides a glossary of
terms used and a table of acronyms used is provided in Appendix 3. 
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma is the most widely known amongst the general population, yet
the commonest skin cancers in Caucasian populations are those arising from keratinocytes: basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010). In 2003, the World Health
Organization estimated that between two and three million ‘non-melanoma’ skin cancers (of which BCC and cSCC are
estimated to account for around 80% and 16% of cases respectively) and 132,000 melanoma skin cancers occur
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globally each year (WHO 2003).
In this diagnostic test accuracy review there are three target conditions of interest (a) melanoma, (b) basal cell carcinoma,
and (c) cutaneous squamous cell carcinoma.
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin.
Cutaneous melanoma refers to any skin lesion with malignant melanocytes present in the dermis, primarily including
superficial spreading, nodular, acral lentiginous, and lentigo maligna melanoma variants (see Figure 1). Melanoma in situ
refers to abnormal melanocytes that are contained within the epidermis and have not yet invaded the dermis, but are at risk
of progression to melanoma if left untreated. Lentigo maligna, a subtype of melanoma in situ in chronically sun-damaged
skin, denotes another form of proliferation of abnormal melanocytes. All forms of melanoma in situ can progress to invasive
melanoma if growth breaches the dermoepidermal junction during a vertical growth phase , however malignant
transformation is both lower and slower for lentigo maligna than for other forms of melanoma in situ (Kasprzak 2015).
Melanoma in situ and lentigo maligna are both atypical intraepidermal melanocytic variants. Melanoma is one of the
most dangerous forms of skin cancer, with the potential to metastasise to other parts of the body via the lymphatic
system and blood stream. It accounts for only a small percentage of skin cancer cases but is responsible for up to
75% of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015
), with an estimated 55,000 deaths (Ferlay 2015). The highest incidence is observed in Australia with 11,405 new cases
of melanoma of the skin (ACIM 2014) and in New Zealand with 2,341 registered cases (HPA and MelNet NZ 2014) in
2010. For 2014 in the USA, the predicted incidence was 73,870 per annum and the predicted number of deaths 9,940
(Siegel 2015). The highest rates in Europe are seen in north-western Europe and the Scandinavian countries, with
highest incidence reported in Switzerland of 25.8 per 100,000 in 2012. Rates in the UK have trebled from 4.6 and 6.0
per 100,000 in men and women, respectively in England in 1990, to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012
). In the UK, melanoma has one of the fastest rising incidence rates of any cancer, and has had the biggest projected
increase in incidence between 2007 and 2030 (Mistry 2011). In the decade leading up to 2013, age standardised
incidence increased by 46%, with 14,500 new cases in 2013 and 2,459 deaths in 2014 (Cancer Research UK 2017).
Rates are higher in women than in men; however, the rate of incidence in men is increasing faster than in women (
Arnold 2014).The rising incidence in melanoma is thought to be primarily related to an increase in recreational sun
exposure and tanning bed use and an increasingly ageing population with higher lifetime recreational ultraviolet (UV)
exposure, in conjunction with possible earlier detection (Linos 2009; Belbasis 2016). Putative risk factors, including
eye and hair colour, skin type and density of freckles, history of melanoma, sunburn, and presence of particular
lesion types, are reviewed in detail elsewhere (Belbasis 2016).
A database of over 40,000 US patients from 1998 onwards which assisted the development of the 8th American
Joint Committee on Cancer (AJCC) Staging System indicated a five-year survival of 97% to 99% for stage I
melanoma, dropping to between 32% and 93% in stage III disease depending on tumour thickness, the
presence of ulceration and number of involved nodes (Gershenwald 2017). While these are substantial increases relative
to survival in 1975 (Cho 2014), increasing incidence between 1975 and 2010 means that mortality rates have remained
static during the same period. This observation coupled with increasing incidence of localised disease, suggests that
improved survival rates may be due to earlier detection and heightened vigilance (Cho 2014). Targeted therapies
for stage IV melanoma have improved survival expectation and immunotherapies are evolving such that long term
survival benefit is being documented (e.g. using BRAF-inhibitors (Chapman 2012; Villanueva 2010) and MEK inhibitors
(Larkin 2014; Dummer 2014), and immunomodulation (Chapman 2011; Hamid 2013; Hodi 2010).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the bulge and interfollicular epidermis (Grachtchouk 2011
). BCC growth is usually localised, but it can infiltrate and damage surrounding tissue, sometimes causing
considerable destruction and disfigurement, particularly when located on the face (Figure 1). The four main
subtypes of BCC are superficial, nodular, morphoeic or infiltrative, and pigmented. They typically present as slow-
growing asymptomatic papules, plaques, or nodules which may bleed or form ulcers that do not heal (Firnhaber 2012
). People with a BCC often present themselves to healthcare professionals with a non-healing lesion rather than
specific symptoms such as pain. Many lesions are diagnosed incidentally (Gordon 2013).
BCCs most commonly occur on sun-exposed areas of the head and neck (McCormack 1997), and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin types I and II (Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer history; immunosuppression; arsenic
exposure; and genetic predisposition, such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over the last
four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been explained
by an ageing population, changes in the distribution of known risk factors, particularly ultraviolet radiation, and
improved detection due to the increased awareness amongst both practitioners and the general population (Verkouteren
2017). Hoorens 2016 points to evidence for a gradual increase in the size of BCCs over time, with delays in diagnosis
ranging from 19 to 25 months.
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According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low risk BCCs are
nodular lesions occuring in patients older than 24 years old who are not immunosuppressed and do not have Gorlin
syndrome. Furthermore, low risk lesions are usually located below the clavicle; small (< 1 cm) with well-defined
margins; not recurrent following incomplete excision; and not in awkward or highly visible locations (NICE 2010).
Superficial BCCs are also typically low risk and may be amenable to medical treatments such as photodynamic
therapy or topical chemotherapy (Kelleners-Smeets 2017). Assigning BCCs as low or high risk influences the
management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on the H-area of the face (Lear 2014) and can arise from long-standing
untreated lesions or from a recurrence of aggressive basal cell carcinoma after primary treatment (Lear 2012).
Very rarely, BCC metastasises to regional and distant sites resulting in death, especially cases of large neglected
lesions in those who are immunosuppressed or those with Gorlin syndrome (McCusker 2014). Rates of metastasis are
reported at 0.0028% to 0.55% (Lo 1991), with very poor survival rates. It is recognised that basosquamous carcinoma
(more like a high risk SCC in behaviour and not considered a true BCC) is likely to have accounted for many cases of
apparent metastases of BCC hence the spuriously high reported incidence in some studies of up to 0.55% which is
not seen in clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinocytes of the outermost layer (epidermis) of the skin. People with cSCC often
present with an ulcer or firm (indurated) papule, plaque, or nodule (Firnhaber 2012; Griffin 2016) often with an
adherent crust and poorly defined margins (Madan 2010). cSCC can arise in the absence of a precursor lesion or it can
develop from pre-existing actinic keratosis or Bowens disease (squamous cell carcinoma in situ) with an estimated
annual risk of progression being <1% to 20% for newly arising lesions (Alam 2001) and 5% for pre-existing lesions (Kao
1986). It remains locally invasive for a variable length of time, but has the potential to spread to the regional lymph
nodes or via the bloodstream to distant sites, especially in immunosuppressed individuals (Lansbury 2010). High risk
lesions are those arising on the lip or ear, recurrent cSCC, lesions arising on non-exposed sites, scars or chronic
ulcers, tumours more than 20mm in diameter and depth of invasion more than 4mm and poor differentiation on
pathological examination (Motley 2009). Perineural nerve invasion of at least > 0.1 mm in diameter is a further
documented risk factor for high risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; Dabski 1986; 
Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients, cSCC is the most
common form of skin cancer, with estimates of the risk of developing cSCC 65 to 253 times that of the general
population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic recurrence of cSCC at five
years is estimated at 8% and 5% respectively (Rowe 1992). The five-year survival rate of metastatic cSCC of
the head and neck is around 60% (Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is wide local excision of the lesion, to remove both the
tumour and any malignant cells that might have spread beyond the visible margins of the surrounding skin (Sladden 2009; 
Marsden 2010; NICE 2015a; Garbe 2016; SIGN 2017). Recommended surgical margins vary according to tumour
thickness (Garbe 2016) and stage of disease at presentation (NICE 2015a).
Treatment options for BCC and cSCC include surgery, other destructive techniques such as cryotherapy or
electrodesiccation and topical chemotherapy. A Cochrane systematic review of 27 randomised controlled trials (RCTs)
of interventions for BCC found very little good quality evidence for any of the interventions used (Bath-Hextall 2007a).
Complete surgical excision of primary BCC has a reported five-year recurrence rate of <2% (Griffiths 2005; Walker 2006
), leading to significantly fewer recurrences than treatment with radiotherapy (Bath-Hextall 2007a). After apparent
clear histopathological margins (serial vertical sections) after standard excision biopsy with 4mm surgical peripheral
margins taken there is a 5-year reported recurrence rate of around 4% (Drucker 2017). Mohs micrographic surgery,
whereby horizontal sections of the tumour are microscopically examined intraoperatively, and re-excision is undertaken
until the margins are tumour-free, can be considered for high risk lesions such as on the centre of the face where
standard wider excision margins might lead to incomplete excision or considerable functional impairment (Bath-Hextall
2007a; Motley 2009; Lansbury 2010; Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall 2007a) found a
single trial comparing MMS with a 3mm surgical margin excision in BCC (Smeets 2004); the update of this study showed
non-significantly lower recurrence at 10 years with Mohs micrographic surgery (4.4% compared to 12.2% after surgical
excision, P = 0.10) (van Loo 2014).
The main treatments for high risk BCC include standard surgical excision, Mohs micrographic surgery, and
radiotherapy. For low risk or superficial subtypes of BCC, or for those with small and or multiple BCCs at low risk
sites (Marsden 2010), destructive techniques other than excisional surgery may be used (e.g. electrodesiccation and
curettage or cryotherapy (Alam 2001; Bath-Hextall 2007a)). Alternatively, non-surgical (‘non-destructive’) treatments
may be considered (Bath-Hextall 2007a; Kim 2014; Drew 2017), including topical chemotherapy such as imiquimod (
Williams 2017), 5-fluorouracil (5-FU) (Arits 2013), ingenol mebutate (Nart 2015) and photodynamic therapy
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(PDT) (Roozeboom 2016). Bath-Hextall 2007aNon-surgical treatments are most frequently used for superficial forms
of BCC, with one head to head trial suggesting topical imiquimod is superior to PDT and 5-FU (Jansen 2018). Although
non-surgical approaches are increasingly used, they do not allow histological confirmation of tumour clearance, and
their efficacy is dependent on accurate characterisation of the histological subtype and depth of tumour such that a
baseline diagnostic biopsy can be helpful. The 2007 systematic review of BCC interventions found limited evidence
from very small RCTs for these approaches (Bath-Hextall 2007a), which have only partially been filled by subsequent
studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most BCC trials have compared interventions within the same
treatment class, and few have compared medical versus surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway inhibitor is now available for the treatment of metastatic or
locally advanced BCC based on the pivotal study ERIVANCE BCC (Sekulic 2012). It is licensed for use in these
patients where surgery or radiotherapy is inappropriate, e.g. for treating locally advanced periocular and orbital BCCs
with orbital salvage of patients who otherwise would have required exenteration (Wong 2017). However, NICE has
recently recommended against the use of vismodegib based on cost effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with predetermined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Estimates of
recurrence after MMS, surgical excision, or radiotherapy, which are likely to have been evaluated in higher risk
populations, have shown pooled recurrence rates of 3%, 5.4% and 6.4%, respectively with overlapping confidence
intervals; the review authors advised caution when comparing results across treatments (Lansbury 2013).
Index test(s)
Teledermatology is a term used to describe the delivery of dermatological care through information and
communication technology (Bashshur 2015). It uses imaging modalities to provide specialist dermatology services
either to other healthcare professionals (such as general practitioners), or to patients directly (Ndegwa 2010). It is
considered a valuable tool in the diagnosis and management of skin disease, because of the visual nature of skin
lesions / rashes (Warshaw 2011). Teledermatology allows an increased information flow between primary care
physicians and dermatologists, which could lead to a reduction in waiting times and limit unnecessary referrals (Ndegwa
2010; Warshaw 2010b; Bashshur 2015). In rural areas, where access to speciality services can have significant and
potentially off-putting travel and time implications for the patient, teledermatology has the potential to widen access to
specialist opinion.
Teledermatology consultations can be conducted in two main ways, store-and-forward or ‘asynchronous’, and live
interactive or ‘synchronous’ (Ndegwa 2010). With the store-and-forward approach, clinicians and patients are
separated by both time and space, as electronic digital images are taken and then transmitted to a dermatologist
for review at a later unspecified time (Warshaw 2011). The pictures can be digital photographic (or ‘macroscopic’)
images, or can be magnified dermoscopic images taken using a dermatoscope. Images are often accompanied by a
summary of the patient history and demographic information as part of a consultation package (Ndegwa 2010).
Furthermore, recent developments in smartphone technology have also introduced a new platform for transferring
lesion images from one setting to another (Chuchu 2018). The store-and-forward approach is advantageous as it
requires less sophisticated technology and lower-cost equipment (Warshaw 2011); however, it does not allow the
specialist to take a direct history, request additional views, or communicate in detail the purpose of management to
the patient or referrer (Ndegwa 2010).
Live interactive teledermatology uses video-conferencing and image transmission to connect the patient, referrer
and dermatologist in real time (Ndegwa 2010). The dermatologist and patient can interact verbally in a similar
manner to a traditional clinic-based encounter, but more extensive telecommunications infrastructure and time are
needed (Ndegwa 2010).
Clinical Pathway 
The diagnosis of melanoma can take place in primary, secondary, and tertiary care settings by both generalist and
specialist healthcare providers. In the UK, people with concerns about a new or changing skin lesion will usually
present first to their general practitioner (GP) or, less commonly, directly to a specialist in secondary care, which could
include a dermatologist, plastic surgeon, other specialist surgeon (such as an ear, nose, and throat (ENT) specialist or
maxillofacial surgeon), or ophthalmologist (Figure 2). Current UK guidelines recommend that all suspicious
pigmented lesions presenting in primary care should be assessed by taking a clinical history and visual inspection
guided by the revised seven-point checklist (MacKie 1990). Those with suspected melanoma or cSCC should be
referred for appropriate specialist assessment within two weeks (Chao 2013; Marsden 2010; NICE 2015a). Evidence
is emerging, however, to suggest that excision of melanoma by GPs is not associated with increased risk compared
with outcomes in secondary care (Murchie 2017). In the UK, low risk BCC are usually recommended for routine referral,
with urgent referral for those in whom a delay could have a significant impact on outcomes, for example due to large
lesion size or critical site (NICE 2015b). Appropriately qualified generalist care providers increasingly undertake
management of low risk BCC in the UK such as by excision of low risk lesions (NICE 2010). Similar guidance is in
place in Australia (CCAAC Network 2008).
Teledermatology consultations can aid more appropriate triage of lesions, providing reassurance for benign lesions and
referral via urgent or non-urgent routes to secondary care (e.g., for suspected basal cell carcinoma. The distinction between
setting and examiner qualifications and experience is important, as specialist clinicians might work in primary care settings
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(for example, in the UK, GPs with a special interest in dermatology and skin surgery who have undergone appropriate
training), and generalists might practice in secondary care settings (for example, GPs working alongside dermatologists in
secondary care, or plastic surgeons who do not specialise in skin cancer). The level of skill and experience in skin cancer
diagnosis will vary for both generalist and specialist care providers and will also impact on test accuracy.
For referred lesions, the specialist clinician will use history-taking, visual inspection of the lesion (in comparison
with other lesions on the skin) usually in conjunction with dermoscopic examination, and palpation of the lesion and
associated regional nodal basins to inform a clinical decision. If melanoma is suspected, then urgent 2mm excision
biopsy is recommended (Lederman 1985; Lees 1991); for cSCC predetermined surgical margin excision or a diagnostic
biopsy may be considered. BCC and pre-malignant lesions potentially eligible for nonsurgical treatment may undergo a
diagnostic biopsy before initiation of therapy. Equivocal melanocytic lesions for which a definitive clinical diagnosis cannot be
reached may undergo surveillance to identify any lesion changes that would indicate excision biopsy or reassurance and
discharge for those that remain stable over a period of time.
Prior test(s)
Although smartphone applications and community- or high street pharmacy-based teledermatology services (for example the
Boots ‘Mole Scanning Service’ www.boots.com/health-pharmacy-advice/skin-services/mole-scanning-service) can
increasingly be accessed directly by people who have concerns about a skin lesion (Kjome 2016), the diagnosis of skin
cancer is still based on history-taking and clinical examination by a suitably qualified clinician. In the UK, this is typically
undertaken at two decision points – first in primary care where the GP makes a decision to refer or not to refer, and then a
second time by a dermatologist or other secondary care clinician where a decision is made to biopsy or excise or not.
Visual inspection of the skin is undertaken iteratively, using both implicit pattern recognition (non-analytical
reasoning) and more explicit ‘rules’ based on conscious analytical reasoning (Norman 2009), the balance of which will
vary according to experience and familiarity with the diagnostic question. Various attempts have been made to
formalise the “mental rules” involved in analytical pattern recognition for melanoma (Sober 1979; Friedman 1985; MacKie
1985; MacKie 1990; Thomas 1998; Grob 1998); however, visual inspection for keratinocyte skin cancers relies
primarily on pattern recognition. Accuracy has been shown to vary according to the expertise of the clinician. Primary
care physicians have been reported to miss over half of BCCs (Offidani 2002) and to misdiagnose one third of BCCs
(Gerbert 2000). In contrast, an Australian study found that trained dermatologists were able to detect 98% of BCCs,
but with a specificity of only 45% (Green 1988).
A range of technologies have emerged to aid diagnosis to reduce the number of diagnostic biopsies or inappropriate
surgical procedures. Dermoscopy using a hand-held microscope has become the most widely used tool used by
clinicians to improve diagnostic accuracy of pigmented lesions, in particular for melanoma (Dinnes 2018b); it is less
well established for the diagnosis of BCC or cSCC. Dermoscopy (also referred to as dermatoscopy or epiluminescence
microscopy or ELM) uses a hand-held microscope and incident light (with or without oil immersion) to reveal
subsurface images of the skin at increased magnification of x 10 to x 100 (Kittler 2001). Used alongside clinical
examination, dermoscopy has been shown in some studies to increase the sensitivity of clinical diagnosis of melanoma
from around 60% to as much as 90% (Kittler 1999; Carli 2002; Bono 2006; Stanganelli 2000) with much smaller
effects in others (Benelli 1999; Bono 2002). The accuracy of dermoscopy depends on the experience of the examiner (
Kittler 2001), with accuracy when used by untrained or less experienced examiners potentially no better than clinical
inspection alone (Binder 1997; Kittler 2002).
The diagnostic accuracy, and comparative accuracy, of visual inspection and dermoscopy have been evaluated in a
further three reviews in this series (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
Role of index test(s)
The use of teledermatology by primary care or by other generalist clinicians has the potential to ensure that people
with suspicious lesions are appropriately referred for examination by a specialist clinician, and people with non-
suspicious lesions are appropriately reassured and managed in primary care. If an accurate triage is made, the
proportion of people who are referred unnecessarily will be minimised and those lesions requiring urgent referral and
treatment correctly identified. By creating an environment where there is facilitated access to more specialist services,
selective dermatology referral could ultimately reduce costs while enabling a faster, more reliable and more efficient
service (Piccolo 2002). Increased information flow between primary care physicians and dermatologists also has
the potential effect of increasing knowledge and reducing isolated decision-making (Bashshur 2015).
When diagnosing potentially life-threatening conditions such as melanoma, the consequences of falsely reassuring a person
that they do not have skin cancer can be potentially fatal, as the delay to diagnosis means that the window for successful
early treatment may be missed. To minimise these false-negative diagnoses, a good diagnostic test for melanoma
demonstrates high sensitivity and high negative predictive value (NPV), i.e., very few of those with a negative test result will
actually have a melanoma. Giving falsely positive test results (meaning the test has poor specificity and a high false-positive
rate) resulting in the removal of lesions that turn out to be benign, is arguably less of an error than missing a potentially fatal
melanoma, but does have implications for patient welfare and costs. False-positive diagnoses not only cause unnecessary
scarring from the biopsy or excision procedure, but also increase patient anxiety whilst they await the definite histology
results and increase healthcare costs as the number needed to remove to yield one melanoma diagnosis increases.
Delay in diagnosis of a BCC as a result of a false-negative test is not as serious as for melanoma because BCCs are usually
slow-growing and unlikely to metastasise. However, delayed diagnosis can result in a larger and more complex excision with
consequent greater morbidity. Very sensitive diagnostic tests for BCC however may compromise on lower specificity leading
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to a higher false-positive rate, and an enormous burden of skin surgery, such that a balance between sensitivity and
specificity is needed. The situation for cSCC is more similar to melanoma in that the consequences of falsely reassuring a
person that they do not have skin cancer can be serious and potentially fatal. Thus, a good diagnostic test for cSCC should
demonstrate high sensitivity and a corresponding high negative predictive value. In summary, a test that can reduce false
positive clinical diagnoses without missing true cases of disease has patient and resource benefits. False-positive clinical
diagnoses not only cause unnecessary morbidity from the biopsy, but could lead to initiation of inappropriate therapies and
also increase patient anxiety.
Alternative test(s)
Teledermatology provides an alternative means for primary care clinicians (and therefore patients) to access specialist
opinion compared to the standard referral process from primary to secondary care. Although the general public can also seek
advice on skin lesions, they may be concerned about doing so via smartphone applications or from services provided within
community or “high street” pharmacies. These are not considered direct alternatives to teledermatology services.
A number of other tests that may have a role in diagnosis of skin cancer have been reviewed as part of our series of
systematic reviews, including visual inspection and dermoscopy (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c),
smartphone applications (Chuchu 2018). reflectance confocal microscopy (RCM) (Dinnes 2018d; Dinnes 2018e),
optical coherence tomography (OCT) (Ferrante di Ruffano 2018a), and computer-aided diagnosis (CAD) techniques
applied to various types of images including those generated by dermoscopy, diffuse reflectance spectrophotometry
(DRS) and electrical impedance spectroscopy (EIS) (Ferrante di Ruffano 2018b), and high frequency ultrasound (Dinnes
2018f). Evidence permitting, the accuracy of available tests will be compared in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison of commonly used diagnostic strategies where tests may be
used singly or in combination.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diagnosis of melanoma aims to identify the most accurate
approaches to diagnosis and provide clinical and policy decision-makers with the highest possible standard of evidence
on which to base decisions. With increasing rates of skin cancer and the push towards the use of dermoscopy and other
high resolution image analysis in primary care, the anxiety around missing early cases needs to be balanced against the
risk of over referrals, to avoid sending too many people with benign lesions for a specialist opinion. It is questionable
whether all skin cancers picked up by sophisticated techniques, even in specialist settings, help to reduce morbidity and
mortality, or whether newer technologies run the risk of increasing false-positive diagnoses. It is also possible that use of
some technologies, e.g., widespread use of dermoscopy in primary care with no training, could actually result in harm by
missing melanomas if they are used as replacement technologies for traditional history-taking and clinical examination of
the entire skin. Many branches of medicine have noted the danger of such "gizmo idolatry" amongst doctors (Leff 2008).
Although teledermatology is increasingly used, the accuracy of different approaches to providing teledermatology services
(e.g. store-and-forward versus live-link modalities, and use of clinical versus dermoscopic images) has yet to be fully
established. A review by Warshaw 2011 suggested that both store-and-forward and live-link teledermatology had acceptable
diagnostic accuracy and concordance when compared with clinical face-to-face diagnosis; however, clinic-based
dermatology had superior diagnostic accuracy (i.e. in comparison to store-and-forward teledermatology consultations). As
with any technology requiring significant investment, a full understanding of the benefits including patient acceptability and
cost-effectiveness in comparison to usual practice should be obtained before such an approach can be recommended;
establishing the accuracy of diagnosis and referral accuracy is one of the key components. Given the rapidly changing
evidence base in skin cancer diagnosis, there is a need for an up-to-date analysis of the accuracy of teledermatology for skin
cancer diagnosis.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
melanoma (Dinnes 2015a); aspects of this review which relate to the diagnosis of BCC and cSCC follow the generic
protocol that was written to cover the reviews in the series for the diagnosis of keratinocyte skin cancers (Dinnes 2015b
). The Background and Methods sections of this review therefore use some text that was originally published in the
protocols (Dinnes 2015a; Dinnes 2015b) and text that overlaps some of our other reviews (Dinnes 2018a; Dinnes 2018b; 
Chuchu 2018).
Objectives 
To determine the diagnostic accuracy of teledermatology for the detection of any skin cancer (melanoma, BCC or cSCC) in
adults, and to compare its accuracy with that of in-person diagnosis.
Accuracy was estimated separately according to the type of teledermatology images used:
i. Photographic images
ii. Dermoscopic images
iii. Photographic and dermoscopic images
Secondary objectives
1) To determine the diagnostic accuracy of teledermatology for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants in adults, and to compare its accuracy with that of in-person diagnosis.
2) To determine the diagnostic accuracy of teledermatology for the detection of invasive melanoma only, in adults, and to
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compare its accuracy with that of in-person diagnosis.
3) To determine the diagnostic accuracy of teledermatology for the detection of BCC in adults, and to compare its accuracy
with that of in-person diagnosis.
4) To determine the diagnostic accuracy of teledermatology for the detection of cSCC in adults, and to compare its accuracy
with that of in-person diagnosis.
5) To determine the referral accuracy of teledermatology, i.e. to compare diagnostic decision making based on
teledermatology images with that of an in-person consultation.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as
outlined in our generic protocols (Dinnes 2015a; Dinnes 2015b) and described in Appendix 4; however, our ability to
investigate these was necessarily limited by the available data on each individual test reviewed.
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status;
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant lesions to those for healthy skin (i.e. with no lesion present).
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five cases of either
melanoma, BCC or cSCC or less than five benign lesions. For studies of referral accuracy where a lesion's final diagnosis
may not be reported, at least 5 ‘positive’ cases as identified by the expert diagnosis reference standard were required. The
size threshold of five is arbitrary. However such small studies are unlikely to add precision to estimate of accuracy.
Participants
We included studies in adults with lesions suspicious for skin cancer or adults at high risk of developing skin cancer. We
excluded studies that recruited only participants with malignant or benign final diagnoses.
We excluded studies conducted in children, or which clearly reported inclusion of more than 50% of participants aged 16 and
under.
Index tests
Studies evaluating teledermatology alone, or teledermatology in comparison with face-to-face diagnosis were included.
The following index tests were eligible for inclusion:
Store-and-forward teledermatology1.
Real-time 'live link' teledermatology2.
Data for face-to-face clinical diagnosis against a histological reference standard was also included where reported, to allow a
direct comparison with teledermatology to be made.
Although primary care clinicians can in practice be specialists in skin cancer, we considered primary care physicians as
generalist practitioners and dermatologists as specialists. Within each group, we extracted any reporting of special interest or
accreditation in skin cancer.
Target conditions
The primary target condition was defined as the detection of any skin cancer, primarily cutaneous melanoma, BCC or cSCC.
Four additional definitions of the target condition were considered in secondary analyses, namely the detection of:
invasive cutaneous melanoma alone1.
invasive cutaneous melanoma or atypical intraepidermal melanocytic variants (including melanoma in situ, lentigo2.
maligna)
BCC and3.
cSCC.4.
We also considered referral accuracy, comparing decision making from teledermatology compared with the face-to-face
decisions for the same lesions. These decisions could include the decision to excise a lesion, follow-up a lesion or refer a
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lesion for face-to-face assessment.
Reference standards
Teledermatology can be assessed in terms of a) diagnostic accuracy in comparison to the final lesion diagnosis and b)
referral accuracy in comparison to a face-to-face expert management decision.
To establish diagnostic accuracy, the ideal reference standard is histopathological diagnosis in all eligible lesions. A qualified
pathologist or dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing a
minimum dataset to include the histopathological features of melanoma to determine the American Joint Committee on
Cancer (AJCC) Staging System (e.g. Slater 2014). We did not apply this minimum dataset requirement as a necessary
inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy are unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore to reflect what happens in reality, we accepted clinical follow-up of benign-appearing lesions as an eligible
reference standard, whilst recognising the risk of differential verification bias (as misclassification rates of histopathology and
follow-up will differ). Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no
histology or clinical follow-up.
All of the above were considered eligible reference standards for establishing lesion final diagnoses (diagnostic accuracy)
with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
To establish referral accuracy of teledermatology (i.e. the ability of the remote observer to approximate an in-person
diagnosis), the action recommended by the remote observer was compared with an in-person ‘expert opinion’ reference
standard (i.e. the diagnosis or management recommendation of an appropriately qualified clinician made face-to-face with
the study participant).
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated. The search strategy was designed to capture
studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was
applied to the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to
assess treatment effectiveness. A sample of 300 records that would be missed by applying this filter was screened
and the filter adjusted to include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for
the staging tests reduced the overall numbers by around 6000. The final search strategy (Appendix 5),
incorporating the filter, was subsequently applied to all bibliographic databases as listed below. The final search
result was cross-checked against the list of studies included in five identified reviews (Bashshur 2015; Ndegwa 2010; 
Warshaw 2011; Whited 2006; Whited 2016). Our search identified all but one of the studies, and this study is not indexed on
MEDLINE. The Information Specialist devised the search strategy, with input from the Trials Search Co-ordinator from the
CSG (Cochrane Skin Group).
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
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The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied.
Searching other resources 
We have included information about potentially relevant ongoing studies in the Characteristics of ongoing studies tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, basal cell carcinoma (BCC), or cutaneous squamous cell carcinoma
(cSCC) were included at initial screening. Inclusion criteria (Appendix 6) were applied independently by both a clinical
reviewer (from one of a team of twelve clinician reviewers) and a methodologist reviewer (JDi or NC) to all full text articles,
disagreements were resolved by consensus or by a third party (JDe, CD, HW, and RM). Authors of eligible studies were
contacted when insufficient data were presented to allow for the construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodological reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to the target condition (in particular to allow the
differentiation of invasive cancers from ‘in situ’ variants) or diagnostic threshold were missing. Authors of conference
abstracts published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper was identified,
we marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 7). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical (as detailed above) and one methodological reviewer (JDi, NC or LFR) independently assessed quality for the
remaining studies; any disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and
RM).
Statistical analysis and data synthesis
Our unit of analysis was the lesion rather than the patient because (i) in skin cancer initial treatment is directed to the lesion
rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii) it is
the most common way in which the primary studies reported data. Although there is a theoretical possibility of correlations of
test errors when the same people contribute data for multiple lesions , most studies include very few people with multiple
lesions and any potential impact on findings is likely to be very small, particularly in comparison with other concerns
regarding risk of bias and applicability. For the diagnosis of melanoma, any BCCs or invasive cSCCs that were correctly
identified by teledermatology but that were identified as melanomas in the ‘disease negative’ group were considered as true
negative test results rather than as false positives, on the basis that excision of such lesions would be a positive outcome for
the participants concerned. For the diagnosis of BCC however, any melanomas or cSCCs that were mistaken for BCCs were
considered false positive results. This decision was taken on the basis that the clinical management of a lesion considered to
be a BCC might be quite different to that for a melanoma or cSCC and could potentially lead to a negative outcome for the
participants concerned, for example if a treatment other than excision was initiated.
For preliminary investigations of the data, estimates of sensitivity and specificity were plotted on coupled forest plots and
in receiver operating characteristic (ROC) space for each index test, target condition and reference standard
combination. When meta-analysis was possible and there were at least four studies, we used a bivariate model to obtain
summary estimates of sensitivity and specificity (Chu 2006; Reitsma 2005). When there were less than four
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studies and little or no heterogeneity was observed in ROC space, we pooled sensitivity and specificity using fixed
effect logistic regression (Takwoingi 2017). Data for face-to-face diagnosis were included only if reported in
comparison to teledermatology diagnosis. Using these direct (head-to-head) comparisons, a comparative meta-
analysis to compare the accuracy of teledermatology with face-to-face diagnosis was not possible because there
were few studies. However, we tabulated results from the studies and estimated differences in sensitivity and
specificity. Since these comparative studies did not report the cross classified results of the two index tests in
those with and without a particular form of skin cancer, we were unable to compute confidence intervals for the
differences using methods that account for the paired nature of the data. Therefore, we assumed independence
between the sensitivities and between the specificities of the two tests, and calculated 95% confidence intervals
for the differences using the Newcombe-Wilson method without continuity correction (Newcombe 1998). Analyses were
performed using Stata version 15 (Stata 2017).
Investigations of heterogeneity
We examined heterogeneity by visually inspecting forest plots of sensitivity and specificity, and summary ROC (SROC) plots.
We were unable to perform meta-regression to investigate potential sources of heterogeneity due to insufficient numbers of
studies.
Sensitivity analyses
Sensitivity analyses were not conducted due to limited data.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), we did not perform tests to detect publication bias.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer;
203 publications were included in at least one review in our series and 848 publications were excluded (see Figure 3
PRISMA flow diagram of search and eligibility results).
Of the 125 studies tagged as potentially eligible for this review of teledermatology, 22 publications were included. Exclusions
from the review were primarily due to: lack of test accuracy data to complete a 2x2 contingency table (31 studies), ineligible
populations (38 studies) or target conditions (n = 19), not accuracy studies (n = 23) and inadequate sample size (less than
five cases of skin cancer, less than five benign lesions, or for referral accuracy, less than five ‘positive’ cases identified by the
expert diagnosis reference standard) (n = 7) or reference standards (11 studies). Of the 31 studies for which a 2x2 table
could not be constructed, 11 reported only agreement between observers or between teledermatology and the reference
standard and 14 had at least one piece of missing data. A list of the 103 studies with reasons for exclusion is provided in
Characteristics of excluded studies, with a list of all studies excluded from the full series of reviews available as a separate
pdf.
The corresponding authors of 12 studies were contacted and asked to supply further information to allow study
inclusion or to clarify diagnostic thresholds or target condition definition. Responses were received from four authors
allowing inclusion of all four studies to this review (Borve 2015; Mahendran 2005; Warshaw 2010; Wolf 2013). One
of the four authors was not able to provide all of the information requested such that the data presented in the
paper could only be partially included in this review (Warshaw 2010).
The 22 included study publications report on a total of 22 cohorts of lesions and provided 96 datasets (individual 2x2
contingency tables). Sixteen studies (73%) including 4057 lesions and 879 malignant cases reported data for the diagnostic
accuracy of teledermatology (Arzberger 2016; Borve 2015; Bowns 2006; Congalton 2015; Coras 2003; Ferrara 2004; 
Grimaldi 2009; Jolliffe 2001a; Kroemer 2011; Massone 2014; Moreno Ramirez 2005; Piccolo 2000; Piccolo 2004; Silveira
2014; Warshaw 2010; Wolf 2013), five of which also reported data for the diagnostic accuracy of expert face-to-face
clinical diagnosis (Coras 2003; Jolliffe 2001a; Kroemer 2011; Piccolo 2000; Warshaw 2010). Six studies (27%) including
1449 lesions reported data for the referral accuracy of teledermatology, i.e. teledermatology diagnosis or management
action as the index test versus expert face-to-face diagnosis or management action as the reference standard (Jolliffe 2001b;
Mahendran 2005; Manahan 2015; Oliveira 2002; Phillips 1998; Shapiro 2004); these studies included 270 ‘positive’ cases as
determined by the reference standard face-to-face decision. A cross-tabulation of studies by reported comparisons, target
conditions and types of image used is provided in Table 1 and summary study details are presented in Appendix 8.
Studies were primarily prospective case series (n = 18; 82%), with two retrospective case series (9%) (Moreno Ramirez
2005; Piccolo 2004) and two case-control studies (9%) (Ferrara 2004; Wolf 2013), three of which retrospectively
selected previously acquired images for prospective evaluation in the study (Piccolo 2004; Ferrara 2004; Wolf 2013
). Studies were conducted in: Europe (n=14; 64%), including five studies from Austria (Arzberger 2016; Kroemer 2011; 
Massone 2014; Piccolo 2000; Piccolo 2004) and four from the UK (Bowns 2006; Jolliffe 2001a; Jolliffe 2001b; Mahendran
2005); North America (Warshaw 2010; Wolf 2013; Phillips 1998; Shapiro 2004) (n=4; 18%); or South America (Oliveira 2002
; Shapiro 2004) (n=2; 9%); or in Australia (Manahan 2015) or New Zealand (Congalton 2015) (n=2; 9%). Eight (36.4%)
studies included only pigmented (Coras 2003; Grimaldi 2009; Jolliffe 2001a; Moreno Ramirez 2005; Piccolo 2000; Wolf
2013) or melanocytic (Ferrara 2004; Piccolo 2004) lesions (Piccolo 2004 restricting to acral lesions only); the remainder
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included any suspicious lesion.
Ten studies were based in primary care or community-based settings. In seven studies, lesion images were acquired in
primary care (Borve 2015; Grimaldi 2009; Mahendran 2005; Massone 2014; Moreno Ramirez 2005;Oliveira 2002; Shapiro
2004), two studies were based in a community skin cancer screening outreach programme with image acquisition for
'remote' assessment by specialists in a secondary care setting (Silveira 2014) or using live transmission video-
conferencing (Phillips 1998), and one recruited participants at high risk of melanoma who took images of their own
lesions that they ‘did not like the look of’ using a smartphone (Manahan 2015). No studies were conducted in high
street pharmacy type settings. Five of the ten studies reported the diagnostic accuracy of the teledermatology image-
based assessment (Borve 2015; Grimaldi 2009; Massone 2014; Moreno Ramirez 2005; Silveira 2014), and five
examined referral accuracy, comparing the teledermatology assessment against specialist in-person assessment
(Mahendran 2005; Manahan 2015 ; Oliveira 2002 ; Phillips 1998; Shapiro 2004). Of these studies, nine were
prospective in design and one was retrospective (Moreno Ramirez 2005).
In 12 studies, lesion images were acquired at a secondary care dermatology or pigmented lesion clinic (Arzberger 2016; 
Congalton 2015; Ferrara 2004; Jolliffe 2001a; Jolliffe 2001b; Kroemer 2011; Piccolo 2000; Piccolo 2004; Warshaw 2010 ; 
Wolf 2013;), from a private dermatology practice (Coras 2003) or in a medical imaging unit (Bowns 2006) at the time
of the patient consultation, and remote image-based diagnoses were made by a second dermatologist. Of these
studies, nine were prospective in design, two studies retrieved routinely collected lesion images for prospective
'teledermatology' examination (Piccolo 2004 ; Wolf 2013) and one did not clearly report how lesion images were
acquired (Ferrara 2004). Six studies reported data only for the diagnostic accuracy of specialist image-based
assessment (Arzberger 2016; Bowns 2006; Congalton 2015; Ferrara 2004; Piccolo 2004; Wolf 2013), five compared
the diagnostic accuracy of image-based diagnosis to that of a dermatologist’s face-to-face diagnosis (Coras 2003; Jolliffe
2001a; Kroemer 2011; Piccolo 2000; Warshaw 2010), and one examined referral accuracy, comparing specialist
image-based assessment against specialist in-person assessment (Jolliffe 2001b).
Ten evaluations reported data using photographic images for teledermatology consultations (Jolliffe 2001a; Jolliffe 2001b; 
Kroemer 2011; Mahendran 2005; Moreno Ramirez 2005; Oliveira 2002; Shapiro 2004; Silveira 2014; Warshaw 2010; Wolf
2013), nine for a combination of clinical and dermoscopic images (Arzberger 2016; Borve 2015; Bowns 2006; Congalton
2015; Coras 2003; Grimaldi 2009; Manahan 2015 ; Massone 2014; Piccolo 2000), and three reported data for
diagnosis using dermoscopic images only (Ferrara 2004; Kroemer 2011; Piccolo 2004). The final study (Phillips 1998)
reported referral accuracy data for live link teledermatology using three cameras: a full-body camera, a lens for close-up
views and a magnifying lens to allow magnified examination and examination with polarised light. The Warshaw 2010 paper
also reported accuracy data for diagnosis using a combination of photographic and dermoscopic images, however we were
unable to obtain underlying 2x2 data to allow the inclusion of this aspect of the study.
Images for store and forward teledermatology were obtained using a mobile phone camera alone (Kroemer 2011) or
coupled with a dermatoscope (Borve 2015; Kroemer 2011; Manahan 2015); using still images from a video camera (Jolliffe
2001a; Jolliffe 2001b); using a combination of film and digital images (Ferrara 2004); or using a digital camera (n
= 13) to acquire photographs (Mahendran 2005; Moreno Ramirez 2005; Oliveira 2002; Shapiro 2004; Silveira 2014; 
Warshaw 2010; Wolf 2013), dermoscopic images (Ferrara 2004; Piccolo 2004) or both (Arzberger 2016; Congalton 2015; 
Coras 2003; Grimaldi 2009; Massone 2014; Piccolo 2000). In Bowns 2006 photographic and dermoscopic images were
acquired in a medical photography unit (equipment not described). Details of the digital cameras and mobile phones used
are provided in Characteristics of included studies. Observers were provided with additional clinical information
along with the digital image of the lesion in 18 studies (82%), three did not clearly report whether additional clinical
information was provided (Arzberger 2016; Grimaldi 2009; Manahan 2015) and one did not provide any further patient
related information (Wolf 2013). The remote observers were reported to be dermatologists in 19 (86%) studies, oncologists in
one, a mixture of dermatologists and other health care professionals (e.g. oncologists, plastic surgeons) in two (9%).
In the five studies providing a direct comparison of teledermatology with in-person evaluation by a dermatologist (Coras
2003; Kroemer 2011; Jolliffe 2001a; Piccolo 2000; Warshaw 2010), diagnosis was based on visual inspection of the
lesion with dermoscopy used for some (proportions not reported) (Coras 2003; Jolliffe 2001a; Kroemer 2011; Warshaw
2010) or for all lesions (Piccolo 2000). One study reported using tpattern analysis (Coras 2003), and the remaining three
(50%) studies did not specify any algorithm used to aid diagnosis. The direct comparison of teledermatology with in-person
evaluation by a general practitioner provided in Grimaldi 2009 was not included in this review as it is not directly relevant to
teledermatology in this context.
For the 16 studies reporting diagnostic accuracy,11 (69%) used histology alone as the reference standard (Arzberger 2016; 
Congalton 2015; Coras 2003; Ferrara 2004; Jolliffe 2001a; Kroemer 2011; Piccolo 2000; Piccolo 2004; Silveira 2014; 
Warshaw 2010; Wolf 2013), three (19%) used both histology and expert opinion for some benign lesions (Borve 2015; 
Bowns 2006; Massone 2014) and two studies (12%) used histology and follow-up of clinically benign appearing
lesions (Grimaldi 2009; Moreno Ramirez 2005). The median number of study participants was 76.5 (inter-quartile
range (IQR) 48.5, 182.2) (reported in 10 studies), and median number of lesions was 116 (IQR 45, 240). The median
prevalence of skin cancer was 30% (IQR 21% to 45%) and median percentage of male participants was 46% (IQR
35%, 47%) (reported in 9 studies). Where reported (8 studies), the median age was 52 years (IQR 43y, 65y) (reported
in 8 studies). Four of the 16 diagnostic accuracy studies did not report the range in age of included participants (Bowns 2006;
Coras 2003; Grimaldi 2009; Wolf 2013), four restricted inclusion to adults only (Borve 2015; Massone 2014; Silveira 2014; 
Warshaw 2010) and eight studies included participants under the age of 16 (Arzberger 2016; Congalton 2015; Ferrara 2004; 
Jolliffe 2001a; Kroemer 2011; Moreno Ramirez 2005; Piccolo 2002; Piccolo 2004); however data were not presented to allow
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data to be extracted excluding children.
For the six studies reporting referral accuracy, the face-to-face reference standard diagnosis was made by the same
dermatologist undertaking the teledermatology assessment in three studies, either within one to two weeks (Oliveira 2002; 
Mahendran 2005) or with a gap of several months between assessments (Jolliffe 2001b), by a dermatology trainee
under the supervision of the tele-dermatologist (Manahan 2015), or a different dermatologist in two studies (Phillips 1998; 
Shapiro 2004). The median number of study participants was 50 (IQR 49, 72) (reported in all 6 studies), and median
number of lesions was 107 (IQR 94, 253). The reported decisions of the face-to-face expert included diagnosis of
malignancy (Oliveira 2002 ; Phillips 1998), decision to excise (Mahendran 2005 ; Phillips 1998 ; Shapiro 2004), or decision
to see face-to-face ( Jolliffe 2001b ; Manahan 2015); the median overall percentage of ‘positive’ expert diagnoses
was 15% (IQR 10 to 41%). The median age of included participants was reported in only one study as 46.7 years (Phillips
1998); two studies reported age ranges of 8 to 94 years (Jolliffe 2001b) and 50 to 64 years (Manahan 2015) and
four did not report the range in ages of included participants (Mahendran 2005 ; Oliveira 2002 ; Phillips 1998 ; Shapiro
2004). The percentage of male participants ranged from 15.7% (Phillips 1998) to 49% (Manahan 2015) (reported in three
studies).
Methodological quality of included studies
The overall methodological quality of included studies is summarized in Figure 4 and Figure 5. At least half of studies were
consider at high or unclear risk of bias for participant selection, reference standard and flow and timing domains while the
majority were at low risk for the index test. The applicability of study findings were of high or unclear concern for the majority
of studies in all domains assessed.
For participant selection, seven studies (32%) were assessed to be at low risk of bias (Borve 2015; Bowns 2006; Grimaldi
2009; Jolliffe 2001b; Mahendran 2005; Oliveira 2002; Warshaw 2010) and five (23%) studies were at high risk (Congalton
2015; Ferrara 2004; Moreno Ramirez 2005; Massone 2014; Wolf 2013). Four studies applied inappropriate
participant exclusions (such as excluding poor quality images, or difficult to diagnose lesions) (Congalton 2015, Massone
2014, Moreno Ramirez 2005, Wolf 2013); and two studies used a case control type study design with separate
selection of malignant cases and lesions with benign diagnosis (Ferrara 2004; Wolf 2013). Two thirds of studies (n = 14)
were considered at high concern for applicability of participants, due to recruitment from secondary care or specialist clinics
rather than from the primary setting in which teledermatology is more likely to be used (12/22; Arzberger 2016; Bowns 2006; 
Congalton 2015; Coras 2003; Jolliffe 2001a; Jolliffe 2001b; Kroemer 2011; Moreno Ramirez 2005; Piccolo 2000; Piccolo
2004; Warshaw 2010; Wolf 2013) and/or due to inclusion of multiple lesions per participant (6/22; Congalton 2015; Grimaldi
2009; Jolliffe 2001b; Kroemer 2011; Manahan 2015; Warshaw 2010). Two studies were rated as low concern for
participant applicability (Oliveira 2002; Phillips 1998).
For the index test, all of the teledermatology assessments were judged at low risk of bias for the index test apart from
Phillips 1998, in which it was unclear whether the teledermatology diagnoses were made blinded to the decision to
the face-to-face clinician (reference standard). One study was judged of low concern for applicability of
teledermatology (Massone 2014) and 12 (45%) studies were of high concern (Arzberger 2016; Bowns 2006; Congalton
2015; Coras 2003; Ferrara 2004; Jolliffe 2001a; Jolliffe 2001b; Kroemer 2011; Piccolo 2000; Piccolo 2004; Warshaw 2010; 
Wolf 2013), due to images acquired by dermatologists based in secondary care settings or from pigmented lesion clinic
databases rather than images acquired in primary care. For the five studies reporting direct comparisons of
teledermatology with face-to-face clinical diagnoses, two (40%) studies were at low risk of bias (Coras 2003; Warshaw 2010
) and three (60%) were judged unclear, as the thresholds used were not clearly pre-specified (Jolliffe 2001a; Kroemer 2011; 
Piccolo 2000). For the comparison between tests, there was no blinding between store-and-forward teledermatology and
face-to-face clinical diagnosis in Jolliffe 2001a; the remaining four comparative studies did not describe any blinding (Coras
2003; Kroemer 2011; Piccolo 2000; Warshaw 2010). One study (20%) was of low concern for applicability of the face-
to face diagnosis (Coras 2003) and four of unclear concern of applicability as the thresholds used for diagnosis were
not clearly reported to allow replication of methods (Jolliffe 2001a; Kroemer 2011; Piccolo 2000; Warshaw 2010).
For the reference standard domain 10 (45%) studies were at low risk of bias (Arzberger 2016; Congalton 2015; Coras 2003; 
Ferrara 2004; Jolliffe 2001a; Piccolo 2000; Piccolo 2004; Silveira 2014; Warshaw 2010; Wolf 2013) and twelve (55%)
were rated as high risk either because they were referral accuracy studies using only expert face-to-face diagnosis as
the reference standard (Jolliffe 2001b; Mahendran 2005; Manahan 2015; Oliveira 2002; Phillips 1998; Shapiro 2004) or
because they were diagnostic accuracy studies that did not meet our criteria for an adequate reference standard (i.e. > 80%
of lesion with histology and up to 20% with clinical follow-up; see Appendix 7) (Borve 2015; Bowns 2006; Grimaldi 2009; 
Kroemer 2011; Massone 2014; Moreno Ramirez 2005). Only two studies clearly reported blinding of the reference
standard diagnosis to the teledermatology assessment (Phillips 1998; Shapiro 2004) and two did not implement any
blinding (Oliveira 2002; Mahendran 2005); these were all referral accuracy studies. Six studies were of low concern
for the applicability of the reference standard, including three of the sixteen diagnostic accuracy studies (Ferrara 2004; 
Piccolo 2004; Warshaw 2010) that clearly reported the level of experience of the histopathologist and three of the six referral
accuracy studies that reported the expertise of the face-to-face reference standard diagnosis.
For flow and timing of participants, two referral accuracy studies were rated as low risk of bias (Jolliffe 2001b; Phillips 1998
) and 17 studies (77%) were at high risk of bias; either because they did not use the same reference standard for all
participants (Borve 2015; Bowns 2006; Grimaldi 2009; Massone 2014; Moreno Ramirez 2005) or they did not
include all study participants in the final analysis (Arzberger 2016; Congalton 2015; Coras 2003; Jolliffe 2001a; Kroemer
2011; Mahendran 2005; Manahan 2015; Massone 2014; Moreno Ramirez 2005; Oliveira 2002; Shapiro 2004; Silveira 2014; 
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Warshaw 2010; Wolf 2013). For flow and timing of participants, 72% (n = 13) were high risk of bias either because they did
not use the same reference standard for all participants or they did not include all study participants in the final analysis.
Fourteen studies (64%) did not clearly report the interval between reference standard and index test.
Findings
Study results are summarised below according to target condition with results of meta-analyses in Table 2 with summary
details in Appendix 8. Lack of data and between study variation in populations, approaches to teledermatology and target
conditions considered, limited the pooled analyses that could be undertaken.
1.1 Target condition: detection of any skin cancer
The diagnostic accuracy of teledermatology assessment for the detection of the primary target condition of any skin cancer
was reported in seven studies with a total of 1588 lesions and 638 cases of skin cancer. Forest plots of study data are
provided in Figure 6 with results of meta-analysis in Figure 7.
Four studies compared diagnosis based on photographic images to histology (Figure 6). In three studies sensitivities
for the correct diagnosis of malignancy ranged from 93% (95% CI 77% to 99%) to 100% (95% CI 75% to 100%) and
specificities from 88% (95% CI 77% to 95%) to 96% (95% CI 82% to 100%) (Jolliffe 2001a; Kroemer 2011; Moreno
Ramirez 2005). All three studies reported a cross-tabulation of lesion final diagnoses against the diagnosis on
teledermatology such that data could be extracted for the detection of any malignancy, regardless of any misclassification of
one skin cancer for another, e.g. a BCC diagnosed as a melanoma or vice versa. Similarly high sensitivity was observed in
Silveira 2014 (96%, 95% CI 94% to 98%) but specificity was outlying at 25% (95% CI 14% to 39%); data here were
presented for the detection of ‘malignant’ versus benign cases with no breakdown of individual lesion diagnoses given. The
low specificity in Silveira 2014 result was likely due to the recruitment of participants with lesions deemed to be highly
clinically suspicious after visual inspection of the lesion during a community screening programme; the prevalence of
malignancy was 87.5% with only 52 benign cases in a sample of 416 lesions.
The pooled result across the four studies indicated summary sensitivity of 94.9% (95% CI 90.1 to 97.4%) and summary
specificity 84.3% (95% CI 48.5 to 96.8%) based on 717 lesions and 452 cases of skin cancer (Table 2; Figure 7).
One study (Kroemer 2011) also reported diagnosis based on dermoscopic images only versus histology, sensitivity
was lower than for assessment using photographic images (85%, 95% CI 71% to 94% versus 93%, 95% CI 82% to
99%) with similar specificities (Figure 6).
Three studies compared image-based diagnosis based on both clinical and dermoscopic images to histology for 928
lesions and 215 cases of skin cancer (Figure 6). Each study used a slightly different threshold to decide test
positivity: the correct classification of lesions as malignant versus benign (Massone 2014), lesions considered
malignant or possibly malignant (Borve 2015), or lesion recommended for excision (Arzberger 2016). Sensitivities
were 100% in all three studies. Specificities ranged from 25% (95% CI 5% to 57%) (Arzberger 2016) to 92% (95%
CI 74% to 99%) (Massone 2014). The latter was a primary care based study for which accuracy data could only be
estimated for a subgroup of 32 of the original 962 lesions (Massone 2014). Arzberger 2016 included participants at
particularly high risk for melanoma, while Borve 2015 included large proportions of seborrhoeic keratosis (19%) and actinic
keratosis (9%) in the disease negative group. These factors may have made differentiating a malignant case from a benign
one more challenging.
No statistical pooling was undertaken for these studies due to variation in threshold and heterogeneity in specificities.
Two studies compared remote image-based assessment with in-person diagnosis by a dermatologist (Jolliffe 2001a; 
Kroemer 2011) for the detection of any skin cancer using the same diagnostic thresholds as for the teledermatology decision.
Jolliffe 2001a reported 100% (95% CI 75% to 100%) sensitivity for both assessments, while Kroemer 2011 reported
100% (95% CI 92% to 100%) sensitivity for in-person diagnosis compared to 93% (95% CI 82% to 99%) for diagnosis
using photographic images and 85% (95% CI 71% to 94%) for dermoscopic image based assessment (Table 3; Figure 6).
Both studies reported only marginal differences in specificity between approaches.
1.2 Target condition: invasive melanoma or atypical intraepidermal melanocytic variants
The diagnostic accuracy of teledermatology assessment for the detection of invasive cutaneous melanoma or atypical
intraepidermal variants was reported in nine studies for a total of 2510 lesions with 206 melanomas (Figure 8), only two
of which also reported data for the detection of any skin cancer (Table 2).
In the four studies comparing diagnosis based on photographic images to histology (1834 lesions and 106
melanomas), sensitivities ranged from 59% (95% CI 42% to 74%) to 100% (95% CI 48% to 100%) and specificities
from 30% (95% CI 22% to 40%) to 100% (95% CI 93% to 100%) (Kroemer 2011; Moreno Ramirez 2005; Warshaw 2010; 
Wolf 2013). In three studies, the data extracted were for the correct diagnosis of melanoma whereas in Wolf 2013, lesions
were classified as ‘atypical’ or ‘typical’ as opposed to reporting the correct diagnosis of melanoma. The difference in the
diagnostic decision recorded in Wolf 2013 is likely to account for the low specificity observed.
The relatively low sensitivity and specificity observed in Warshaw 2010 is difficult to explain but may be related to
differences in population characteristics between studies. Two studies restricted inclusion to pigmented lesions
considered clinically atypical by at least one dermatologist (Wolf 2013) or meeting explicit criteria that might suggest
a higher risk for melanoma (Moreno Ramirez 2005), Wolf 2013 selecting specific lesion types and excluding those with an
equivocal diagnosis. Kroemer 2011 included participants with any lesion type who were either self-referred or referred by a
local doctor to general dermatology clinic. Warshaw 2010 also included any lesion type (pigmented or non-pigmented) from
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participants who required or requested removal of one or more skin lesions (denoted ‘high risk’ by the study authors) or from
patients who were referred by non-dermatology healthcare providers for specialist assessment (denoted as ‘lower risk’);
furthermore, lesions in 30 histopathologic categories with less than 25 lesions were excluded (n=171).
Two studies compared dermoscopic image-based diagnosis to histology (Ferrara 2004; Kroemer 2011), sensitivities were
between 71% (95% CI 29% to 96%) and 100% (95% CI 48% to 100%) and specificities were 60% (95% CI 15% to 95%) to
97% (95% CI 91% to 99%). Ferrara 2004 reported sensitivity of 71% (95% CI 29% to 96%) and specificity 60% (95% CI 15%
to 95%) for the correct differentiation of seven melanomas from five benign lesions. Kroemer 2011 reported very
similar sensitivity and specificity for the correct diagnosis of melanoma using only dermoscopic images to their result
using non-magnified photographic images: sensitivities with both approaches were 100% (95% CI 48% to 100%)
while specificities were 98% (95% CI 96%, 100%) using photographic images compared to 97% (95% CI 91, 99%)
for dermoscopic images. Data were not presented for diagnosis using both clinical and dermoscopic images;
however, the study reports that “re-evaluation of both image types in (discordant cases) did not improve the
diagnostic accuracy of teleconsultations” (Kroemer 2011).
Four studies compared teledermatology based on both clinical and dermoscopic images to histology in 664 lesions
with 93 cases of melanoma or atypical intraepidermal melanocytic variants (Bowns 2006; Congalton 2015; Coras 2003; 
Grimaldi 2009). Summary estimates of sensitivity were 85.4% (95% CI 68.3% to 94.1%) and specificity 91.6% (95% CI
81.1% to 96.5%) (Table 2; Figure 9).
Across the 10 teledermatology datasets the number of melanomas missed ranged from 0 (two datasets, both from Kroemer
2011) to 17 (Warshaw 2010).
Three studies in this group compared teledermatology assessment of images to face-to-face diagnosis by a
dermatologist (Coras 2003; Kroemer 2011; Warshaw 2010) (Table 3). In Warshaw 2010, the diagnostic accuracy of
teledermatology diagnosis of melanoma using photographic images and patient history was considerably lower
compared to an in-person dermatologist diagnosis (using visual inspection with or without the use of dermoscopy as
determined by the individual clinician); data from the author showed that sensitivity was 15% lower for teledermatology
assessment (95% CI -0.33 to 0.06) and specificity was 22% lower (95% CI -0.26 to -0.19) (Table 3). The accuracy of
the expert face-to-face diagnosis was nevertheless relatively low, with sensitivity of 73% (95% CI 57 to 86%) and
specificity 63% (95% CI 61 to 66%) (Figure 8). The two studies comparing teledermatology diagnosis using both macro
and dermoscopic images demonstrated only marginal differences between the two approaches (Coras 2003; Kroemer 2011
) (Table 3).
1.3 Target condition: invasive cutaneous melanoma
The diagnostic accuracy of teledermatology assessment for the detection of invasive melanoma was reported in Piccolo
2000 for 43 lesions selected for their ‘diagnostic difficulty (11 cases of melanoma) and in Piccolo 2004 for the
differentiation of acral melanoma (n=6) from benign acral lesions (n=71) (Figure 10). In Piccolo 2000, the sensitivity for store-
and-forward teledermatology assessment was 82% (95% CI 48% to 98%) and specificity 100% (95% CI 89% to 100%) in
comparison to in-person dermatologist assessment of the same lesions where sensitivity was 73% (95% CI 39% to 94%) and
specificity 97% (95% CI 84% to 100%) (one invasive melanoma missed in the face-to-face encounter was identified using
teledermatology). Similar teledermatology accuracy (based on a consensus’ of 6 out of 11 observers) was obtained for acral
lesions in Piccolo 2004 using only dermoscopic images: observed sensitivity was 83% (95% CI 36 to 100%) and specificity
96% (95% CI 88 to 99%).
1.4 Target condition: BCC
The diagnostic accuracy of teledermatology assessment for the detection BCC was reported in four studies (Figure 11 and
Figure 12):
Three evaluations of photographic images for 301 lesions with 62 cases of BCC (Jolliffe 2001a; Kroemer 2011; Moreno
Ramirez 2005), produced summary estimates of sensitivity of 93.5% (95% CI 84.0% to 97.6%) and specificity 95.8%
(95% CI 92.4% to 97.7%) (Table 2 and Figure 10). A total of four BCCs were missed in two studies (Kroemer 2011; Moreno
Ramirez 2005).
One study (Kroemer 2011) reported lower sensitivity using dermoscopic images (80%, 95% CI 61% to 92%)
compared to photographic images (90%, 95% CI 73% to 98%), due to an additional two BCCs being mistaken for
actinic keratosis. A further study (Bowns 2006) reporting data only for teledermatology using clinical and dermoscopic
images also reported low sensitivity for BCC of 66% (95% CI 46% to 82%). Both studies reported specificities of 93%
and over (Figure 11).
A comparison with expert face-to-face assessment was provided in two studies (Table 3). Kroemer 2011 reported higher
sensitivity and specificity in the face-to-face assessments and Jolliffe 2001a reported almost identical sensitivity and
specificity estimates from the two approaches.
1.5 Target condition: cSCC
Kroemer 2011 also reported accuracy for the detection of cSCC in 104 lesions with 10 cases of cSCC. Sensitivities of
90% (95% CI 55% to 100%) (1 cSCC missed) were achieved for diagnosis based on photographic images and for the
face-to-face assessments, with sensitivity of 60% (4 cSCCs missed) for remote assessment based on dermoscopic
images (95% CI 26% to 88%) (Figure 13). Specificities were over 98% for all three approaches to diagnosis.
1.6 Referral accuracy
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Six studies gave information on diagnostic decision making by teledermatology consultants compared to expert face-
to-face decisions (as the reference standard) (Figure 14).
Four studies reported data for store and forward teledermatology using photographic images, either for the diagnosis
of malignancy (Oliveira 2002), for the decision to excise a lesion (Mahendran 2005; Shapiro 2004), for the decision to
refer versus not refer (Jolliffe 2001b) or to excise or follow-up at a later date (Mahendran 2005). Jolliffe 2001b reported data
both for teledermatology by a dermatologist and by a dermatology registrar. It was not possible to pool results across these
studies due to heterogeneity in the teledermatology
Perfect or almost perfect agreement between teledermatology and face-to-face consultation was observed in two studies
(sensitivities 100% and specificities 98% to 100%; Oliveira 2002; Shapiro 2004), while Mahendran 2005 also reported
100% sensitivity both for the decision to excise a lesion and the decision to excise or follow-up (Figure 14). In Jolliffe 2001b
the sensitivity of teledermatology by the dermatologist was 69% (95% CI 61 to 77%), with 44 lesions recommended for face-
to-face consultation ‘missed’ by the remote observer, compared to 92% for the registrar’s teledermatology assessment (12
lesions ‘missed’).
Specificities were more variable with 69% (95% CI 55 to 81%) and 57% (95% CI 39 to 73%) reported in Mahendran 2005 for
the decision to excise a lesion and the decision to excise or follow-up a lesion and 85% (95% CI 82 to 87%) and 67% (95%
CI 63 to 70%) reported in Jolliffe 2001b for the dermatologist and dermatology registrar for the decision to refer a
lesion. The number of lesions recommended for some action by the teledermatogist that were not recommended
for action by the ace-to-face exert in these studies ranged from 16 (Mahendran 2005) to 217 (Jolliffe 2001b).
Manahan 2015 reported the sensitivity and specificity of the teledermatogist’s decision to recommend a lesion for face-to-
face consultation based on macro and dermoscopic images compared to the same recommendation by the face-to-face
dermatologist (301 lesions; 35 recommended for face-to-face consultation): the resulting sensitivity was 91% (95% CI 77 to
98%) with 3 lesions ‘missed’ and specificity was 89% (95% CI 85 to 93%) with 28 lesions recommended for a face-to-face
visit that were not selected by the in-person dermatologist.
Finally, Phillips 1998 reported data for the accuracy of live link teledermatology using video conferencing compared to a
dermatologist’s face-to-face decision (as the reference standard) for 107 lesions. Data were reported at three different
thresholds: for the correct diagnosis of a skin cancer (melanoma BCC or cSCC), for the classification of a lesion as definitely
or probably malignant, and for the decision to biopsy a lesion. Sensitivities were 67% (95% CI 22 to 96%), 60% (95% CI 15
to 95%) and 82% (95% CI 48 to 98%) respectively, and specificities were 96% (95% CI 90 to 99%) for both the correct
diagnosis of a skin cancer and lesions definitely or probably malignant and 86% (95% CI 78 to 93%).
Investigations of heterogeneity
We were unable to undertake planned formal investigations of heterogeneity due to insufficient number of studies.
Discussion 
Although in some countries teledermatology services may provide recommendations to allow skin cancer management
(including biopsy or excision) in a primary care setting, in the UK teledermatology consultations for the most part ensure that
people with potentially malignant skin lesions are appropriately referred from a generalist (usually primary care) setting for
specialist assessment and treatment. The primary objective of this review was therefore to assess the accuracy of
teledermatology for the detection of any skin cancer in adults, comparing its accuracy with that of an in-person specialist
diagnosis.
Summary of main results
We included 22 studies: 16 considering the diagnostic accuracy of image-based teledermatology (five in comparison to an in-
person assessment), and six examining the referral accuracy of teledermatology assessment. Key results are presented in
the Summary of findings table 1. The overall risk of bias was rated as high or unclear for participant selection, reference
standard and participant flow and timing in at least half of all studies; the majority were considered at low risk of bias for the
index test. The applicability of study findings were of high or unclear concern for the majority of studies in all domains
assessed due to the recruitment of study participants from secondary care settings or specialist clinics rather than from the
primary or community-based settings in which teledermatology is more likely to be used and due to the acquisition of lesion
images by dermatologists or in specialist imaging units rather than by primary care clinicians.
Seven studies addressed our primary objective of the detection of any skin cancer. For the correct diagnosis of lesions as
malignant, summary sensitivity from four studies using photographic images was 94.9% (95% CI 90.1, 97.4%) and summary
specificity 84.3% (95% CI 48.5, 96.8%). Individual study estimates using dermoscopic images or a combination of
photographic and dermoscopic images generally suggested similarly high sensitivities with highly variable specificities.
Limited comparative data suggested similar diagnostic accuracy between teledermatology assessment and in-person
diagnosis by a dermatologist however data were too scarce to draw firm conclusions.
For the detection of invasive melanoma or atypical intraepidermal melanocytic variants both sensitivities and specificities
were very variable, with reported diagnostic thresholds including the correct diagnosis of melanoma, classification of lesions
as ‘atypical’ or ‘typical as well as the decision to refer or to excise a lesion. For teledermatology using photographic images,
sensitivities ranged from 59% (95% CI 42% to 74%) to 100% (95% CI 54% to 100%) and specificities from 30% (95% CI
22% to 40%) to 100% (95% CI 93% to 100%) in four studies. For teledermatology using both photographic and dermoscopic
images summary estimates for another four studies were 85.4% (95% CI 68.3% to 94.1%) for sensitivity and 91.6% (95% CI
81.1% to 96.5%) for specificity. The number of melanomas missed ranged from 0 to 17.
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Referral accuracy data comparing teledermatology against a face-to-face reference standard was based on a number of
different diagnostic decisions including the diagnosis of malignancy, the decision to excise a lesion, the decision to refer
versus not refer, or to excise or follow-up at a later date. Agreement was generally good for lesions considered to require
some positive action by face to face assessment (sensitivities of over 90%). For lesions considered of less concern when
assessed face-to-face (e.g. for those not recommended for excision or referral), agreement was more variable with
teledermatology specificities ranging from 57% (95% CI 39, 73%) to 100% (95% CI 86%, 100%), suggesting that remote
assessment is more likely recommend excision, referral or follow-up compared to in-person decisions.
Sources of heterogeneity
Across all studies, wide variations in sensitivity and specificity were observed for all definitions of the target condition. Studies
were generally small with varying approaches to teledermatology assessment, including the use of clinical and or
dermoscopic images, use of mobile phone cameras, digital cameras or video images, and varying thresholds for deciding
test positivity. The definition of the target condition also varied such that data for the primary objective could only be
extracted from 7 of the 16 studies assessing diagnostic accuracy, 9 studies reporting data only for the detection of individual
skin cancers. . These factors somewhat limited our ability to pool results across studies and further, to draw conclusions
regarding the accuracy of teledermatology. .
Observed limitations of primary studies
Overall, four key limitations of the studies were observed:
1) the spectrum (or case mix) of different lesion types varied across studies, with a relatively high prevalence of malignant
lesions
Study participants were largely recruited from secondary care settings or from pigmented lesion clinic databases
rather than from primary care or other limited prior testing settings and half of studies assessing diagnostic
accuracy relied on a histological reference standard, i.e. all included participants underwent lesion excision. In
others, accuracy data could be extracted for less than a quarter of lesions assessed at a virtual lesion clinic (Congalton 2015
) or as part of a preventative medical screening programme (Massone 2014). Recruited participants are therefore
more likely to have lesions with a higher index of suspicion of malignancy compared to those for whom a GP might
have considered a teledermatology assessment in practice, thereby limiting the generalisability of study results. These
‘spectrum effects’ are an increasingly recognised concept for medical tests, often leading to lower sensitivity and
higher specificity when applied in settings with participants with limited prior testing compared to participants further
down the referral pathway (Usher-Smith 2016). The direction of effect is not consistent across tests and diseases
however (Leeflang 2013), the mechanisms in action often being complex and sometimes difficult to identify.
2) study definitions of ‘malignancy’ varied and teledermatology results were often not provided according to lesion type
In four included studies, the reported definition of malignancy did not accord with our protocol defined definition, with
studies including melanoma metastases, Bowens disease or ‘in situ cSCC’, actinic keratosis, or severely dysplastic
naevi as ‘malignant’. In some cases, data were reported to allow reclassification of these lesions as disease negative
for at least some of the reported thresholds for test positivity (Borve 2015; Massone 2014), however, for others (Bowns 2006;
Congalton 2015), reclassification of these lesions as disease positive was not possible and these studies could only be
included in our analyses for the detection of individual skin cancers (melanoma or BCC). Other studies had to be excluded
from the review altogether due to varying definitions of ‘malignant’ (e.g. Borve 2013; Manahan 2015a; Tandjung 2015). The
lack of teledermatology results according to lesion type further limited our ability to comment on the implications of missed
malignancies; the failure to pick up a melanoma or cSCC potentially carrying more severe consequences in comparison to a
missed BCC.
3) the definition of a positive teledermatology result varied and was not always relevant to decision making in practice
Of the 16 diagnostic accuracy studies, only three studies reported data for the decision to excise a lesion (one for any skin
cancer and two for the detection of melanoma), and five reported data for teledermatologists’ classification of lesions as
malignant (or probably malignant). Nine of the sixteen studies focused on teledermatologists’ ability to correctly diagnose
lesions as melanomas (n=8) or as BCCs (n=4) which, although of interest, is not the primary factor driving teledermatology
decisions in practice where the key judgement in most circumstances is whether or not a lesion should be referred for a face-
to-face consultation.
4) insufficient comparisons were available for the diagnostic accuracy of teledermatology-based diagnosis and diagnosis
based on a face-to-face dermatology clinic visit
Only five of the 16 studies assessing diagnostic accuracy included a comparison of teledermatology-based diagnosis
with diagnosis based on in-person diagnosis by a dermatologist; two for the detection of any skin cancer (Jolliffe 2001a; 
Kroemer 2011) and three for the detection of melanoma (Jolliffe 2001a; Kroemer 2011; Piccolo 2000). We were
therefore unable to adequately assess whether a teledermatology diagnosis of malignancy accurately reflects a
diagnosis made in-person. The six studies of referral accuracy suggest that diagnosis of individual lesions using
store-and-forward teledermatology could miss around 10% of lesions recommended for clinical action (e.g. surgical
excision) during a face-to-face consultation (even up to 31% in one study) and is also likely to recommend an action
is required for lesions that are considered of less or no concern when seen in-person. In practice, a face-to-face
consultation also allows a total body skin examination which may lead to incidental skin cancers being picked up
which could also be missed by the teldermatology referral of only one or two lesions (Hanson 2016).
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Our systematic review of dermoscopy as an addition to visual inspection of a lesion for the diagnosis of melanoma
found in-person dermoscopy (including 26 studies) to be substantially more accurate compared to diagnosis based on
dermoscopic images (including 60 studies) (RDOR 4.65, 95% CI 2.43, 9.08.5; P<0.0001) (Dinnes 2018b). Despite a
number of contributing factors, including differences in study populations, different algorithms to assist test interpretation
and differences in observer experience, we concluded that remote test interpretation cannot approximate a physical,
face-to-face patient to clinician interaction. In particular, total body skin examination is likely to have a significant impact
on the decision to excise a lesion suspected to be melanoma (Grob 1998; Argenziano 2012; Aldridge 2013). Only
two of the 22 included teledermatology studies mentioned the use of total body photography (Arzberger 2016; Phillips 1998
). It is notable also, that across the 60 image-based evaluations in the review of dermoscopy, half (30/60) were
blinded to all other patient information and only 17 (28%) provided observers with the photographic image of the same
lesion to assist test interpretation (Dinnes 2018b). It is not inconceivable that an image-based assessment with full patient
information provided in the context of a proper teledermatology consultation would provide a closer approximation of the
diagnostic decision that would be made with the patient present.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure was planned to allow test accuracy to be estimated according to varying definitions
of the target condition and a detailed and replicable analysis of methodologic quality was undertaken.
The main concerns for the review are the lack of studies, small sample sizes, heterogeneity in teledermatology assessments,
inadequate reporting of primary studies to allow quality to be fully judged and importantly, the lack of clinical applicability of
the findings due to participant recruitment from, and image acquisition in, referral settings.
In comparison to other available systematic (Ndegwa 2010; Warshaw 2011) and non systematic (Bashshur 2015; Whited
2006; Whited 2016) reviews, our review provides a focus on the triaging or diagnosis of skin cancer as opposed to
the evaluation of teledermatology for any dermatological disorder. The two most recently published reviews either
found evidence generally in support of teledermatology (Bashshur 2015) or suggesting inferior accuracy compared to
in-person assessments for pigmented lesions (Whited 2016). We, on the other hand, were unable to identify sufficient
evidence to establish the diagnostic accuracy of teledermatology in comparison to a face-to-face clinical assessment.
Our reviews of the diagnostic accuracy of visual inspection of suspicious skin lesions for the detection of melanoma (Dinnes
2018a) and of dermoscopy in comparison to visual inspection of a suspicious skin lesion (Dinnes 2018b) suggest that image-
based assessment may not be equivalent to a face-to-face patient: clinician interaction. However, both reviews focused on
the correct diagnosis of melanoma as opposed to any skin cancer, neither included studies that were specifically designed to
evaluate teledermatology programmes and did not examine any effect on accuracy from potential improvements in image
quality over time.
Our a priori decision to exclude studies with fewer than five malignant cases could be construed as a weakness of the
review; however, of the seven studies excluded on this basis, five were also excluded due other reasons such as
inability to construct a 2x2 contingency table or ineligible study populations and one used multiple images of only four
lesions to examine the effect of the positioning of a lesion within an image on clinicians ability to detect it (Chen 2002
). The final study which was excluded only on the basis of sample size reported the effect of adding dermoscopic
images to an existing teledermatology consultation system for 63 lesions fulfilling the criteria for teleconsultation (Moreno-
Ramirez 2006); all three malignant lesions were correctly picked up using both photographic images and with the addition of
dermoscopic images (100% sensitivities) while specificities were 65% and 78% respectively.
We were also unsuccessful in our attempts to contact the authors of 8 of 12 studies which could have been eligible
for inclusion in the review, especially those studies which reported only agreement between observers or
agreement with final lesion diagnoses rather than a providing results in a 2x2 contingency table format.
Furthermore, only partial data was provided to allow the inclusion of one study in the review (Warshaw 2010); the
review would be considerably strengthened if data for teledermatology using dermoscopic images could have been
included. Finally, the review was limited to the identification of skin cancer rather than assessing the potential
additional benefits of teledermatology such as positive identification of benign lesions such as actinic keratosis (Janda 2015).
Ongoing technological advances are continually improving the quality, clarity and colour-rendition of digital images taken with
cameras and mobile phones. The ability to zoom in on new larger image files potentially provides even more detailed
information compared to observation of a lesion with the naked eye alone. Such advances could be of particular help in the
triage of lesions with no distinguishing features (for example for the identification of amelanotic melanomas), the additional
magnification potentially giving subtle clues to aid diagnosis. Although we have documented the equipment used to obtain
images in the included studies we are unable to identify any clear effects from changes in technology.
Our review of the diagnostic accuracy of teledermatology was also unable to evaluate a number of other pertinent factors:
i. the archiving and auditable trail provided by a teledermatology consultation. With conventional face-to-face consultations,
much of the interchange is verbal and unrecorded; for teleconsultation however, every aspect of the referral and diagnostic
opinion are recorded such that it can be reviewed and audited at a later date.
ii. the possibility of ‘crowd-review’ of lesion images. In-person clinical assessment is often conducted by a single clinician,
consultation with other qualified clinicians reserved for more difficult lesions or to support more junior clinicians. The nature of
teledermatology diagnosis lends itself to lesion review by multiple clinicians and to have virtual multidisciplinary review of
cases if necessary.
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iii. changing the referral behaviour of primary care clinicians. The availability of a teledermatology service could result in a
specialist opinion being sought for much earlier presentations of conditions than would normally be the case, which not only
changes the spectrum of lesion types observed by teledermatologists, potentially impacting on their accuracy, but could
ultimately result in over diagnosis and treatment. For example, some lesions identified and either excised or treated
nonsurgically following a teleconsultation might have resolved spontaneously if monitored for longer in primary care, or if
referred for a standard face-to-face consultation. The effect on referral behaviour is likely to be exacerbated where ease of
access to a teledermatology service for a specialist opinion may be preferred by GP trainees to seeking the opinion of a
more experienced GP.
iv. possible over-reliance by GPs and reassurance for patients on a benign diagnosis from a teledermatology consultation.
As with all clinical consultations, a diagnostic opinion from a teledermatology consultation is limited to the quality of the
clinical information provided and the circumstances at the time of consultation. If those circumstances change, for example if
a pigmented lesion diagnosed as ‘benign’ evolves or changes its nature in some way, then that lesion should be reviewed.
‘Safety-netting’ such lesions is an important part of management and monitoring in primary care.
Applicability of findings to the review question
The data included in this review are unlikely to be generally applicable to the intended setting. The majority of studies
recruited participants from secondary care or referral settings rather than from primary care settings where patients are far
less likely to have skin cancer, and potentially suspicious lesions are likely to be earlier in their development and evolution.
Lesion images were often acquired in secondary care rather than being acquired in primary care and transmitted for a
specialist opinion using teledermatology. Considerable heterogeneity in approaches to teledermatology were also observed
limiting generalisability.
Authors' conclusions 
Implications for practice 
Studies were generally small and heterogeneous and methodological quality was difficult to judge due to poor reporting.
Bearing in mind concerns regarding the applicability of study participants and of lesion image acquisition in specialist
settings, our results suggest that teledermatology can be relied upon to correctly identify the majority of malignant lesions.
Using a more widely defined threshold to identify ‘possibly’ malignant cases or lesions that should be considered for excision
is likely to appropriately triage those lesions requiring face-to-face assessment by a specialist.
Implications for research 
Despite the increasing use of teledermatology on a national and international level, the evidence base to support its
ability to accurately triage lesions from primary to secondary care is lacking and further prospective and pragmatic
evaluation is needed. Consecutive series of participants with suspicious skin lesions judged to require a specialist
opinion by GPs should be recruited (i.e. excluding those clearly judged to be malignant or benign) and referred for
store-and-forward teledermatology in comparison to routine referral to a dermatologist. The reason for referral (e.g.
exclusion of melanoma to avoid an urgent or ‘2 week wait’ referral, exclusion of cSCC or BCC, or exclusion of “any
skin cancer”) should be clearly recorded. “State-of-the-art” digital photography should be used (potentially utilising
mobile phone cameras) to allow the full benefit of current technology to be exploited, and compared with smartphone
applications, and systematic follow-up of non-excised lesions implemented to avoid over-reliance on a histological
reference standard. The level of training and experience of both the referring and specialist clinicians should be
explicit to allow the generalisability of results to be judged. Any future research study needs to be clear about the
diagnostic pathway followed by study participants, and should conform to the updated Standards for Reporting of
Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
Due to the small number of studies available, a single review has been produced that evaluates the accuracy of
teledermatology in all skin cancers; this replaces the two reviews intended in the protocols to separately address cutaneous
melanoma and keratinocyte cancers.
Primary objectives and primary target condition have been changed from detection of cutaneous invasive melanoma alone
and detection of BCC or cSCC as per the two protocols, to the detection of any skin cancer, as the appropriate triage of any
malignant skin lesion to specialist care is the key issue for teledermatology. The detection of the target condition of invasive
melanoma alone has instead been included as a secondary objective.
Heterogeneity investigations and sensitivity analyses were limited by the data available.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.,
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis, restriction
to analysis of per patient data was not performed due to lack of data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Arzberger 2016
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: May to Oct 2009
Country: Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Study participants with at least one
of the following factors associated with moderate-to-
high risk of melanoma: (i) personal or first-degree
relative history of melanoma; (ii) history of dysplastic
naevi; (iii) > 5 atypical naevi; (iv) > 100 naevi; (v)
lesion suspicious for melanoma were included in the
study
Setting: Specialist Clinic (Pigmented Skin Lesion
Clinic Medical Univeristy of Graz)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. eligible: 70; No.
included: 20
Sample size (lesions): No. eligible:1922; No.
included: 23
Participant characteristics: 
Age (yrs): Range: 11-81; Gender: Male: 35, Female
35
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: After clinical examination patients had total body photography
performed by a by an experienced dermatology nurse or dermatology resident (took on the role of a
"melanographer"), images were taken using the MoleMap program , without regard of the decision
made at the FtF examination. Without regard to the medical decision resulting from the F2F
evaluation, the melanographer acquired body-sector photographs (Nikon D40 and D50 digital SLR,
Nikon Corporation Tokyo, Japan) and photographs of selected skin lesions were those that were: "(i)
highly suspicious; (ii) concerning; (iii) changing and/or different; (iv) > 3 mm; (v) itching, bleeding,
inflamed; or (vi) suspicious for basal cell carcinoma (BCC) or squamous cell carcinoma". Selected
lesions had a close-up macroscopic and a dermoscopic image taken. Images were then uploaded to a
centralized server in New Zealand, which was accessible to the participating TDs.
Nature of images used: clinical and dermoscopic
Any additional patient information provided: total body images
Observer qualifications (remote diagnosis); Dermatologists (experts in dermoscopy)
Diagnosis based on: Single observer
Number: 4
Method of diagnosis: Four remote teledermoscopy experts evaluated the total body images and
dermoscopic images, and gave a recommendation for each lesion
Management options(diagnostic threshold): The recommendations for management included: “self-
monitoring”, “short-term monitoring” and “excision”
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histology
Details: Histology (excision) 
Lesions were selected for excision after conventional F2F
total body and dermoscopic examination of all lesions,
performed by an individual dermatologists with expertise
in the assessment of pigmented lesions.
Histopathological examination of excised lesions was
performed at the Dermatopathology Laboratory at the
Medical University Graz, Graz, Austria
- No. patient/lesions: 23
- Disease positive: 9
- Disease negative: 14
Target condition (Final diagnoses) 
- Melanoma (invasive): 8
- Melanoma (in situ): 1
- BCC: 2
- Other: 12 melanocytic nevi
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
50 patients were excluded from the final analysis (48
patients were discharged with the recommendation to
do monthly self-skin examination and 2 patients were
followed up)
20 patients had their lesions excised (included in the
final analysis)
The interval between index test and reference
standard is not clearly reported, however it appears to
be simultaneously
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-up
following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
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Notes -
 
Borve 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Jan 2011-Dec
2012
Country: Sweden
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All patients over 18 years of age
with one or more skin lesions of concern requiring
referral to a dermatologist were eligible for inclusion
in the study using the TDS referral system.
Setting: Primary this is where patients were
recruited, (20 primary healthcare centres (PHCs) in
western Sweden);
Prior testing: N/A
Setting for prior testing: N/A
Exclusion criteria: Excluded patients were those who
did not fulfil the inclusion criteria, did not attend the
face-to-face (FTF) visit(s), did not comply or if their
skin lesions were located on a body part that could
not be photographed.
Sample size (patients): No. eligible: 902; No.
included: 816
Participant characteristics:
Age (yrs): mean = 54 years (range 18-93 years)
Gender: Females n = 474 (61.3%))
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: For all eligible participants, GPs used the smartphone TDS
referral system. The GP took one clinical and one dermoscopic image using an iPhone 4 with a
FotoFinder Handyscope app, alongside this a standardised query form is filled out including all the
relevant clinical information. This is then sent through a secure web-based TDS platform (Tele-Dermis)
with a secure socket layer encryption. Simultaneously the participating dermatologists are sent an
email that a new referral is ready for assessment.
Nature of images used: clinical photographs and dermoscopic images
Any additional patient information provided: clinical information
Diagnosis based on: Single; number of examiners 4
Observer qualifications (remote diagnosis): Dermatologist and Dermatology resident (3 specialists in
dermatology and one resident in dermatology)
Method of diagnosis: The dermatologists logged onto the Tele-Dermis® platform to review the referrals
on an17- or 19-inch liquid crystal display monitor. They chose from standardised triage responses
including an assessment of the nature of the lesion (benign, malignant or unclear), one or more
possible diagnoses, the priority given (high, within 2 weeks; medium, within 4 weeks or low, within
8–12 weeks), suggested management (none, medical therapy, destructive therapy or surgery) and,
finally, a dermoscopic description.
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Histological plus expert diagnosis
Histology: (n=551)
Details: All MMs and SCCs (keratoacanthomas were
classified as SCCs) were confirmed histopathologically.
The final diagnosis was confirmed histopathologically in
292 TDS referrals (36%) and 259 paper referrals (35%)
Expert diagnosis (face to face diagnosis at Dermatology
clinic) (n=265)
Method of diagnosis: Dermatologists used dermoscopy to
evaluate the study lesions and also carried out full body
skin examination
Prior test data: All relevant clinical information (FTF visits
were not blinded to the results of the teledermoscopists)
Diagnostic threshold: Not reported
Diagnosis based on: Single
Number of examiners: Not reported
Observer qualifications: Dermatologists (Specialists in
dermoscopy)
Experience in practice: High
Experience with index test: High
#
Target condition (Final diagnoses) 
Malignant: Malignant melanoma: 19 (2.3%); Melanoma in-
situ: 16 (2.0%); Squamous cell carcinoma: 17 (2.1%);
Squamous cell carcinoma in situ: 7 (0.9%); Basal cell
carcinoma: 109 (13.4%); Actinic keratosis: 61 (7.5%);
Other malignant: 0
Benign: Dysplastic nevi: 89 (10.9%); Benign naevus: 236
(28.9%); Seborrhoeic keratosis: 125 (15.3%); Other
benign: 137 (16.8%)
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
1. Excluded participants: None reported
2. Time interval to reference test: All patients
were called to attend a FTF visit at the
corresponding department of Dermatology. A
suspicion of MM or SCC was triaged within 2
weeks. After the triage process, all patients were
managed according to standard protocols at the
hospitals independently of the referral method.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Bowns 2006
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Not reported
Country UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients (with skin lesions) who were
either referred to the 2-week wait or ‘target’ clinics, or
those initially referred to the normal outpatient service
but who were diverted by the consultant on the basis of
the referral form.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic):
Prior testing: - Clinical and/or dermatoscopic suspicion
(Not clearly described, but all referred with certain
degree of concern based on referral to 2-week wait or
urgency graded by consultant based on referral letter)
Setting for prior testing: Primary
Exclusion criteria: Not reported
Sample size (patients): Not reported but < 256 as a
number of patients were referred for > 1 lesion, all
treated as independent
Sample size (lesions): No. eligible: 267; No. included:
256
Participant characteristics: Not reported
Age (yrs): Broken down by age band; 61% were aged
over 55
Gender: Male: 46.9%
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: lesion images were taken at the Medical Photography Unit
(equipment not described) before an outpatient appointment with a dermatologist using both normal
photographic methods and a dermatoscope.
Nature of images used: Clinical and Dermoscopic
Any additional patient information provided: Initial referral forms or letter provided
Method of diagnosis: An independent dermatologist assessed the photographs and gave their most
likely diagnosis and level of confidence in the diagnosis. They also gave an opinion on whether the
lesion was malignant and a recommendation on whether they would wish to see the patient.
Diagnosis based on: Single observer
Number of examiners: 3 consultants
Observer qualifications (remote diagnosis): Dermatologist (experience not reported)
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis plus other
Details: Histology was undertaken in 164 cases,
including 78/85 malignant cases and 86/171 benign
cases (50.3%)
Face to Face diagnosis/Expert opinion 
- Details: final diagnoses for 92 lesions reached by FtF
decision only (visual inspection +/-use of dermoscopy
(not specified)), including 7/85 malignant ('mainly with
diagnoses of BCC or Bowen’s disease') and 85/171
benign cases
Number of examiners: 7 consultant dermatologists
Experience in practice: Not reported
Experience with index test: Not reported
Target condition (Final diagnoses as per expert
clinical diagnosis and histology) 
-Malignant: Melanoma (invasive): 19 - Melanoma (in
situ): 5; - BCC: 29; - cSCC: 16; - Other malignant: 1
Benign: Severe dysplasia: 3; - Sebhorrheic keratosis:
70; - Benign naevus: 64; - 'Benign' diagnoses: 9
Bowen's/in situ SCC; 15 solar keratosis; 25 other
benign
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: 11 excluded - Wrong
lesion imaged (n=7), Histology already
undertaken (n=3), Image file lost (n=3)
2. Time interval to reference test: Medical
photographs were taken immediately prior to
face to face consultation. Reference diagnosis
was based on face to face with or without
histology. Time to histology not reported
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
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Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Congalton 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: 1st April 2012 to
31st of March 2013
Country: New Zealand
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All patients referred from primary
care with skin lesions suspicious for melanoma
triaged via a virtual lesion clinic (VLC) instead of
being seen face-to-face at a hospital clinic. Referrals
that indicated 1–6 lesions of concern were included.
Setting: Secondary (general dermatology) and
Private care
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Primary
Exclusion criteria: Difficult to diagnose lesions--
location/site of lesion skin lesions on scalp and
genitals were generally excluded, as were those
where body site was not clearly identified in the
referral.
Sample size (patients): No. eligible: 345; No.
included: 310
Sample size (lesions): No. included: 613
Participant characteristics: 
Age (yrs): Median: 58; Range: 15-92
Gender: Male: 142; Female 168
Race/Ethnicity (%): White: 242 (78%); Black or
African American: 12 (4%); Hispanic or Latino: 3
(<1%); Asian: 16 (5%); Other: Maori - 16 (5%)Pacific
islanders - 12 (3%); Missing: 12 (4%)
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: Patients attended two imaging clinics run by a private
teledermatology company (MoleMap NZ). Total body photography not offered. Macroscopic and
dermoscopic images were captured using a Canon G6 camera or MoleCam; regional anatomic views
captured using Nikon D3100. Information on the referred lesions such as whether the patient had
noticed any changes in size, colour, bleeding and itching was recorded. Hair and eye colour, skin type,
previous history of sun exposure and family/personal history of skin cancers were also captured. Files
were archived using proprietary software (MoleMap NZ) and uploaded to a secure server via a virtual
private network.
Nature of images used: Clinical and dermoscopic images
Any additional patient information provided: Patient details
Diagnosis based on: Single observer
Number of examiners 2
Observer qualifications (remote diagnosis): Dermatologist
Method of diagnosis: Using the MoleMapDiagnose software, two experienced dermatologists reviewed
patient details and images remotely, making a diagnosis and suggesting management.
Management options(diagnostic threshold): options included: "(i) specialist assessment or excision of
the lesion; (ii) re-imaging in 3-months’ time to detect change (e.g., atypical naevus without criteria for
immediate excision); (iii) discharge to care of general practitioner (GP) e.g., for cryotherapy or topical
therapy; (iv) self-monitoring and (v) lesion of no concern."
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard?
If a threshold was used, was it pre-specified?
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner?
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Was the test interpretation carried out by an experienced examiner?
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histology alone; 129 lesions
were excised; 123 considered suspicious for
malignancy on teledermatology. 5 considered benign
and 1 'undiagnosable',
Target condition (Final diagnoses as per expert
clinical diagnosis and histology) 
- Melanoma (in situ and invasive, or not reported): 48
- Other malignant: NMSC=45
- 'Benign' diagnoses: 32
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: One patient was
excluded from further analysis because he
attended the VLC after the referred lesion had
been excised;A further 484 lesions assessed
a the virtual lesion clinic but with no final
diagnoses reported cannot be included.
2. Time interval to reference test: Medical
photographs were taken immediately prior to
face to face consultation.
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Unclear
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other
index tests or testing strategies?
Was the interval between application of the index tests less than one month?
Are there any concerns that the test comparison could have introduced bias?
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner?
Are there concerns that the test comparison differs from the review question?
Notes
Notes -
 
Coras 2003
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection 16 month period.
Does not say the date
Country Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented skin lesions undergoing
excision due to diagnosis of melanoma or atypical nevus,
to rule out melanoma or at the patient's request
Setting: Secondary (general dermatology)
(teledermatoscopy diagnosis); Private care- Face to face
diagnosis
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 90; No. included: 45
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
In person assessment (for those comparing FtF vs histology)
Method of diagnosis: Participating dermatologists with experience in dermatoscopy established a
clinical diagnosis based on pattern analysis after personal consultation with the patient in their private
practice clinics.
Prior test data: Not reported
Diagnostic threshold: Not reported
Diagnosis based on: Single
Number of examiners: 3
Observer qualifications: Dermatologist (experts with great experience in dermoscopy)
Experience in practice: High
Experience with index test: High
#
Teledermatology
Acquisition and transmission of images: Each of the participating dermatologists acquired digital
images after face to face consultation using the same technical equipment (Dermogenius ultra - hand-
held CCD camera with pixel size 512x512), and sent them via an email attachment with corresponding
patient data and medical history.
Nature of images used: Clinical photographs and dermoscopic images
Any additional patient information provided: Clinical examination and/or case notes
Observer qualifications (remote diagnosis): Physician experienced in dermatoscopy
Diagnosis based on: Single observer
Method of diagnosis: A physician evaluated the images and made a diagnosis based on the images
and history of the patient
Other detail: The participating dermatologists used the same technical equipment for the acquisition of
digital images.
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histology
Details: The histological diagnosis of majority
of cases was performed at the Department of
Dermatology Regensburg
Target condition (Final diagnoses) 
- Melanoma (in situ and invasive, or not
reported): 16
- 'Benign' diagnoses: 29
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: They reported that
many images were of poor quality (10) and that
only 45 biopsies were done 50 patients who did
not have histology excluded
2. Time interval to reference test:Unclear
3. Time interval between index test(s): most
likely days (email transmission of images for
remote assessment).
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Each of the participating dermatologists who
conducted a face to face clinical diagnosis
acquired digital images of the lesion, and send
them via an email attachment with corresponding
patient data and medical history.
Was each index test result interpreted without knowledge of the results
of other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one
month? Unclear
Are there any concerns that the test comparison could have introduced
bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes
Are there concerns that the test comparison differs from the review question? Lowconcern
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Notes
Notes -
 
Ferrara 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Not reported
Country Not reported; likely Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Pigmented melanocytic lesions
with dermoscopic images (a single image per case)
and accompanying histological material were
retrieved; approach to lesion selection was not
described.
Setting: Unspecified
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 12
Participant characteristics: 10 males and two
females, aged 14–79 years (median 41).
Lesion characteristics: Seven lesions had been
removed from the trunk, four from the limbs and one
from the face. The lesions ranged in size from 4 mm
to 14 mm in diameter (median 6 mm).
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: Dermoscopic images were either acquired on film
(Dermaphot) and then digitized (n=8) or were acquired directly from a digital camera (n=4); (MoleMax
or Videocap) photographic images were also available in 9/12 cases.
Nature of images used: - dermoscopic images
Any additional patient information provided: Clinical examination and/or case notes
Observer qualifications (remote diagnosis): Dermatologist
Diagnosis based on: Single observer
Number of examiners: 3
Method of diagnosis: Stored images were viewed on a standard-resolution colour monitor by 3 remote
consultants in a single session; the teledermoscopy diagnosis (melanoma or other lesion type) was
recorded by a single consultant (GA), followed by a teledermatopathology diagnosis (by LC based on
histological image). The original histological diagnosis from the consultation file was then presented
(by GF, apparently along with the original clinical diagnosis). “Dermoscopic–pathological remarks”
were made (by HPS) and finally a consensus diagnosis was reached by two consultants (LC and
HPS); the latter was taken as the ‘gold standard’ for the study
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis alone
Details: Twelve cases with dermoscopic images (a
single image per case) and accompanying histological
material were retrieved from consultation files. The
conventional histopathology diagnosis was regarded as
the gold standard: a consensus diagnosis between two
consultants was requested in order to minimize any
influence of the
previous dermatopathology diagnosis
Target condition (Final diagnoses) 
- Melanoma (in situ and invasive, or not reported): 7
- Invasive melanoma-4, Melanoma in-situ-3,
'Benign' diagnoses: 5, Junctional nevus 1; Reed naevus
1; Blue naevus 1; Actinic lentigo 1; Spitz naevus 1
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
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B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: Not reported
2. Time interval to reference test: images
taken at time of FtF consultation; interval to
excision NR
3. Time interval between index test(s): Not
reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Grimaldi 2009
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Oct 2005 - Mar
2006
Country Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
#164f The use of teledermatology for the diagnosis of skin cancer in adults
39 / 167
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Cutaneous pigmented lesions with
digital images forwarded by primary care physicians
to a referral centre for confirmation of diagnosis.
Setting: Primary (Lesions selected for referral by
GPs; accuracy of GP diagnosis assessed);
- Secondary (general dermatology); Telediagnosis
by expert observer also assessed
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Lesions whose removal had been
explicitly demanded by the patients for aesthetic
reasons, as well as those irritated or subjected to
trauma
Sample size (patients): No. included: 197
Sample size (lesions): No. included: 235
Participant characteristics: Not reported
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
In person face to face clinical assessment by GP not included in this review
Teledermatology
Acquisition and transmission of images: Images acquired by PCPs using Konica Minolta
Dimage Z10 digital cameras (zoom 0, automatic setting, macro off, flash off) coupled with 3Gen 37
mm dermoscopes (with annular white LED lamp). All PCPs involved in the programme were asked not
to start any therapy, but to send the images acquired to the reference centre first. All photographed
lesions were uploaded from the peripheral units to the central research unit for telediagnosis with only
a two-step judgment (before and after dermoscopy) formulated by the sending physician.
Nature of images used: Clinical photographs; Dermoscopic images
Any additional patient information provided: Unclear
Observer qualifications (remote diagnosis);Dermatologist; Plastic surgeons
Number of observers: unclear
Experience in practice: High experience or ‘Expert’
Experience with index test: Not described
Method of diagnosis: Unclear but telediagnosis may also have followed ABCD, study states "after
second appraisal of the images received made by the reference unit) the appropriate guidelines for
every case, established in relation to the formulated and controlled diagnosis...When the diagnosed
lesion was considered as ‘needing control’ by the medical staff of the reference centre, the patient was
included in a periodic observation programme, according to which images of the lesions were recorded
and compared at set intervals, according to a protocol If the cutaneous lesion was judged as ‘needing
surgery’ the therapeutic programme (radical removal, sentinel lymph node biopsy, reconstructive
surgery, other therapies) was carried out at the Plastic Surgery Unit of the University of Siena in all
cases, after verification of the digital images and checks on the patient"
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis plus
follow up
Details: Two hundred and nineteen benign lesions
were investigated by dermoscopic follow up (after 2,
4 and 6 months) in the peripheral centres, and in all
cases the diagnosis was confirmed (no clinical
change) by telediagnosis from the main centre.
These cases were subsequently controlled at regular
6 month follow-up checks. Sixteen lesions were
labelled as ‘to be removed’ at the final check.
Histology (not further described) No. patients/lesions:
16; Disease positive: 5; Disease negative: 11
Clinical FU plus histology of suspicious lesions
Length of FU: 6 months
- No. patients: 219; Disease positive: 0; Disease
negative: 208
Target condition (Final diagnoses) 
- Melanoma (in situ and invasive, or not reported): 5
- Other: 230 benign
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
1. Excluded participants: Not reported
2. Time interval to reference test: Not
reported
3. Time interval between index test(s): All the
digital images from the peripheral centres
(235 lesions) were forwarded to the
reference centre in real time
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other
index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes
Are there concerns that the test comparison differs from the review question? Lowconcern
Notes
Notes -
 
Jolliffe 2001a
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection Not reported
Country UK
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients referred by their GP for
dermatological assessment of a pigmented lesion at the
Pigmented Lesion Clinic
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: not explicitly mention but most likely clinical
examination
Setting for prior testing: Primary
Sample size (patients): No. eligible: 138; No. included:
138
Sample size (lesions): No. eligible: 144 No. included:
144-clinical diagnosis 140-telederm
Participant characteristics: 
Age (yrs): - Range: 15-94 years
Gender: - Male: 48 (34%) ; Female 90 (66%)
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
In person face to face clinical assessment
Method of diagnosis: At the Pigmented Lesion Clinic a clinical diagnosis (+/- the use of dermoscopy)
based upon information in the referral letter and examination findings was made and recorded by the
examining doctor
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported
Diagnosis based on: Single
Number of examiners: 1
Observer qualifications: Dermatologist
Experience in practice: Unclear
Experience with index test: Unclear
#
Teledermatology
Acquisition and transmission of images: The examining doctor using a single chip video camera,
obtained an image of the pigmented lesion. The image was then archived using proprietary software
and images were transmitted through a Fast Screen Machine2 video overlay card and viewed on a 15
inch monitor.
Nature of images used: Clinical
Any additional patient information provided: Clinical examination and/or case notes
Observer qualifications (remote diagnosis);Dermatologist
Diagnosis based on: Single observer
Number of observers:1
Method of diagnosis: The anonymous video images and the general practitioner's referral letter were
then viewed several months later by the same doctor who performed the in-person assessment and a
diagnosis made.
Management options: Not reported
Teledermatology
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis alone
Lesions had been excised either to confirm or refute
clinical suspicion of malignancy or atypia. No patient
had a lesion removed on account of the study
Target condition (Final diagnoses) 
Malignant 
- Melanoma (in situ and invasive, or not reported): 2;
Lentigo maligna: 2; BCC: 9
Benign diagnoses
Atypical naevus: 5; Benign melanocytic naevus: 89;
Seborrhoeic keratosis: 9; Solar lentigo: 7; Blue
naevus: 4; Freckle: 2; Spitz naevus: 2; Dermoid cyst:
2; Pyogenic granuloma: 2; Congenital naevus: 1;
Naevus sebaceous: 1; Dermatofibroma: 1;
Haemangioma: 1; Abscess: 1; Nodular hidradenoma:
1; Noncaseating granuloma: 1; Apocrine
hidrocystoma: 1; Angiokeratoma circumscriptum: 1
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
1. Excluded participants: In four cases it was
impossible to make a diagnosis from the
image, due to poor image quality.
2. Time interval to reference test: Not
reported
3. Time interval between index test(s): The
same doctor viewed the images several
months after examining the patient in clinic
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
The anonymous video images and the general
practitioner's referral letter were then viewed
several months later by the same doctor and a
diagnosis made.the same doctor who performed
the clinical examination viewed the images. The
doctor's potential memory of a lesion may
therefore be perceived to be a source of bias. In
reality over 800 pigmented lesions had been
seen by this doctor between the in-person and
video examinations, making memory of a specific
lesion less likely.
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one
month? No
Are there any concerns that the test comparison could have introduced
bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes -
 
Jolliffe 2001b
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Not reported
Country: UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: All patients referred to the dermatology
departments of the Royal Free Hospital or the
Whittington Hospital during the study period by their GPs
for assessment of a pigmented lesion
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: GP referral for dermatological assessment
at a Pigmented Lesion Clinic
Setting for prior testing: Primary
Exclusion criteria: None reported
Sample size (patients): No. included: 611
Sample size (lesions): No. included: 819
Participant characteristics: 
Age (yrs): Range: 8 to 94 years
Gender: Male: 196 (24%); Female 90 (66%)
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: lesion images were taken by the examining doctor using a
single-chip video camera; images were viewed on a 15-inch monitor and stored as JPEG files with
minimum compression; overhead artificial illumination was used throughout and the best image used if
a series were taken.
Nature of images used: Clinical
Any additional patient information provided: Clinical examination and/or case notes
Observer qualifications (remote diagnosis);Dermatologist
Diagnosis based on: Single observer
Number of observers: 3
Method of diagnosis: images were viewed several months later alongside GP referral information
independently by all three doctors.
Management options: The clinician made a decision whether a lesion warranted a referral or not on
the basis of the image and referral information.
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Expert diagnosis (face to face
diagnosis at Dermatology clinic)
Details: Participants were seen in clinic by a registrar or
one of two consultant dermatologists. Following history
taking and clinical examination, a treatment plan was
formed (reassure, review with photograph or biopsy
lesion) and clinical diagnosis recorded. Clinical diagnoses
were then grouped into lesions `not to be missed' (i.e.
reference standard positive) including “malignant
melanoma, basal cell carcinoma (BCC), atypical naevus,
keratoacanthoma and pyogenic granuloma (owing to the
potential clinical confusion with amelanotic melanoma)”
and benign lesions (i.e. reference standard negative),
including benign melanocytic naevus, seborrhoeic
keratosis, congenital naevus, dermatofibroma, solar
lentigo and actinic keratosis.
Target condition (Final diagnoses as per expert clinical
diagnosis) 
Disease positive: Melanoma (invasive): 9; BCC: 19;
Lentigo maligna 1
Disease negative: Sebhorrheic keratosis:152; Benign
melanocytic naevus 361; Postinflammatory
hyperpigmentation 2; Blue naevus 2; Atypical naevus
112; Nail infection 2; Congenital naevus 27; Haematoma
2; Dermatofibroma 25; Eczema 2; Solar lentigo 23;
Keratoacanthoma 1; Foreign body 1; Angioma 18;
Abscess 1; Actinic keratosis 13; Spitz naevus 1;
Fibroepithelial polyp 11; Dermoid cyst 1; Viral wart 10;
Apocrine hidradenoma 1; Chloasma 1; Comedone 5;
Cutaneous horn 1; Dermatosis papulosis nigrans 4;
Congenital arteriovenous malformation 1; Naevus
sebaceus 4; Psoriasis 1; Scar/fibrosis 3; Spider naevus 1;
Pyogenic granuloma 2
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Patients had the FtF consultation first before
having their lesions images. The images were
then viewed several months later in conjunction
with the GP's referral information by all three
doctors independently.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application
of index test(s) of at least: 3 months for melanoma or cSCC or 6 months
for BCC?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Kroemer 2011
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Not reported
Data collection: Prospective
Period of data collection: Reports "a 3
month period" - no dates mentioned
Country: Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients self-referred or referred by a
local doctor for evaluation of a skin tumour.men or women
with benign and/or malignant skin tumours of melanocytic
or nonmelanocytic origin.
Setting: Secondary (general dermatology) Medical U of
Graz, Austria. Dept of Derm
Prior testing: Clinical suspicion of malignancy without
dermatoscopic suspicion; Patient request for
evaluation/excision physician or self referral
Setting for prior testing: Primary; all patients were self
referred or referred by a local doctor
Exclusion criteria: None reported
Sample size (patients): No. eligible: 88; No. included: 80 of
88
Sample size (lesions): No. eligible: 113 lesions; No.
included: They report 104 of 113 tumours of 80 of 88
patients were tele-evaluated. If you add all in table 1, you
get more than 113 (there were up to 3 (total 322) clinical
and 3 dermoscopic (total 278) images).
Participant characteristics: 
Age (yrs): Mean: missing; Median: 69; - Range: 3-93
Gender: Male: 41/88 available. Not stated who withdrew;
Female 47/88 were available. Not clear who remained
Race/Ethnicity (%): Missing: not stated, but they are
Austrian
Lesion characteristics Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
In person face to face clinical assessment
Method of diagnosis: Not clear from paper how in-person assessment was conducted but most likely
visual inspection of the skin (+/- use of dermoscopy) no algorithm described
Prior test data: unclear
Diagnostic threshold: unclear
Diagnosis based on: single
Number of examiners: unclear
Observer qualifications: not reported
Experience in practice: not reported
Experience with index test: not reported
#
Teledermatology
Acquisition and transmission of images: Lesions were selected during the outpatient visit and up to
three clinical (autofocus mode) and dermoscopic images (macro mode) images were obtained by the
clinician using a mobile phone with a built in mega-pixel camera (for clinical photos) (Nokia N73 with a
built-in 3.2-megapixel camera; Nokia, Helsinki, Finland) with the addition of a pocket dermoscopy
device attached to the camera lens for dermoscopic images (DermLite II PRO HR; 3Gen LLC, Dana
Point, CA, U.S.A.). Images were stored in JPEG format and saved on a computer USB port. Clinical
and dermoscopic datasets of each lesion together with relevant clinical information (age, sex, tumour
onset, location and patient history) were separately transmitted via a virtual private network for online
consultation
Nature of images used: Clinical photographs and Dermoscopic images
Any additional patient information provided: Clinical examination and/or case notes relevant clinical
information
Observer qualifications (remote diagnosis); Dermatologist (board certified with clinical expertise in
teledermatology and dermoscopy)
Diagnosis based on: Single observer; n = 1
Method of diagnosis: A board-certified dermatologist (H.P.S.) with clinical expertise in teledermatology
and dermoscopy reviewed each set of clinical and dermoscopic images separately. The lesions were
grouped into four diagnostic categories (benign melanocytic, benign nonmelanocytic, malignant
melanocytic and malignant non-melanocytic skin tumours). The teleconsultant based on this then
recorded one primary and one differential diagnosis
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
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Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis and
Expert diagnosis
Details: Histopathology was used as the gold
standard in 78/104 (75%), including for 32/58 benign
lesions (55%) . According to ethical principles and to
the standards of routine practice, the clinical and
dermoscopic face-to-face (FTF) diagnoses were
considered adequate in those patients with clinically
and dermoscopically benign and nonsuspicious
lesions (i.e. 44% of benign group), and no biopsy
procedure was performed.
Target condition (Final diagnoses) 
Malignant
- Melanoma (invasive): 2, Melanoma (in situ): 1, BCC:
30, cSCC:10, Lentigo maligna: 3
Benign
- Sebhorrhoeic keratosis: 6, Actinic keratosis: 17,
Bowen's disease 1, Benign naevus:15, Other: Soft
tissue tumour 4, angioma 4 , solar lentigo 3, virus
induced tumour 1, trichilemmoma 0, and other 7
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge of
the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: 3 patients declined
participation. In 33% of cases, no history could
be obtained. 2 clinical and 18 dermoscopic
pictures were inadequate, so 104 tumours
from 80 patients were included
2. Time interval to reference test: It does not
state
3. Time interval between index test(s): It says
there was a month delay between clinical and
dermoscopic telederm picture evaluation
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
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A. Risk of Bias
Comparative
There was a month delay between face to
face assessment and clinical and dermoscopic
telederm evaluation
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one month?Yes
Are there any concerns that the test comparison could have introduced
bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes -
 
Mahendran 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: no dates, but over
18 months
Country: UK
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with a suspicious skin
lesion seen by their local GP, had to have a lesion
worthy of dermatologist assessment, had to be
willing to have photographic images taken of the
lesion, had to be willing to see a dermatologist
outpatient
Setting: Primary this is where patients were
recruited; Secondary (general dermatology) This is
where the final diagnosis was made
Prior testing: Clinical suspicion of malignancy
without dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: 15% Poor quality index test image
Sample size (patients): No. included: unclear
Sample size (lesions): No. included: 106
Participant characteristics: None reported
Lesion characteristics Not reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: GPs took images of suspicious skin lesions using a digital
camera (Nikon Coolpix 950 digital camera (1200 x 1600 pixel resolution), the photograph together with
all the relevant history and details about the skin lesion were sent via email to the dermatology
department
Nature of images used: Clinical photographs
Any additional patient information provided: Past history; dermographics, site of lesion
Observer qualifications (remote diagnosis); Dermatologist (Consultant dermatologists)
Diagnosis based on: Single observer (diagnosis made by one of 2 consultants)
Method of diagnosis: The remote observer gave a diagnosis or differential diagnosis plus a
hypothetical management plan where possible.
Management options: Management options included reassuring the patient, minor operation, no action
but further review appointment required
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Expert diagnosis (face to face
diagnosis at Dermatology clinic)
Details: All of the patients were subsequently seen in the
dermatology outpatient clinic by one of the same two
consultants within 2 weeks and the clinical diagnosis and
actual management plan were recorded; lesions also
seen FTF by a trainee dermatologist (specialist registrar
year 3) ‘blinded’ to the consultants’ reports but the 2x2
data appear to be for the consultant FTF assessment
Target condition (Final diagnoses) 
Malignant 
- Melanoma (invasive): 4, BCC: 37, cSCC 4
Benign diagnoses
- AK 10, Bowen's 7, SC 4; Lentigo maligna 1; - atypical
dysplastic nevi 6; Sebhorrheic keratosis: 27; Benign
naevus: 20; Other: dermatofibroma 11; Inflammatory
dermatoses 8; Haemangioma 3; Scar 3; Viral wart 3;
Cellular naevus 2; Chondrodermatitis nodularis helices 2;
Congenital naevus 2; Dilated pore of Winer 2; Lesion
resolved 2; Squamous papilloma 2; Blue naevus 1; Halo
naevus 1; Lichenoid keratosis 1; Myxoid cyst 1; Pressure
sore 1; Pyogenic granuloma 1; Sebaceous gland
hyperplasia 1
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without
knowledge of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: 57 ‘excluded’ as
could not be managed by TD and no FtF
decision given; either insufficient quality for
assessment (n=24) or need to see in clinic to
make a decision
2. Time interval to reference test: within 2
weeks
3. Time interval between index test(s): not
stated
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Yes
Could the patient flow have introduced bias? High risk
Comparative
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A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Manahan 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: Australia
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Participants aged 50–64 years at
high risk of melanoma (fair skin type, previous skin
excisions, personal or family history) recruited via the
'QSkin' study (500/43,794 participants were mailed
an invitation to participate; plus volunteers who
requested participation (n=59) after learning about
the study via university websites or in the local news.
Only those with a suitable smartphone could
participate. Participants instructed to submit "photos
of moles or spots that they ‘did not like the look of’",
and were given instructions about how to select
lesions based on asymmetry and colour.
Setting: Community
Prior testing: None
Setting for prior testing: N/A
Exclusion criteria: No smartphone
Sample size (patients): 500 (invited) plus 58
volunteers; Of the 230 who completed the
questionnaire, the first 58 who expressed interest
and had a suitable smartphone were enrolled. 50
attended for FtF skin examination, 1 of whom was
later excluded
Sample size (lesions): 341 lesions included; 309 with
a primary teledermatology diagnosis
Participant characteristics: 
Age (yrs): 50 to 64 yrs; Gender: 49% male; Other:
31% with first-degree family member with melanoma
and 90% self-reported a fair
skin type
Lesion characteristics: Back 106 (34%);
Chest/abdomen 57 (18%); Legs 56 (18%); Arms 46
(15%); head/neck 44 (14%)
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
#164f The use of teledermatology for the diagnosis of skin cancer in adults
55 / 167
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: Study primarily aimed to evaluate skin self-examination (SSE)
(participants randomised to receive 10-step guide to SSE) and mobile teledermatology. All participants
used Handyscope FotoFinder dermoscope smartphone attachment (FotoFinder Systems GmbH, Bad
Birnbach, Germany) and Handyscope app, to obtain and send magnified lesion image along with a
second clinical (macro) image to verify the anatomical site of each skin lesion.
Nature of images used: Clinical and dermoscopic
Any additional patient information provided: 
Diagnosis based on: Single observer
Number of examiners: n=1
Observer qualifications (remote diagnosis): Board certified dermatologist, experienced in
teledermatology
Method of diagnosis: Unclear; method of viewing images not reported. Dermatologist indicated
whether the photograph was suitable to provide a diagnosis before making management
recommendation.
Management options: primary diagnosis, with up to two differential diagnoses (cannot extract 2x2),
and whether clinical skin examination (FtF) was required (Action).
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Face-to-face expert diagnosis
(referral accuracy)
Details: Clinical skin examination performed by a
dermatology registrar under supervision of the
dermatologist who undertook the telediagnosis.The
same management options were recommended in the
FtF consultation
Target condition (Clinical diagnoses FtF) 
Malignant: BCC 13; SCC/IEC 1
Benign: Atypical naevus 4; benign naevus 165; solar
lentigo 22; Sebhorrheic keratosis 81. Non-pigmented:
actinic keratosis 34; dermatofibroma 2; other 18
Recommendation to see FtF (ref standard): 35
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
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B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist?
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 8 /58 participants did not
attend for FtF examination; 1/58 outwith age
restriction; 32/341 lesions did not appear to have a
primary teledermatology diagnosis
Time interval to reference test: not reported
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-up
following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Massone 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: February 2008 to
February 2010
Country: Austria
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients undergoing health
screening for a health insurance company at three
preventive health care centres in Austria selected by
general practitioners (GP) for second-opinion
teleconsulting as part of a preventative medical
screening programme
Setting: Private care
Prior testing: Clinical and/or dermatoscopic
suspicion
Setting for prior testing: Private care
Exclusion criteria: Poor quality index test image
Sample size (patients): No. eligible: 112; No.
included: 30
Sample size (lesions): No. eligible: 121; No.
included: 32
Participant characteristics: 
Age (yrs): Mean: 47; Median: 47; Range: 18-84
Gender: Male: not reported for the number of
patients for which data is presented only given the
overall number from eligible patients 642 (93%)
Female not reported for the number of patients for
which data is presented only given the overall
number from eligible patients 48 (7%)
Lesion characteristics: not reported
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: GPs screened patients and if they noted a suspicious skin
lesion then they acquired dermoscopic and if needed photographic images of the same skin lesion.
photographic images were taken using a digital camera, with the addition of a polarised light contact
dermatoscope for the dermoscopic images (Canon Powershot digital camera (Canon Inc., Tokyo,
Japan) and DermLite Photo; 3Gen LLC, San Juan Capistrano, CA, USA) adjusted from MoleMax
System (Derma Medical Systems, Vienna, Austria)). Images correlated by only age, sex and location
of the lesion were transmitted via a virtual private network for teleconsultation. No personal patients'
data were transmitted.
Nature of images used: Clinical photographs and dermoscopic images
Any additional patient information provided: age, sex and location of the lesion
Diagnosis based on: Single observer
Number of examiners: 2
Observer qualifications (remote diagnosis): Dermatologist (with high experience of dermoscopy)
Method of diagnosis: One of two dermatologists reviewed the images within 48hrs. They first reviewed
the quality of images on a 3-point scale, ranging from excellent (1) to low quality (3). Secondly they
assessed the lesion and grouped them into one of four groups (1) benign melanocytic, (2) malignant
melanocytic, (3) benign non-melanocytic and (4) malignant non-melanocytic lesions and defined them
according to WHO guidelines.
Management options: They also recorded management of the patient as follows "(i) no further
treatment or follow-up in 3, 6 or 12 months interval in case of benign skin lesions, (ii) referral to a local
dermatologist for FTF examination in case of suspicious skin lesions and (iii) excision in case of
suspected malignancy."
Teledermatology
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis plus Face
to Face diagnosis/Expert opinion
Details: Patients visiting the health care centres were
coming from different towns of Austria therefore no
institutions were specifically recommended but the
patients were free to select a dermatologist of their
choice for further assessment. No feedback was
requested, it was possible to collect follow up data
only for the patients referred to the Department or that
responded to a phone call or a letter. Of these cases
only 19 had histology and 13 had a face to face expert
assessment.
Histology (not further described) 
- No. patients/lesions: 19; Disease positive: 7; Disease
negative: 12
Expert opinion 
- No. patients: 13; Disease positive: 0; Disease
negative: 13
Target condition (Final diagnoses) 
Malignant Melanoma: 2, BCC: 5
Benign Dysplastic nevi: 11, Sebhorrheic keratosis: 4,
Other: Angioma=2 Porokeratosis=1 Actinic
keratosis=1
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
1. Excluded participants: it was possible to
collect follow up data only for the patients
referred to the Department or that responded
to a phone call or a letter. A total of 112
patients were eligible as attending the
department of dermatology but of these 82
patients were lost to follow up
2. Time interval to reference test: not reported
3. Time interval between index test(s): not
reported
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Moreno Ramirez 2005
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
Period of data collection: between January and
April 2004
Country: Spain
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: 
Patients with pigmented, circumscribed lesions fulfilling
at least one of the following criteria: a changing lesion
(‘ABCD changes’), recent lesion (less than three-year
history), multiple lesions (more than 20 melanocytic
naevi counted by the GP), symptomatic lesion (pain,
itching, bleeding),or concerned about moles.
Setting: Specialist unit (skin cancer/pigmented lesions
clinic)
Prior testing: Most likely clinical examination (the
reasons for teleconsultation were listed as concern
about moles; recent pigmented lesion; changing lesions;
symptoms; multiple lesions)
Setting for prior testing: Unspecified
Exclusion criteria: Not reported
Sample size (patients): No. eligible: 219; No. included:
57 patients included in the final analysis
Participant characteristics: 
Age (yrs): Mean: 43 years; Range: 2-84years
Gender: Male: 77 (35%); Female 142 (65%)
Lesion characteristics: not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: Two digital pictures were taken by the GP using a digital
camera at a resolution of 1600x1200 pixels (Coolpix 4300, Nikon). A panoramic view of the lesion area
and a close up of the lesion were taken. Images were inserted into a word document with relevant
clinical information. This was transmitted via the intranet to an email account at the pigmented lesion
clinic (PLC).
Nature of images used: Clinical photographs
Any additional patient information provided: Clinical examination and/or case notes
Diagnosis based on: Unclear how many remote observers
Number of examiners: not reported
Observer qualifications (remote diagnosis): Dermatologist
Method of diagnosis: At the teleconsultation, observers classified the lesions as being either "benign
melanocytic naevus, multiple melanocytic naevi (>20 naevi as seen on teleconsultation), atypical
naevus,7 congenital naevus, blue naevus, solar lentigo, lentigo maligna, melanoma, special
melanocytic lesion (genital naevus, acral naevus, recurrent naevus), seborrhoeic keratoses, basal cell
carcinoma (BCC), dermatofibroma, vascular lesion, non-pigmented lesion, or a ‘difficult to diagnose’
lesion". After evaluation of the pictures and clinical information, a report was returned to the GP at the
primary-care centre, with suggestions regarding the diagnosis and management of the case
Management options: The management options were limited to ‘referral’ or ‘non-referral’ of the patient
to the face-to-face clinic. Patients who had readily identifiable benign lesions such as benign
melanocytic naevus, solar lentigo, seborrhoeic keratoses, dermatofibroma, vascular lesions and non-
pigmented lesions were not referred to the PLC. All other remaining categories were routinely referred
to the PLC for face to face assessment.
Teledermatology
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis plus face
to face diagnosis/Expert opinion
Details: At the PLC, physical and dermoscopic
examinations were carried out, as well as excisional
biopsy in suspicious or malignant cases, and follow-up
of patients with risk factors for melanoma (16/25
benign underwent histology)
Target condition (Final diagnoses) 
- Melanoma (in situ): 1, BCC: 23, Lentigo maligna 3
- dysplastic nevi 16, common nevi 8 Blue nevi 4
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
1. Excluded participants: difficult to diagnosis cases
excluded
2. Time interval to reference test: unclear--only mention
"Teleconsultation reports were sent to the GP in a
mean time of 44 h (range 2–96 h). Patients referred to
the face-to-face clinic were seen within the following
two weeks (mean¼8 days, range 5–14).
Dermatologistsat the PLC spent an average of 2.3 h
per week in evaluating the teleconsultations received."
3. Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Oliveira 2002
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear but appears
prospective
Period of data collection: NR
Country: Brazil
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Participants with suspect
dermatological identified by an assistant nurse who
had undergone training to identify potentially
malignant skin lesions. Only those who attended for
face-to-face assessment were included.
Setting: Primary care; Centro de Saúde Escola
Geraldo de Paula Souza (primary care public health
service)
Prior testing: None
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): 103 eligible; 90 included
Sample size (lesions): 90
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: Lesions photographed in primary care by an assistant nurse
using a Kodak DC265 Zoom digital camera. 2 hr training in the use of the camera was provided and
included instruction on the installation of the camera’s software and transferring the images to the PC.
Images were sent by nurse with an electronic case report form and included her diagnostic impression
whether the lesion was non-malignant or malignant
Nature of images used: Clinical
Any additional patient information provided: Patient record
Diagnosis based on: Single observer
Number of examiners: 1
Observer qualifications (remote diagnosis): Dermatologist from the Department
of Dermatology of the Faculty of Medicine of the University of São Paulo
Method of diagnosis: Not clearly described. All cases were assessed remotely by a dermatologist prior
to the in-person evaluation
Management options: Malignant or benign; malignant diagnosis indicated biopsy needed
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Expert diagnosis (referral
accuracy)
Details: Within a week the same dermatologist
saw the patient in-person. Patients were
referred for biopsy when skin cancer was the
suspected diagnosis. The in person
assessments by the dermatologist
(and the biopsy results in a few cases)
were used as reference.
Target condition (FtF diagnoses) 
Malignant 
Benign
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the
results of the index tests? No
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist?
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 2 lesions without a tele-
dx
Time interval to reference test: 1 week from
photographs being taken
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Phillips 1998
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported but appears
prospective
Period of data collection: 1996
Country: US
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Participants attending four skin
cancer screenings at community hospitals in rural
eastern North Carolina.
Setting: Community
Prior testing: None
Setting for prior testing: N/A
Exclusion criteria: None reported
Sample size (patients): 51
Sample size (lesions): 107
Participant characteristics: 
Age (yrs): 46.7y; Male: 8 (15.7%)
Lesion characteristics: 
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: All sites were on a 1/2 T-1 link (786 kbs). All sites had three
cameras available, each of which was used in evaluating the patients: a full-body camera, a lens for
viewing the lesions close up, and a magnifying lens that allowed even closer views as well as
examination with polarized light (CLI CODEC (Panasonic 3-chip or Canon 1-chip)). All monitors
offered 620 lines of resolution. It is not clear who operated the cameras during the teleconsultations.
The in-person evaluation was conducted first so that if a complete skin examination was performed,
representative lesions were selected by the on-site physician for evaluation by the remote physician.
Nature of images used: Live link
Any additional patient information provided: Physicians could communicate directly with the patient
Diagnosis based on: Single observer
Number of examiners: 2; each examiner was the on-site physician at two screenings and the "remote
physician" at two screenings.
Observer qualifications (remote diagnosis): Dermatologist
Method of diagnosis: 
Management options: Most likely diagnosis for a given lesion; the degree of concern that a specific
lesion was malignant; and recommendation as to whether to do a biopsy of the lesion.
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Expert diagnosis (referral
accuracy)
Details: All patients were first evaluated by the on-site
physician. Patients were given a choice of having a
total body examination, only the sun-exposed skin, or
a specific lesion(s) evaluated by the on-site physician.
This physician recorded specific lesions on an image
of the human body and the most likely diagnosis for a
given lesion; the degree of concern that a specific
lesion was malignant; and recommendation as to
whether to do a biopsy of the lesion. If a complete skin
examination was performed, representative lesions
were selected by the on-site physician for evaluation
by the remote physician. The patient was
subsequently seen by the remote dermatologist, and
the same data were recorded.
Target condition (FtF diagnoses) 
Malignant: BCC 2; SCC 3; lentigo maligna 1
Benign: SK 27; BN 32; AK 14; lentigo 10; Other 30
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist?
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None described
Time interval to reference test: Consecutive
Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? Low risk
Comparative
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A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Piccolo 2000
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: states 3 months
but no specific dates given
Country: Austria (Graz)
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin lesions
selected because of their diagnostic difficulty and
subsequently excised for a histopathological
evaluation.
Setting: Unspecified described as a multicentre study
Prior testing: lesions included in the study were
selected because of their diagnostic difficulty does not
specify what prior tests were done
Setting for prior testing: Unspecified
Exclusion criteria: Poor quality index test image (all
images scoring 4 were excluded from the study)
Sample size (patients): No. included: 40 patients
Sample size (lesions): No. included: 43
Participant characteristics: 
Age (yrs): Median 39.5 years, (range 3–91 years)
Gender: Male: 21 (53%); Female 19 (47%)
Lesion characteristics 
Lesion site: Face 2; Head 1, Neck 1, Trunk 8, Arms 3,
Legs 7, Back 20, Buttocks 1
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
In person face to face clinical assessment
Method of diagnosis: All lesions were examined with a dermatoscope during the face to face clinical
diagnosis. Diagnosis was made by a expert dermatologist based on clinical features and dermoscopic
findings. No specific algorithm (e.g. the Stolz index) was used for dermoscopic diagnosis.
Prior test data: Unclear
Diagnostic threshold: Not reported
Diagnosis based on: Single
Number of examiners: 1
Observer qualifications: Dermatologist (an expert in the diagnosis of pigmented skin lesions)
Experience in practice: High
Experience with index test: High
Teledermatology
Acquisition and transmission of images: Each image was acquired following the in-person consultation
with the digital camera at a fixed 10-fold magnification. Two different lenses were used to capture
clinical and dermoscopic images (DCS 460,Kodak, Rochester, NY, USA), which used a Nikon body
(N90, Nikon, Tokyo, Japan); original image size 2036x3060 pixels in RGB colour mode (32 bit/pixel),
then compressed to 511x768 pixels (24 bit/pixel). These were stored on a prototype teledermatology
workstation and distributed to remote centres via email together with basic patient data (initials, age,
sex and site of the lesion).
Nature of images used: Clinical photographs and dermoscopic images
Any additional patient information provided: patient data (initials, age, sex and site of the lesion).
Diagnosis based on: Single observer
Number of examiners 11
Observer qualifications (remote diagnosis): Dermatologists (6), residents in dermatology (2), Internist
(1), GP (1), Oncologist (1)
Experience in practice: Not described
Experience with index test: Mixed experience (low and high experience combined)
Method of diagnosis: Not reported
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis alone
Details:All lesions were excised for a histopathological
evaluation
Target condition (Final diagnoses)
- Melanoma (in situ and invasive, or not reported): 11,
BCC: 3
- Sebhorrheic keratosis: 2, Benign naevus:
Melanocytic naevus 23, 'Benign' diagnoses:
Angiokeratoma 1, lentigines 3
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: Not reported
2. Time interval to reference test: Not
reported
3. Time interval between index test(s): Not
reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Remote observers received images via
email
Was each index test result interpreted without knowledge of the results of other
index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High
Notes
Notes -
 
Piccolo 2004
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection: Not reported
Country: Multicentre study participating centres
were in Italy, Japan, Austria and Slovenia
Images used were from University of Graz
Austria and University of L'Aquila Italy
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with melanocytic acral
lesions (71 common melanocytic naevi and 6
melanomas) from 73 patients at the Department of
Dermatology University of Graz and Department of
Dermatology, University ofL’Aquila
Setting: Secondary
Prior testing: Selected for excision (no further
detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): No. included: 73
Sample size (lesions): No. included: 77
Participant characteristics: 
Age (yrs): Mean: 28 years; range: 4 to 77 years
Gender: Male: 34; Female 39
Lesion characteristics 
Lesion site: 67 lesions located on the lower
extremities (58 on the plantar surface, 4 on the
external part of the foot, 3 on the toe, and 2 on the
dorsal aspect of the foot) and 10 on the upper
extremities (8 on the palm and 2 on the finger).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Teledermatology
Acquisition and transmission of images: Dermoscopic images of 48 melanocytic acral lesions were
acquired at the Department of Dermatology, University of Graz, using the MoleMax II System at 30x
magnification. Dermoscopic photographs acquired with Heine Dermaphot equipment at 10x
magnification were retrieved from the database of the Department of Dermatology, University of
L’Aquila images. All images in the study were compressed (to facilitate email transmission) at the
Department of Dermatology,University of L’Aquila.The images selected represented all the acral
lesions included in the databases of the two dermatology departments. photographic images were not
included. The dermoscopic images, together with the essential clinical data (age and sex of patient
and site of the lesion), were transmitted individually by email to 11 colleagues in eight remote centres.
Nature of images used: Dermoscopic images
Any additional patient information provided: Case notes
Diagnosis based on: Single observer
Number of examiners 11 dermatologists
Observer qualifications (remote diagnosis): Dermatologist (varying experience from high to low
dependant on numbers of years of specialization in pigmented skin lesions)
Method of diagnosis: Images were analysed the images on a PC monitor by each observer, first to
diagnose acral melanoma or atypical lesions, and second to categorize the lesions according to the
Saida classification. An acral naevus was considered to be atypical when at least 6 of the 11
observers made this diagnosis.
Management options: Observers also made a management recommendation of digital dermoscopy
follow-up or surgical excision
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis alone
Details: All lesions had been surgically excised and
histopathologically diagnosed by two dermatopathologists.
Target condition (Final diagnoses) 
- Melanoma: 6 acral melanomas
- Benign naevus: 71 acral melanocytic naevi
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
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B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: none reported
2. Time interval to reference test: not
reported
3. Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Shapiro 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: July 10 1998, and
August 4, 2000
Country: US
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
#164f The use of teledermatology for the diagnosis of skin cancer in adults
73 / 167
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: PCP referred only those patients
with skin growths that posed a true diagnostic
challenge
Setting: Primary, recruitment of study participants
from PCP (Estimated 50% of PCP patients have
dermatologic lesions that are encountered during
routine evaluation and 3% present exclusively for
dermatologic reasons)
- Private (face to face consultation with the local
dermatologist in private practice)
- Secondary care (images sent from PCP to
academic dermatologist for SAF dermatological
consultation)
Prior testing: A network community PCP recruited
patients whom he judged to require dermatologic
consultation for evaluation of a cutaneous growth
Setting for prior testing: Primary
Exclusion criteria: Patients who underwent previous
evaluation by a dermatologist were excluded from
the study
Sample size (patients): No. eligible: 61; No.
included: 49
Sample size (lesions): not reported
Participant characteristics: not reported
Lesion characteristics not reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: Images were acquired by the primary care physician (PCP)
using an Olympus D-600L digital camera. The first image captured the head and upper trunk. This was
followed by an image of the affected body part.The image and a clinical history were downloaded to a
personal computer using a serial port interface and accompanying software.The image transmission
was performed via e-mail using HUPNet, a private encrypted University of Pennsylvania Health
System area network
Nature of images used: Clinical photographs
Any additional patient information provided: clinical history
Observer qualifications (remote diagnosis): Dermatologist (n=1); (academic dermatologist with over 20
years experience in clinical dermatology)
Diagnosis based on: Single observer
Number of observers:1
Method of diagnosis: The images were reviewed by the PCP immediately before they were sent to a
board certified academic dermatologist for teledermatologic consultation.After assessing the case, the
teledermatologist notified the PCP of the diagnosis or differential diagnosis and indicate on a standard
data collection sheet whether a sampling biopsy was necessary. The reason for recommending biopsy
was specified as well.
Management options: asked to choose a management plan from 15 entries including 3 biopsy plans
(to rule out malignancy, to establish a diagnosis, or to remove a benign lesion for cosmetic purposes)
Teledermatology
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Face to face diagnosis as reference standard 
Method of diagnosis: The patients were simultaneously
scheduled for an FTF visit with the local dermatologist
(F.C.L.), who is in private practice, within 1 month. The
FTF dermatologist completed a standardized
consultation form notifying the PCP of his decision
regarding the diagnosis, differential diagnosis, and
whether a biopsy was indicated. A biopsy was
performed at that visit by the FTF dermatologist if the
FTF dermatologist or the SAF teledermatologist
favoured biopsy of the lesion
Prior test data: The telediagnosis triage decision was
contained in a sealed envelope which was opened by
the FTF dermatologist after making his decision.
Biopsy was then carried out by the FTF dermatologists
if recommended by either dermatologist.
Diagnostic threshold: Not described
Diagnosis based on: Single
Number of examiners: One
Observer qualifications: Dermatologist
Experience in practice: over 20 years of experience in
clinical dermatology
Experience with index test: High
Target condition (for 26 lesions undergoing biopsy; 23
on dermatologist recommendation and 3 at patient
request)
Malignant: 5 BCC, 4 cSCC Benign: 17 benign
neoplasms
Assumed benign (no biopsy): 23 (including one patient
who refused biopsy)
Is the reference standards likely to correctly classify the target
condition? No
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
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B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: 11 breached the study
protocol and were not included in the analysis. Of the
latter 11, 4 failed to present to the FTF dermatologist, 4
saw a different FTF dermatologist, 1 died of unrelated
causes before seeing the FTF dermatologist, and 2
underwent evaluation of different lesions by the SAF
teledermatologist and FTF dermatologist.
2. Time interval to reference test: The patients were
simultaneously scheduled for an FTF visit with the local
dermatologist (F.C.L.), who is in private practice, within
1 month.
3. Time interval between index test(s): N/A
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Silveira 2014
Patient Selection
A. Risk of Bias
Patient Sampling
Study design:Case series
Data collection: Prospective
Period of data collection April 2010 and July
2011
Country Brazil
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
#164f The use of teledermatology for the diagnosis of skin cancer in adults
76 / 167
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Individuals with skin lesions that
were determined to be suspicious after a direct
visual inspection by a physician. All of the patients
examined at the Mobile Prevention Unit were
previously screened by a nurse from the local
municipality who was trained at Barretos Cancer
Hospital.
Setting: Community Mobile Prevention Unit (MPU)
Prior testing:Not described
Setting for prior testing: Unspecified
Exclusion criteria: none reported
Sample size (lesions): No. included: 416
Participant characteristics: 
Age (yrs): Mean 63.5, (range 19 to 93 years)
Gender: Not reported
Lesion characteristics: Site:- Head and Neck 273
(75.0); Trunk 28 (7.6); Upper limbs 61 (16.7); Lower
limbs 2 (0.5) Skin type scale;- 1-2 295 (81); 3-4 69
(19); 5-6 0 (0)
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: Community (patients were evaluated in the MPU, and their
lesions were photographed by the MPU physician using a digital camera - Sony Cybershot DSC-5780
digital camera with 8.1-megapixel resolution)
Nature of images used: Clinical photographs
Any additional patient information provided: information such as age, skin complexion, location of the
lesion, stage and pathology results were collected
Observer qualifications (remote diagnosis): Oncologists at the Barretos Cancer Hospital (BCH); both
the oncologists and the MPU physician have more than 10-years of experience in skin cancer
screening
Number of observers:2
Diagnosis based on: Single observer
Method of diagnosis: All of the digital images were coded, stored and submitted at random to two
oncologists at BCH, they were blinded to the MPU physician’s diagnosis and pathology reports, and
classified the images using the following options: 1) a malignant lesion, oncological treatment is
indicated; 2) a benign lesion, no treatment required; 3) unknown; or 4) a low-quality image
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Face to face diagnosis
A. Risk of Bias
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B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard: Histological diagnosis
Details: Lesions classified as possibly
malignant at the mobile unit were excised
or biopsied
Target condition (Final diagnoses) 
- Melanoma: 5, BCC: 286, cSCC: 59,
Malignant other:14
- Benign diagnosis: 52
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 21 (4.6%) were excluded from
the study because of poor quality photos, leaving 439
patients with pathological results. 23/439 (5.2%) were
excluded because of incomplete data preventing the
identification of the patient,
Interval between reference standard and index test:
appears consecutive “lesions were imaged,
biopsied/removed and submitted for histopathological
examination” 364 (87.5%) were confirmed to be
malignant by the biopsy, 52 were diagnosed by expert
opinion
Was there an appropriate interval between index test and
reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-
up following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Warshaw 2010
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Nov 2002 to Aug
2005
Country: US
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients enrolled at the Department of
Veteran Affairs dermatology clinic who required (or
requested) removal of one or more skin neoplasms
('high-risk group') and participants who were referred to
general dermatology clinic by non-dermatology
healthcare providers for evaluation of a skin neoplasm
(lower risk group). Biopsied lesions only were included.
Warshaw 2009 and Warshaw 2009a included data for
participants primary lesions only whereas Warshaw
2010 includes all biopsied lesions, pigmented or non-
pigmented, from histopathologic lesion categories with
>=25 lesions
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: individuals requesting or referred for
skin tag removal only or with papulosquamous or
eczematous conditions (non-neoplastic), previous
biopsy of the lesion, and inability to comprehend and
give informed consent
Sample size (patients): No. eligible: 2152; No. included:
NR
Sample size (lesions): No. eligible: 3021 enrolled; 1685
biopsied and eligible for inclusion; No. included: 1514
Age: Mean: Pigmented: 66 Non-pigmented: 71; Range:
Pigmented: 23-94 Non-pigmented: 21-94
Gender: Male: Pigmented: 519 (95.8%) Non-
pigmented: 712 (97.8%)
Race/Ethnicity - White: Pigmented: 97.1% Non-
pigmented: 98.9%; Black or African American:
Pigmented: 1.3% Non-pigmented: 0.7%; Other:
Pigmented: 1.5% Non-pigmented: 0.4%
High risk characterisitics
- History of melanoma: Pigmented: 34; 6.3% Non-
pigmented: 16; 2.2%
- History of non-melanoma skin cancer: Pigmented:
147; 27.1% Non-pigmented: 260; 35.7%
Lesion characteristics
- Clinical characteristics (appearance)
- Non-pigmented (%): For index lesions only (n=1270):
728 (57.3%)
- Other: Pigmented: 19.4% size change, 16.6% itching,
9.6% bleeding Non-pigmented: 32.1%% size change,
23.9% itching, 26.6% bleeding
Lesion site
- Head/Neck: Pigmented: 38.2% Non-pigmented:
70.1%
- Trunk: Pigmented: 24.2% Non-pigmented: 13.9%
- Upper limbs/shoulder: Pigmented: 31.2% Non-
pigmented: 12.0%
- Lower limbs/hip: Pigmented: 5.7% Non-pigmented:
3.0%
- Buttock/groin: Pigmented: 0.7% Non-pigmented: 1.1%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
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Index tests
In person assessment
Method of diagnosis: Visual inspection +/- use of dermoscopy ("the clinical examination could include
all options normally available in the clinical setting (eg, palpation, diascopy, dermatoscopy)
Prior test data: Selected for excision (no further detail)
Diagnostic threshold: Qualitative (Recorded primary diagnosis and up to two differential diagnoses,
plus a choice of four basic management plans (remove/biopsy/destroy, observe/ reassure, antifungal
treatment, antibiotic treatment, anti-inflammatory treatment)
Primary diagnosis Clinicians had a choice of 17 common diagnoses for one primary and up to two
differential diagnoses
Diagnosis based on: Single observer
Number of examiners: 11 staff dermatologists
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with index test: Not described
#
Teledermatology
Acquisition and transmission of images: The standard method used in most teledermatology settings
at the onset of the study,15-20 and PLD images were obtained for each lesion following in-person
consultation. Two macro images (distance and close-up; digital Nikon Coolpix 4500 with a Nikon SL-1
ring flash [Nikon, Melville, NY]) were obtained of each lesion. In addition, for lesions more than 2 mm
in height, a macro angle (approximately 908 from the skin surface) was also taken. One PLD (digital
Nikon Coolpix 4500 with a 3Gen DermLite lens attachment) was also obtained. (Dermoscopy images
taken and accuracy reported but insufficient data obtained from authors to allow their inclusion in this
review. Dermoscopy images unlikely to have influenced macro image interpretation as "for each
participant, a sequence of two image ‘‘packages’’ was sent. The teledermatologist received a macro
package (distance and close-up, with or without an angle image) alone or with a PLD image.
Nature of images used: Clinical photographs
Any additional patient information provided: Clinical examination and/or case notes (the standardized
patient and lesion history collected by the research assistants)
Observer qualifications (remote diagnosis); Dermatologist (with > 5 years experience and recognised
pigmented skin lesion expert)
Diagnosis based on: Single observer
Number of observers:3
Method of diagnosis: Using the same diagnostic and management categories as used by clinic
dermatologists, the teledermatologists recorded one primary diagnosis, up to two differential
diagnoses, and a management plan for each lesion.
Teledermatology
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Histological reference standard. A board-certified
dermatopathologist who was not involved with any clinic
assessments coded all histopathologic diagnoses based
on the pathology report.
- No. patients/lesions: 1514
Target condition 
Malignant Melanoma: 41, BCC: 410, cSCC: 240
Benign 'Benign' diagnoses: benign keratoses 223;
dysplastic nevi 154; actinic kerastoses 145;
benign nevi 138; cysts 73; benign appendageal tumours
35; lentigines 29; benign vascular neoplasms 26
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Yes
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: histopathologic categories with
<25 lesions (n=171)
Time interval to reference test: Patients (from the VA
clinic) were scheduled for a research appointment
before, but on the same day as, their dermatology
clinic consult appointment. But timing to histology not
reported Patients from the general dermatology clinic
undergoing a biopsy for a skin neoplasm (because of
physician recommendation or patient request) were
also invited to participate. - likely that photographs
taken on same day as excision but again not reported
as such
Time interval between index test(s): Immediate -
photographs taken on day of FtF appointment
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum follow-up
following application of index test(s) of at least: 3 months for
melanoma or cSCC or 6 months for BCC?
Could the patient flow have introduced bias? High risk
Comparative
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A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other
index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes
Are there concerns that the test comparison differs from the review question? Lowconcern
Notes
Notes -
 
Wolf 2013
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection /
Prospective interpretation
Period of data collection Not reported
Country US
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented lesions that were
considered atypical in clinical appearance by at least one
dermatologist and for which a clear histologic diagnosis had
been rendered by a board-certified dermatopathologist.
Images selected from image database in following
categories: categories: invasive melanoma, melanoma in
situ, lentigo, benign nevus (including compound, junctional,
and low-grade dysplastic nevi), dermatofibroma, seborrheic
keratosis, and hemangioma. Sampling not described.
Setting: - Unspecified
Prior testing: - Selected for excision (no further detail)
Setting for prior testing: - Unspecified
Exclusion criteria: Study exclusion criteria:
Poor quality index test image, Images that contained any
identifiable features, such as facial features, tattoos, or
labels with patient information, were excluded or cropped to
remove the identifiable features or information. Lesions with
equivocal diagnoses, such as “melanoma cannot be ruled
out” or “atypical melanocytic proliferation,” were excluded,
as were Spitz nevi, pigmented spindle cell nevus of Reed,
other uncommon or equivocal lesions, and lesions with
moderate or high-grade atypia.
Sample size (patients): Not reported
Sample size (lesions): 188
Participant characteristics: Not reported
Lesion characteristics: Not reported
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not
match the review question? High
Index Test
Index tests
Teledermatology
Acquisition and transmission of images: 
The images of skin lesions were selected from a database of images that are captured routinely before
skin lesion removal to allow clinicopathologic correlation in making medical management decisions.
Only used close-up images of lesions and those that contained any identifiable features, such as facial
features, tattoos, or labels with
patient information, were excluded or cropped to remove the identifiable features or information.
Nature of images used: photographic images
Any additional patient information provided: No further information used
Method of diagnosis: Application 4 which was run on a smartphone sent each image to a board-
certified dermatologist for evaluation, and assessment that was returned to the user within 24 hours.
The identity of the dermatologist was not given, and it was unclear whether all the images were read
by the same dermatologist or
by several different dermatologists. The output given was “atypical,” which was considered to be a
positive test result, or “typical,” which was considered to be a negative test result.
Diagnosis based on: Unlcear how many observers
Number of examiners: Unclear
Observer qualifications (remote diagnosis): Board certified dermatologist
Experience in practice: Unclear
Experience with index test: Unclear
Teledermatology
#164f The use of teledermatology for the diagnosis of skin cancer in adults
84 / 167
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Face to face diagnosis
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard - Histological diagnosis
alone
Details: Histology (not further described) 
Target condition (Final diagnoses) 
Malignant - Melanoma (in situ and
invasive): 60
Benign - 'Benign' diagnoses: 128
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
For studies comparing teledermatology/face to face clinical diagnosis to histology, was histology interpretation
carried out by an experienced histopathologist or by a dermatopathologist? Unclear
For studies comparing teledermatology to face to face diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: We reviewed a
total of 390 images for possible inclusion in
this study. We excluded 202 as being of
poor image quality, containing identifiable
patient information or features, or lacking
sufficient clinical or histological information.
2. Time interval to reference test: N/A
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
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Notes
Notes -
 
Footnotes
ABCD(E) - asymmetry, border, colour, differential structures (enlargement); AK - actinic keratosis; AMN – atypical
melanocytic naevi; BCC - basal cell carcinoma; BD – Bowen’s disease; BN – benign naevi; BPC – between person
comparison (of tests); CAD – computer assisted diagnosis; CCS – case control study; CD – compact disc; CM – cutaneous
melanoma; CMM - cutaneous malignant melanoma; CS – case series; cSCC – cutaneous squamous cell carcinoma; DF –
dermatofibroma; Dx – diagnosis; ELM – epiluminescence microscopy; FPs - false positives; FU – follow-up ; GP – general
practitioner; H&E – haematoxylin and eosin stain; LPLK – lichen planus-like keratosis; LS – lentigo simplex; MM – malignant
melanoma; MiS – melanoma in situ (or lentigo maligna); MN – melanocytic naevi; MSDSLA - multispectral digital skin lesion
analysis device; N/A – not applicable; NC – non comparative; NMLs – non melanocytic lesions; NR – not reported; P –
prospective; PCPs – primary care providers; PLC – pigmented lesion clinic; PSL – pigmented skin lesion; R –retrospective;
RCM – reflectance confocal microscopy; RCT – randomised controlled trial; SCC - squamous cell carcinoma; SD – standard
deviation; SDDI - short-term sequential digital dermoscopy imaging; SK – seborrhoeic keratosis; SN – Spitz nevi; SSM –
superficial spreading melanoma; SVS – support vector system; VI – visual inspection; WPC – within person comparison (of
tests)
Characteristics of excluded studies 
Armstrong 2007
Reason for exclusion EXCLUDE not a primary study
 
Baba 2005
Reason for exclusion EXCLUDE on study population
 
Badertscher 2015
Reason for exclusion ~EXCLUDE on 2x2 data; for VI/Derm - only gives number of correct diagnoses (not
broken down by TP/TN) and gives GP 'score' between T0 and T1
~EXCLUDE on index test - not a teledermatology study
 
Barnard 2000
Reason for exclusion EXCLUDE on target condition; The primary target condition are not relevant to our
reviews.
 
Bashshur 2015
Reason for exclusion EXCLUDE not a primary study narrative review
 
Bataille 2011
Reason for exclusion EXCLUDE conference abstract
 
Bergmo 2000
Reason for exclusion EXCLUDE not a primary study
 
Borve 2013
Reason for exclusion EXCLUDE on target condition; includes 1 melanoma metastases and 1 in situ
SCC as D+ (these make up 5% of malignant group); author contacted (Table 2
provides estimates of the diagnostic accuracy of the face-to-face dermatologist and
the two teledermoscopists, however in order to include the results in our review we
would need the underlying 2x2 contingency tables for these statistics. Is it at all
possible for you to provide us with them for each observer, particularly in regard to the
'Primary diagnosis' and the 'Benign vs malignant')
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Boyce 2011
Reason for exclusion EXCLUDE on study population No breakdown given- just 7 suspicious lesions.
EXCLUDE on reference standard; No data given but only 7 referred on for formal
assessment. Definitely <50% histology rate
 
Braun 2000
Reason for exclusion EXCLUDE on 2x2 data
~EXCLUDE but contact authors. can get sensitivity from table II but specificity unclear
- appears to give n/% of correct identification of each lesion type rather than FPs Table
II describes accuracy - is this % correct per lesion type? Do you have data on numbers
misclassified as melanoma, or other malignancy, i.e. FPs? Is there overlap with later
publications, e.g. Coras 2003?
 
Brown 2000
Reason for exclusion EXCLUDE not a primary study
 
Burgiss 1997
Reason for exclusion EXCLUDE on reference standard reports actions on tele-diagnosis (primarily for cost
purposes) and does not give final diagnoses (histo) or FtF diagnosis for all lesions
 
Chen 2002
Reason for exclusion EXCLUDE on sample size
Study was based on individual patient images (<5 cases). Only 4 lesions in total used
in study (nBCC x 1, SK x1, KA x1, AK x1). 
 
D'Elia 2007
Reason for exclusion EXCLUDE on study population
Not focused on suspected skin cancer
EXCLUDE on 2x2 data; looks at agreement between diagnoses only
 
Di Stefani 2007
Reason for exclusion EXCLUDE on sample size; <5 malignant: of 7 excised: one melanoma (melanoma in
situ associated with a nevus), one pigmented BCC, and five melanocytic nevi. Both
tele-dx recommended the 2 malignancies for excision but no further breakdown of
agreement/disagreement given
EXCLUDE on 2x2 data 7 'D+' according to FtF decision to excise but only reports
kappa values for agreement with tele-dx
 
Du Moulin 2003
Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Edison 2008
Reason for exclusion EXCLUDE on study population
 
Eminovic 2009
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Reason for exclusion EXCLUDE not a primary study
EXCLUDE on study population
EXCLUDE on target condition
 
Fabbrocini 2008
Reason for exclusion EXCLUDE on 2x2 data; there isn't sufficient data provided for each index test to
populate 2x2 table
EXCLUDE but contact authors: As we can only include DTA studies - Do you have a
cross tabulation of each clinician's diagnosis (e.g. at threshold of >=3 on 7 point
checklist) against the histological diagnosis and/or a cross tabulation of the remote
diagnosis against the Face to Face diagnoses?
 
Ferrandiz 2007
Reason for exclusion EXCLUDE on study population; all have a strong clinical diagnosis of NMSC or fast
growing tumour, the purpose of the test is primarily to inform treatment plans 
EXCLUDE on 2x2 data; a) 4 of the original 134 appear to have missing histology and
b) don’t know what the additional clinical cases of each lesion were classed as on
histology e.g. the 14 extra BCCs and 5 KAs
 
Ferrandiz 2012
Reason for exclusion EXCLUDE on target condition
on included CM
 
Gilmour 1998
Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Granlund 2003
Reason for exclusion EXCLUDE on study population
 
Griffiths 2010
Reason for exclusion EXCLUDE on reference standard
 
Harrison 1998
Reason for exclusion EXCLUDE on target condition - no breakdown of final diagnoses (histo) or of
recommendations from FtF consultation
EXCLUDE on sample size - can't tell how many D+ for either reference standard
EXCLUDE on 2x2 data - no underlying data provided; diagnostic 'accuracy' of
teleconsultation reported as 71% for 210 patients compared to 49% for the referring
general practitioners (49%). Also states that "telemedicine was able to detect
malignancies in 94% of cases compared with only 70% detected by general
practitioners.
 
Heffner 2009
Reason for exclusion EXCLUDE on target condition
 
Hicks 2003
Reason for exclusion EXCLUDE not a primary study
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High 2000
Reason for exclusion EXCLUDE on study population - not all suspected of skin cancer 'dermatologic
conditions' including dermatitis, acne, verruca, etc.
EXCLUDE on 2x2 data - reports agreement only; no breakdown of
diagnoses/management decisions
EXCLUDE on reference standard; Table of final diagnoses appears to be based on
FtF diagnoses with histology obtained for 69/106 (65%), so is ineligible for a tele-dx vs
histo comparison (diagnostic acuracy) and is not tele-dx vs FtF (referral accuracy)
either
 
Hue 2016
Reason for exclusion EXCLUDE on reference standard - final diagnoses/FtF decisions given only for 17
recommended for rapid referral on tele-dx; no data for remaining 395 with non-urgent
derm referral/annual FU recommendation/discharge.
EXCLUDE on sample size - for Tele-dx vs Histo, only 5 excised incl 1 melanoma
EXCLUDE on 2x2 - no data for tele-dx vs FtF
 
Hwang 2014
Reason for exclusion EXCLUDE on study population
 
Ishioka 2009
Reason for exclusion EXCLUDE on target condition
No breakdown of disease positive 'malignant' provided
 
Kahn 2013
Reason for exclusion EXCLUDE on target condition
 
Knol 2006
Reason for exclusion EXCLUDE on study population
 
Krupinski 1999
Reason for exclusion EXCLUDE on 2x2 data; reports only diagnostic concordance/agreement
 
Lamel 2012
Reason for exclusion EXCLUDE on 2x2 data reports only summary concordance in diagnosis and
management decisions between decisions based on mobile phone image and in
person; insufficient detail to work out referral accuracy.
EXCLUDE but contact authors: Study presents data on diagnostic and management
concordance between in person and remote (via mobile phone app) diagnoses, are
any diagnostic accuracy data available, e.g. observers diagnosis of malignant lesion
when assessed remotely versus FtF diagnosis of malignancy?
 
Lamminen 2000
Reason for exclusion EXCLUDE not a primary study
 
Lesher 1998
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Reason for exclusion EXCLUDE on study population - incl people with 'skin problems' (incl wide range of
diagnoses)
EXCLUDE on sample size - could extract referral accuracy (tele-dx vs FtF) but only 4
lesions with malignant diagnosis on FtF (4 BCCs).
 
Lewis 1999
Reason for exclusion EXCLUDE on 2x2 data; Study appears to meet all eligibility criteria but disease
prevalence not given alongside sensitivity/specificity.
EXCLUDE but contact authors: authors contacted (Sensitivity and specificity of remote
diagnosis in comparison to FtF diagnosis are provided but we would need number D+
in order to complete 2x2 table)
 
Loane 1998
Reason for exclusion EXCLUDE on study population
 
Loane 1998a
Reason for exclusion EXCLUDE not a primary study
 
Loane 2000
Reason for exclusion EXCLUDE on study population
not focused on potentially malignant skin lesions; cannot derive any comparative data
for detection of 'tumours'
 
Loane 2001
Reason for exclusion EXCLUDE not a primary study
 
Loane 2001a
Reason for exclusion EXCLUDE on study population
 
Lowitt 1998
Reason for exclusion EXCLUDE on study population
 
Lyon 1997
Reason for exclusion EXCLUDE on 2x2 data: for operative referrals, only histo diagnosis given with overall
no. of disagreements by FtF and tele-dx; no clear breakdown of index test results to
derive 2x2
EXCLUDE on study population; not all suspected of skin cancer
 
Martinez-Garcia 2007
Reason for exclusion EXCLUDE on 2x2 data Not test accuracy
EXCLUDE on reference standard - no reference standard reported; describes only
tele-dx
 
Massone 2007
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Reason for exclusion EXCLUDE on reference standard - does not meet our criteria for for diagnostic
accuracy ref standard (only 12/25 (48%) of benign group with histo, including 1 AK as
benign instead of malignant); and data not presented to allow extraction of referral
accuracy (tele-dx vs FtF) [incls 955 lesions and reports tele-dx recommendations for
all 955; 121 were recommended for excision or for FtF consult but FU data only
available for 32 of these (19 with histo dx and 13 with FtF diagnosis)]
EXCLUDE on 2x2 data - data not clearly presented to allow extraction of referral
accuracy (tele-dx vs FtF alone); can only extract tele-dx vs FtF diagnosis of malignany
if we assume that all 7 malignant lesions were diagnosed as such by FtF - from table 2
we only know that all 7 were excised presumably following FtF consult.
 
May 2008
Reason for exclusion EXCLUDE on 2x2 data: no data for a 2x2 table
EXCLUDE on index test - effect on consultant priority of GP referral with photograph
vs referral with no accompanying photograph
 
McGraw 2009
Reason for exclusion EXCLUDE on study population
 
McManus 2008
Reason for exclusion EXCLUDE on study population
 
Moreno-Ramirez 2006
Reason for exclusion EXCLUDE on sample size - comparison is Tele-dx vs final diagnosis (58/61 were
biopsied); only 1 melanoma and 2 BCC
 
Moreno-Ramirez 2007
Reason for exclusion EXCLUDE on reference standard: does not meet either criteria for eligible reference
standard.
Table 1 crosstabs the telediagnosis (refer/not refer) against a gold standard which
appears to be a combination of the face to face diagnosis (for those with clinically and
dermoscopically benign and nonsuspicious lesions, and with a diagnostic confidence
level of 3 after the face to face diagnosis) and histology (those with higher concern at
FtF evaluation were excised).
 
Moreno-Ramirez 2009
Reason for exclusion EXCLUDE on study population
EXCLUDE on reference standard
 
Ndegwa 2010
Reason for exclusion EXCLUDE not a primary study
Technology report
 
Nordal 2001
Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Oakley 1997
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Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Oakley 2006
Reason for exclusion EXCLUDE on 2x2 data; insufficient data presented.
EXCLUDE but contact authors: We are looking to compare telederm dx with FtF
diagnosis within a diagnostic accuracy framework (i.e. in a 2x2 contingency table) but
in order to include your paper we would need information on the misdiagnoses. Using
the FtF diagnosis as the gold standard, we can use the data in Table 2 to derive the
'sensitivity' of the tele-Dx agreement for diagnosis of melanoma, BCC and SCC
(%agreement), but we would need to know the % of tele-dx reports that 'misdiagnosed'
the other lesion types as malignant in order to derive 'specificity'. Would you be at all
able to supply this data?
We could use the data in Table 6 to cross-tabulate the management decisions
between the two approaches, if we collapse the tele-Dx cat3 and cat4 groups together.
However the % agreement for the teledermatology classification adds to greater than
100.
 
Oztas 2004
Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Pak 1999
Reason for exclusion EXCLUDE not a primary study
review of service
 
Pak 2002
Reason for exclusion EXCLUDE conference abstract
no full text paper found 
 
Pak 2003a
Reason for exclusion EXCLUDE on study population
 
Pak 2003b
Reason for exclusion EXCLUDE on study population
 
Pak 2007
Reason for exclusion EXCLUDE on reference standard
reference standard not clear 
 
Pak 2009
Reason for exclusion EXCLUDE not a primary study
 
Patro 2015
Reason for exclusion EXCLUDE on target condition
 
Perednia 1998
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Reason for exclusion EXCLUDE on study population; not all suspected of skin cancer
EXCLUDE on index test; not an evaluation of accuracy of teledermatology but of effect
of access to telemedicine on GP confidence and referral decisions
 
Phillips 1997
Reason for exclusion EXCLUDE on sample size - 68 lesions; FtF diagnosis of 4 skin cancers (tele- and FtF
diagnoses concordant for 1 melanoma and 2 BCC; FtF dx of 1 additional SCC in 1
further patient); no final diagnoses (Histo) recorded
EXCLUDE on 2x2 data – presents agreement between observers only
EXCLUDE on study population – not all suspected of skin cancer
 
Piccolo 1999
Reason for exclusion EXCLUDE on 2x2 data - Reports data for tele-dx, FtF and Histo; breakdown of
discordant results between Tele-dx vs FtF and Tele-dx vs Histo is given but only gives
number (%) concordant; does not give number TP and TN to allow 2x2 to be
estimated for either comparison
 
Piccolo 2002
Reason for exclusion EXCLUDE not a primary study; review article
 
Rashid 2003
Reason for exclusion EXCLUDE on study population
 
Ribas 2010
Reason for exclusion EXCLUDE on study population
 
Romero 2010
Reason for exclusion EXCLUDE on study population
 
Romero 2014
Reason for exclusion EXCLUDE on study population
 
Seidenari 2004
Reason for exclusion EXCLUDE on 2x2 data; No data to populate 2x2 table just ROC curve values given. 
EXCLUDE but contact authors; TABLE 5 provides AUC values for each diagnosis for
both formats and observers; requested data in 2x2 format, e.g. for melanoma 'certain'
against final diagnosis and for melanoma 'certain or fairly certain' against final
diagnosis?
 
Senel 2013
Reason for exclusion EXCLUDE on 2x2 data
no accuracy data available For teledermatology it looks like they have only given us
the % of correct diagnoses (Table 6) per dermatologist for but give no breakdown by
disease positive/negative so can’t work out 2x2 data. 
 
Shin 2014
Reason for exclusion EXCLUDE on target condition
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Tait 1999
Reason for exclusion EXCLUDE on study population - not all suspected of skin cancer 'people with visible
skin lesion or lesions' (wide range in diagnoses recorded)
 
Tan 2010
Reason for exclusion EXCLUDE on reference standard. No reference standard described
EXCLUDE on 2x2 data. Not test accuracy; reports agreement between 5
dermatologists' tele-diagnosis, not against histology or FtF diagnosis
 
Tan 2010a
Reason for exclusion EXCLUDE on 2x2 data. Study appears to meet eligibility criteria however,although
sensitivity and specificity values are provided in Table 4 per Dermatologist it is not
possible to work back to the underlying 2x2 (final diagnoses by histopath not given and
FtF diagnoses for the same 491 lesions differ in Table 1 according to Dermatolgost A
and Dermatologist B)
 
Tandjung 2015
Reason for exclusion EXCLUDE on target condition 'Malignant' includes: AK, Bowen's, dysplastic nevus,
lentigo maligna, SCC, BCC, MM, keratoacanthoma
EXCLUDE on index test GPs sent images for teledermatology opinion; then free to
send for biopsy or not; results shown are only for those that were biopsied, according
to Teledermatology advice
 
Taylor 2001
Reason for exclusion EXCLUDE on study population. Not all suspected of skin cancer; wide variety of
conditions included
EXCLUDE on 2x2 data. Reports % agreement only
 
Tucker 2005
Reason for exclusion EXCLUDE on target condition. No breakdown of either final diagnoses or tele-dx
EXCLUDE on 2x2 data. Reports agreement only
EXCLUDE on study population - not all suspected of skin cancer
 
van der Heijden 2013
Reason for exclusion EXCLUDE on 2x2 data - only reports Kappa values for histology vs FtF and histology
vs Tele-dx (for each of 4 teledermatologists) but no underlying data given.
 
Vano-Galvan 2011
Reason for exclusion EXCLUDE on study population not specific to skin cancer, popl includes infectious
disease and inflammatory disease
EXCLUDE on 2x2 data. Only gives % agreement between tele-dx and FtF (gold
standard)
 
Warshaw 2009
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Reason for exclusion EXCLUDE on 2x2 data. Only reports accuracy.
EXCLUDE duplicate or related publication; author contacted in regard to 2010 paper
EXCLUDE but contact author. Study presents diagnostic accuracy of teledermatology
and clinic diagnosis in comparison to histopathology; in order to include in our review,
data would need to be presented as a 2x2 contingency table, either per type of
malignancy e.g. tele-dx classification of melanoma vs not melanoma against
histological diagnosis of melanoma/not melanoma, or with malignant diagnoses
grouped together, ie tele-dx of malignancy vs not malignant against same histological
breakdown. Ideally we would like this data for the clinic diagnosis and for each method
of tele-diagnosis. Is it at all possible to provide this information? Same would go for the
study of non-pigmented lesions (also Warshaw 2009), and if possible for the
2010 paper reporting the subgroup of lesions >=25mm (Warshaw 2010).
**Author provided some data for detection of melanoma only and for use of macro
images only for 2010 paper (pigmented and non-pigmented lesion combined)
 
Warshaw 2009a
Reason for exclusion EXCLUDE on 2x2 data. Only reports accuracy.
EXCLUDE duplicate or related publication; author contacted in regard to 2010 paper
EXCLUDE but contact author. See Warshaw 2010
 
Warshaw 2010a
Reason for exclusion EXCLUDE on 2x2 data; Not test accuracy - inter-observer agreement for sub-sample
of Warshaw 2009 / Warshaw 2010 trial
 
Warshaw 2015
Reason for exclusion EXCLUDE on 2x2 data; only gives agreement between Teledermatology diagnosis
and Face to Face diagnosis
 
Watson 2010
Reason for exclusion EXCLUDE on target condition
 
Weingast 2013
Reason for exclusion EXCLUDE on study population
 
Weinstock 2002
Reason for exclusion EXCLUDE not a primary study
 
Weinstock 2009
Reason for exclusion EXCLUDE not a primary study
 
Whited 1999
Reason for exclusion EXCLUDE on 2x2 data. only gives % agreement between tele-dx and FtF and %
correct diagnoses of Tele-dx vs histo
 
Whited 2002
Reason for exclusion EXCLUDE not a primary study
 
Whited 2003
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Reason for exclusion EXCLUDE not a primary study
 
Whited 2004
Reason for exclusion EXCLUDE not a primary study
 
Whited 2006
Reason for exclusion EXCLUDE not a primary study; review article
 
Whited 2010
Reason for exclusion EXCLUDE not a primary study
 
Whited 2016
Reason for exclusion EXCLUDE not a primary study
 
Williams 2001
Reason for exclusion EXCLUDE not a primary study
 
Williams 2007
Reason for exclusion EXCLUDE not a primary study
 
Wootton 2000
Reason for exclusion EXCLUDE on study population
EXCLUDE on target condition
 
Zelickson 1997
Reason for exclusion EXCLUDE on study population
 
Footnotes
ABCD(E) - asymmetry, border, colour, differential structures (enlargement); AK - actinic keratosis; AMN – atypical
melanocytic naevi; AUC - area under curve; BCC - basal cell carcinoma; BD – Bowen’s disease; BN – benign naevi; CM –
cutaneous melanoma; CMM - cutaneous malignant melanoma; CSCC – cutaneous squamous cell carcinoma; Derm –
dermoscopy; DF – dermatofibroma; Dx – diagnosis; ELM – epiluminescence microscopy; FNs- false negatives; FPs - false
positives; FtF - face-to-face; FU – follow-up ; GP – general practitioner; H&E – haematoxylin and eosin stain; Histo -
histology; LPLK – lichen planus-like keratosis; LS – lentigo simplex; MM – malignant melanoma; MiS – melanoma in situ (or
lentigo maligna); MN – melanocytic naevi; N/A – not applicable; NMLs – non melanocytic lesions; NR – not reported; PCPs –
primary care providers; PLC – pigmented lesion clinic; PSL – pigmented skin lesion; ROC - receiver operating characteristic;
SCC - squamous cell carcinoma; SK – seborrhoeic keratosis; SN – Spitz nevi; SSM – superficial spreading melanoma; tele-
Dx - teledermatology diagnosis; VI – visual inspection.
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of teledermatology for the detection of skin cancer in adults?
Population: Adults with lesions suspicious for skin cancer
Index test: Teledermatology (TD) using photographic and/or dermoscopic images
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Question: What is the diagnostic accuracy of teledermatology for the detection of skin cancer in adults?
Comparator test: Face-to-face diagnosis using visual inspection and/or dermoscopy
Target condition: Any skin cancer, including invasive melanoma and atypical intraepidermal melanocytic variants,basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), or any other skin cancer
Reference standard: Histology with or without long term follow-up (diagnostic accuracy); Expert face-to-face diagnosis(for referral accuracy)
Action:
If accurate, positive results ensure the malignant lesions are not missed but are appropriately
referred for specialist assessment or are treated appropriately in a non-referred setting, and those
with negative results can be safely reassured and discharged.
Quantity of evidence Number of studies Total lesions Total cases
Diagnostic accuracy 16 4057 879
Referral accuracy 6 1449 270
Limitations 
Risk of bias: 
Low risk for participant selection in 7 studies; high risk (5) from case control design (2) or
inappropriate exclusion criteria (4). Low risk for teledermatology assessments (22). Low risk for
comparison with face-to-face diagnosis (2/5); unclear (3). Low risk for reference standard (10/22);
high risk from use of expert diagnosis alone - referral accuracy (6) or inadequate reference
standard (6). High risk for participant flow (17) due to differential verification (5), and exclusions
following recruitment (14); timing of tests was not mentioned in 14 studies.
Applicability of
evidence to question:
High concern (14/22) for applicability of participants due to recruitment from secondary care or
specialist clinics (12) or inclusion of multiple lesions per participant (6). High concern for
applicability of teledermatology assessments (12/22) due to images acquired by dermatologists
secondary care settings or in medical imaging units rather than images acquired in primary care.
Low concern for reference standard (6/22); unclear concern due to lack of information concerning
the expertise of the histopathologist (13) or expert face-to-face diagnosis (3).
FINDINGS: 
Seven studies reported diagnostic accuracy data for the primary target condition of any skin cancer; 9 studies for the
detection of invasive melanoma or atypical intraepidermal melanocytic variants; 2 studies for invasive melanoma alone; and
four studies for BCC alone. Six studies reported only referral accuracy data (teledermatology decisions versus face-to-face
decisions). The findings presented are based on results for the primary target condition of any skin cancer and for the
detection of invasive melanoma or atypical intraepidermal melanocytic variants.
DIagnostic accuracy
data Number of datasets Total lesions Total malignant
Test: TD using
photographic images
for any skin cancer
4 717 452
Three studies reported a cross-tabulation of lesion final diagnoses against the diagnosis on
teledermatology such that data could be extracted for the detection of any malignancy, regardless
of any misclassification of one skin cancer for another, e.g. a BCC diagnosed as a melanoma or
vice versa; and one study presented data for the detection of ‘malignant’ versus benign cases with
no breakdown of individual lesion diagnoses given. Summary sensitivity was 94.9% (95% CI 90.1
to 97.4%) and summary specificity 84.3% (95% CI 48.5, 96.8%). Two studies providing a direct
comparison between teledermatology assessment and in-person diagnosis by a dermatologist the
data suggested similar accuracy between approaches; however, data were too scarce to draw firm
conclusions.
Test: TD using clinical
and dermoscopic
images for any skin
cancer
3 928 215
Sensitivities were 100% in all three studies. Specificities ranged from 25% (95% CI 5% to 57%) to
92% (95% CI 74% to 99%). Studies used varying thresholds to decide test positivity and included
highly selected populations. No statistical pooling was undertaken.
Test: TD using
photographic images
for invasive melanoma
or atypical
intraepidermal
melanocytic variants
4 1834 106
Sensitivities ranged from 59% (95% CI 42% to 74%) to 100% (95% CI 54% to 100%) and
specificities from 30% (95% CI 22% to 40%) to 100% (95% CI 93% to 100%). Diagnostic
thresholds were correct diagnosis of melanoma (n=3) or classification as ‘atypical’ or ‘typical’.
Populations also varied, some including only atypical or higher risk pigmented lesions and
excluding equivocal lesions and others including both pigmented and non-pigmented lesions who
were either self-referred or were deemed to require lesion excision. The number of melanomas
missed ranged from 0 to 17.
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Question: What is the diagnostic accuracy of teledermatology for the detection of skin cancer in adults?
Test: TD using
photographic and
dermoscopic images for
invasive melanoma or
atypical intraepidermal
melanocytic variants
4 664 93
Summary estimates were 85.4% (95% CI 68.3% to 94.1%) for sensitivity and 91.6% (95% CI
81.1% to 96.5%) for specificity. Sensitivities were lower for the correct diagnosis of melanoma (71%
to 81%) compared to the decision to refer or to excise a lesion (96% to 100%). The number of
melanomas missed ranged from 0 to 7.
All data (referral
accuracy)
6 1449 270
TD diagnoses were reported based on photographic images alone (n=4), photographic and
dermoscopic images (1) and using live link TD (1). Diagnostic decisions on TD varied, including the
diagnosis of malignancy, the decision to excise a lesion, the decision to refer versus not refer, or to
excise or follow-up at a later date. For store and forward TD sensitivities were generally above 90%
indicating good agreement between remote image-based decisions with the face to face reference
standard for lesions considered to require some positive action by face to face assessment.
Specificities were more variable ranging from 57% (95% CI 39 to 73%) to 100% (95% CI 86% to
100%) suggesting that remote assessment is more likely recommend excision, referral or follow-up
for lesions considered of less concern when assessed face-to-face.
Footnotes
BCC - basal cell carcinoma; CI - confidence interval; cSCC - cutaneous squamous cell carcinoma; TD - teledermatology
Additional tables 
1 Cross tabulation of included studies against target condition assessed, by type of images used for
teledermatology
Studies of diagnostic accuracy - Teldermatology vs Histology
FtF diagnosis2
vs Histology
Teldermatology 
vs expert FtF
Study Any skin cancer Melanoma1 BCC cSCC   Action
Arzberger
2016
Photo/Derm (excise
or not)
         
Borve 2015
Photo/Derm (dx as
malignant/ possibly
malignant)
         
Bowns 2006   Photo/Derm (dxas MM/MiS)
Photo/Derm
(dx as BCC)
     
Congalton
2015
  Photo/Derm
(excise or not)
       
Coras 2003   Photo/Derm* (dxas MM/MiS)
    dx as MM  
Ferrara 2004   Derm only (dx asMM/MiS)
       
Grimaldi 2009   Photo/Derm*(excise or not)
   
[GP dx as suspicious
for malignancy; data
not included]
 
Jolliffe 2001a Photo only* (dx asany SC) <5 MM
Photo only* (dx
as BCC)
  dx as any SC
dx as BCC
 
Kroemer 2011
Photo only*
Derm only* (dx as
malignant)
Photo only*
Derm only* (dx
as MM/MiS)
Photo only*
Derm only* (dx
as BCC)
Photo
only*
Derm only*
(dx as
cSCC)
dx as malignant
dx as MM/MiS
dx as BCC
dx as cSCC
 
Massone
2014
Photo/Derm (dx as
malignant)
         
Moreno
Ramirez 2005
Photol only (dx as
malignant)
Photo only (dx
as MM/MiS)
Photo only (dx
as BCC)
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Studies of diagnostic accuracy - Teldermatology vs Histology
FtF diagnosis2
vs Histology
Teldermatology 
vs expert FtF
Study Any skin cancer Melanoma1 BCC cSCC   Action
Piccolo 2000   Photo/Derm* (dxas MM)
    dx as MM  
Piccolo 2004   Derm only (dx asMM)
       
Silveira 2014 Photo only (dx asmalignant)
         
Warshaw
2010
  Photo only* (dx
as MM/MiS)
    dx of MM/MiS  
Wolf 2013   Photo only (dxas atypical)
       
Studies of referral accuracy - Teledermatology versus expert face-to-face decision
Jolliffe 2001b           Clin only (refer ornot)
Mahendran
2005
          Clin only (excise
or not)
Manahan
2015
          Clin/Derm (see
FtF)
Oliveira 2002           Clin only (dx asmalignant)
Phillips 1998          
Live link
(dx as any SC;
def/prob
malignant/
excise or not)
Shapiro 2004           Clin only (exciseor not)
Footnotes
BCC - basal cell carcinoma; cSCC - cutaneous squamous cell carcinoma; Derm - dermoscopic images; dx - diagnosis; FtF -
face-to-face; FU - follow-up; MiS - melanoma in situ (atypical intraepidermal melanocytic variants); MM - invasive melanoma;
Photo - photographic images; Rx - treat or treatment; SC - skin cancer; TD - teledermatology
1 all include melanoma in situ as disease positive apart from Piccolo 2000 and Piccolo 2004 which report detection of
invasive melanoma only
2 face to face diagnosis by an expert/dermatologist unless otherwise stated
*Includes a direct comparison with expert face-to-face diagnosis versus Histology
2 Summary estimates of sensitivity and specificity for teledermatology
Index test*, target condition StudiesCases/Number of
participants
Summary sensitivity
(95% CI) %
Summary specificity
(95% CI) %
Teledermatology photographic image, Any 4 452 / 717
94.9
(90.1 to 97.4)
84.3
(48.5 to 96.8)
Teledermatology photographic/dermoscopic
image, MM+MiS
4 93 / 664 85.4
(68.3 to 94.1)
91.6
(81.1 to 96.5)
Teledermatology photographic image vs
histology, BCC
3 62 /301 93.5
(84.0 to 97.6)
95.8
(92.4 to 97.7)
Footnotes
Any - any skin cancer; BCC - basal cell carcinoma; CI - confidence interval; MM+MiS = Invasive melanoma and atypical
intraepidermal melanocytic variants
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*Reference standard was histology for all comparisons
3 Direct comparisons of teledermatology with face-to-face diagnosis of melanoma and other types of skin
cancer
Study Sensitivity (true positives/cases) % Difference
(95% CI) 
Specificity (true negatives/non cases) % Difference
(95% CI)
Any skin cancer
  Teledermatology photographic
image
Expert
face-to-
face 
  Teledermatology 
photographic image
Expert face-
to-face
 
Jolliffe
2001a
100 (13/13) 100
(13/13)
0.00
(-2.28, 2.28)
92.9 (118/127) 94.7
(124/131)
-1.74
(-8.18, 4.49)
Kroemer
2011
93 (43/46) 100
(46/46)
-0.06
(-0.17, 0.02)
88 (51/58) 90 (52/58) -0.02
(-0.14, 0.10)
  Teledermatology dermoscopic
image
Expert
face-to-
face 
  Teledermatology dermoscopic
image
Expert face-
to-face
 
Kroemer
2011
85 (39/46) 100
(46/46)
-0.15
(-0.28,
-0.04)
91 (53/58) 90 (52/58) 0.02
(-0.13, 0.09)
Invasive melanoma or atypical intraepidermal melanocytic variants
  Teledermatology
photographic+dermoscopic
image
Expert
face-to-
face
  Teledermatology
photographic+dermoscopic
image
Expert face-
to-face
 
Coras
2003
81 (13/16) 88
(14/16)
-0.06
(-0.32, 0.20)
93 (27/29) 93 (27/29) 0.00
(-0.16, 0.16)
  Teledermatology dermoscopic
image
Expert
face-to-
face 
  Teledermatology dermoscopic
image
Expert face-
to-face 
 
Kroemer
2011
100 (5/5) 100 (5/5) 0.00
(-0.43, 0.43)
98 (97/99) 99 (98/99) -0.01 (-0.06,
0.04)
Warshaw
2010 59 (24/41)
73
(30/41)
-0.15 (-0.33,
0.06) 41 (604/1473)
63
(930/1473)
-0.22 (-0.26,
-0.19)*
Invasive melanoma
  Teledermatology
photographic/dermoscopic
image
Expert
face-to-
face 
  Teledermatology
photographic/dermoscopic
image
Expert face-
to-face 
 
Piccolo
2000
81.8 (9/11) 72.7
(8/11)
9.10
(-25.2, 41.2)
100 (32/32) 96.9 (31/32) 3.13
(-7.90, 15.7)
Basal cell carcinoma
  Teledermatology photographic
image
Expert
face-to-
face 
  Teledermatology 
photographic image
Expert face-
to-face
 
Jolliffe
2001a
100 (9/9) 100 (9/9) 0.00
(-29.9, 29.9)
97.0 (127/131) 97.8
(132/135)
-0.83
(-5.60, 3.68)
Footnotes
CI - confidence interval;
* denotes statistically significant difference
References to studies
Included studies 
#164f The use of teledermatology for the diagnosis of skin cancer in adults
100 / 167
Arzberger 2016
* Arzberger E, Curiel-Lewandrowski C, Blum A, Chubisov D, Oakley A, Rademaker M, et al. Teledermoscopy in High-
risk Melanoma Patients: A Comparative Study of Face-to-face and Teledermatology Visits. Acta Dermato-
Venereologica 2016;96(6):779-83. [Other: ER4:25012365; PubMed: 26776245]
Borve 2015
Borve A, Dahlen Gyllencreutz J, Terstappen K, Johansson Backman E, Aldenbratt A, Danielsson M, et al. Smartphone
teledermoscopy referrals: a novel process for improved triage of skin cancer patients. Acta Dermato-Venereologica 2015;
95(2):180-90. [ PubMed: 24923283]
Bowns 2006
* Bowns IR, Collins K, Walters SJ, McDonagh AJ. Telemedicine in dermatology: a randomised controlled trial. Health
Technology Assessment (Winchester, England) 2006;10(43):iii-iv, ix-xi, 1-39. [Other: ER4:15465874; PubMed: 17049140]
Congalton 2015
* Congalton AT, Oakley AM, Rademaker M, Bramley D, Martin RC. Successful melanoma triage by a virtual lesion
clinic (teledermatoscopy). Journal of the European Academy of Dermatology & Venereology 2015;29(12):2423-8. [Other:
ER4:25012348; PubMed: 26370585]
Coras 2003
* Coras B, Glaessl A, Kinateder J, Klovekorn W, Braun R, Lepski U, et al. Teledermatoscopy in daily routine--results of
the first 100 cases. Current Problems in Dermatology 2003;32:207-12. [Other: ER4:18375040; PubMed: 12472014]
Ferrara 2004
Ferrara G, Argenziano G, Cerroni L, Cusano F, Di Blasi A, Urso C, et al. A pilot study of a combined
dermoscopic–pathological approach to the telediagnosis of melanocytic skin neoplasms. Journal of Telemedicine and
Telecare 2004;10(1):34–8. [ PubMed: 15006214]
Grimaldi 2009
* Grimaldi L, Silvestri A, Brandi C, Nisi G, Brafa A, Calabro M, et al. Digital epiluminescence dermoscopy for
pigmented cutaneous lesions, primary care physicians, and telediagnosis: a useful tool? Journal of Plastic,
Reconstructive & Aesthetic Surgery: JPRAS 2009;62(8):1054-8. [Other: ER4:15465940; PubMed: 18547883]
Jolliffe 2001a
* Jolliffe VM, Harris DW, Whittaker SJ. Can we safely diagnose pigmented lesions from stored video images? A
diagnostic comparison between clinical examination and stored video images of pigmented lesions removed for
histology. Clinical & Experimental Dermatology 2001;26(1):84-7. [Other: ER4:15465970; PubMed: 11260186]
Jolliffe 2001b
Jolliffe VM, Harris DW, Morris R, Wallace P, Whittaker SJ. Can we use video images to triage pigmented lesions? British
Journal of Dermatology 2001;145(6):904-10. [ PubMed: 11899143]
Kroemer 2011
* Kroemer S, Fruhauf J, Campbell TM, Massone C, Schwantzer G, Soyer HP, et al. Mobile teledermatology for skin
tumour screening: diagnostic accuracy of clinical and dermoscopic image tele-evaluation using cellular phones. British
Journal of Dermatology 2011;164(5):973-9. [Other: ER4:15465982; PubMed: 21219286]
Mahendran 2005
* Mahendran R, Goodfield MJ, Sheehan-Dare RA. An evaluation of the role of a store-and-forward teledermatology
system in skin cancer diagnosis and management. Clinical & Experimental Dermatology 2005;30(3):209-14. [Other:
ER4:15465998; PubMed: 15807671]
Manahan 2015
Manahan MN, Soyer HP, Loescher LJ, Horsham C, Vagenas D, Whiteman DC, et al. A pilot trial of mobile, patient-performed
teledermoscopy. British Journal of Dermatology 2015;172(4):1072-80.
Massone 2014
* Massone C, Maak D, Hofmann-Wellenhof R, Soyer HP, Fruhauf J. Teledermatology for skin cancer prevention: an
experience on 690 Austrian patients. Journal of the European Academy of Dermatology & Venereology 2014;
28(8):1103-8. [Other: ER4:17941088; PubMed: 24372877]
Moreno Ramirez 2005
* Moreno Ramirez D, Ferrandiz L, Bernal AP, Duran RC, Martin JJ, Camacho F. Teledermatology as a filtering system
in pigmented lesion clinics. Journal of Telemedicine & Telecare 2005;11(6):298-303. [Other: ER4:15466016; PubMed:
16168166]
Oliveira 2002
#164f The use of teledermatology for the diagnosis of skin cancer in adults
101 / 167
Oliveira MR, Wen CL, Neto CF, Silveira PS, Rivitti EA, Bohm GM. Web site for training nonmedical health-care workers to
identify potentially malignant skin lesions and for teledermatology. Telemedicine Journal and E-health 2002;8(3):323-32.
Phillips 1998
Phillips CM, Burke WA, Allen MH, Stone D, Wilson JL. Reliability of telemedicine in evaluating skin tumors. Telemedicine
Journal 1998;4(1):5-9.
Piccolo 2000
* Piccolo D, Smolle J, Argenziano G, Wolf IH, Braun R, Cerroni L, et al. Teledermoscopy--results of a multicentre study
on 43 pigmented skin lesions. Journal of Telemedicine & Telecare 2000;6(3):132-7. [Other: ER4:15466059; PubMed:
10912329]
Piccolo 2004
* Piccolo D, Soyer HP, Chimenti S,Argenziano G, Bartenjev I, Hofmann-Wellenhof R, et al. Diagnosis and
categorization of acral melanocytic lesions using teledermoscopy. Journal of Telemedicine & Telecare 2004;
10(6):346-50. [Other: ER4:15466061; PubMed: 15603633]
Shapiro 2004
* Shapiro M, James WD, Kessler R, Lazorik FC, Katz KA, Tam J, et al. Comparison of skin biopsy triage decisions in
49 patients with pigmented lesions and skin neoplasms: store-and-forward teledermatology vs face-to-face
dermatology. Archives of Dermatology 2004;140(5):525-8. [Other: ER4:15466120; PubMed: 15148095]
Silveira 2014
Silveira CE, Silva TB, Fregnani JH, da Costa Vieira RA, Haikel RL, Syrjänen K, et al. Digital photography in skin cancer
screening by mobile units in remote areas of Brazil. BMC Dermatology 2014;14:19. [ PubMed: 25539949]
Warshaw 2010
Warshaw EM, Gravely AA, Nelson DB. Accuracy of teledermatology/teledermoscopy and clinic-based dermatology for
specific categories of skin neoplasms. Journal of the American Academy of Dermatology 2010;63(2):348-52.
Wolf 2013
Wolf JA, Moreau JF, Akilov O, Patton T, English JC 3rd, Ho J, et al. Diagnostic inaccuracy of smartphone applications for
melanoma detection. JAMA Dermatol 2013;149(4):422-6. [ PubMed: 23325302]
Excluded studies 
Armstrong 2007
Armstrong AW, Dorer DJ, Lugn NE, Kvedar JC. Economic evaluation of interactive teledermatology compared with
conventional care. Telemedicine Journal and E-health 2007;3(2):91-9. [DOI: 10.1089/tmj.2006.0035]
Baba 2005
Baba M, Seckin D, Kapdagli S. A comparison of teledermatology using store-and-forward methodology alone, and in
combination with Web camera videoconferencing. Journal of Telemedicine and Telecare 2005;11(7):354-60. [DOI:
10.1258/135763305774472097]
Badertscher 2015
Badertscher N, Tandjung R, Senn O, Kofmehl R, Held U, Rosemann T, et al. A multifaceted intervention: no increase in
general practitioners' competence to diagnose skin cancer (minSKIN) - randomized controlled trial. Journal of the European
Academy of Dermatology & Venereology 2015;29(8):1493-9.
Barnard 2000
Barnard CM, Goldyne ME. Evaluation of an asynchronous teleconsultation system for diagnosis of skin cancer and other skin
diseases. Telemedicine Journal and E-health 2000;6(4):379-84.
Bashshur 2015
Bashshur RL, Shannon GW, Tejasvi T, Kvedar JC, Gates M. The Empirical Foundations of Teledermatology: A Review of
the Research Evidence. Telemedicine Journal and E-Health 2015;21(12):953-79.
Bataille 2011
Bataille V, Hargest E, Brown V, Blackwell V, Dawe S, Cooper A, et al. A teledermatology pilot study in Hertfordshire: Triage
of 2-week-wait referrals. British Journal of Dermatology 2011;165(Suppl 1):137-8.
Bergmo 2000
Bergmo TS. A cost-minimization analysis of a realtime teledermatology service in northern Norway. Journal of Telemedicine
and Telecare 2000;6(5):273-7.
Borve 2013
Borve A, Terstappen K, Sandberg C, Paoli J. Mobile teledermoscopy-there's an app for that! Dermatology Practical &
#164f The use of teledermatology for the diagnosis of skin cancer in adults
102 / 167
Conceptual 2013;3(2):41-8.
Boyce 2011
Boyce Z, Gilmore S, Xu C, Soyer HP. The remote assessment of melanocytic skin lesions: A viable alternative to face-to-
face consultation. Dermatology 2011;223(3):244-50.
Braun 2000
Braun RP, Meier M, Pelloni F, Ramelet AA, Schilling M, Tapernoux B, et al. Teledermatoscopy in Switzerland: a preliminary
evaluation. Journal of the American Academy of Dermatology 2000;42(5 Pt 1):770-5.
Brown 2000
Brown N. Exploration of diagnostic techniques for malignant melanoma: an integrative review. Clinical Excellence for Nurse
Practitioners 2000;4(5):263-71.
Burgiss 1997
Burgiss SG, Julius CE, Watson HW, Haynes BK, Buonocore E, Smith GT. Telemedicine for dermatology care in rural
patients. Telemedicine Journal and E-health 1997;3(3):227-33. [DOI: 10.1089/tmj.1.1997.3.227]
Chen 2002
Chen K, Lim A, Shumack S. Teledermatology: influence of zoning and education on a clinician's ability to observe peripheral
lesions. Australasian Journal of Dermatology 2002;43(3):171-4.
D'Elia 2007
D'Elia PB, Harzheim E, Fisher PD, Ramos MC, Bordin R. Agreement between dermatological diagnoses made by direct
observation and digital images [Concordancia entre diagnosticos dermatologicos feitos presencialmente e por imagens
digitais]. Anais Brasileiros de Dermatologia 2007;82(6):521-7.
Di Stefani 2007
Di Stefani A, Zalaudek I, Argenziano G, Chimenti S, Soyer HP. Feasibility of a two-step teledermatologic approach for the
management of patients with multiple pigmented skin lesions. Dermatologic Surgery 2007;33(6):686-92.
Du Moulin 2003
Du Moulin MF, Bullens-Goessens YI, Henquet CJ, Brunenberg DE, de Bruyn-Geraerds DP, Winkens RA, et al. The reliability
of diagnosis using store-and-forward teledermatology. Journal of Telemedicine and Telecare 2003;9(5):249-52.
Edison 2008
Edison KE, Ward DS, Dyer JA, Lane W, Chance L, Hicks LL. Diagnosis, diagnostic confidence, and management
concordance in live-interactive and store-and-forward teledermatology compared to in-person examination. Telemedicine
Journal and E-Health 2008;14(9):889-95. [DOI: 10.1089/tmj.2008.0001]
Eminovic 2009
Eminovic N, de Keizer NF, Wyatt JC, ter Riet G, Peek N, van Weert HC, et al. Teledermatologic consultation and reduction in
referrals to dermatologists: a cluster randomized controlled trial. Archives Dermatology 2009;145(5):558-64.
Fabbrocini 2008
Fabbrocini G, Balato A, Rescigno O, Mariano M, Scalvenzi M, Brunetti B. Telediagnosis and face-to-face diagnosis reliability
for melanocytic and non-melanocytic 'pink' lesions. Journal of the European Academy of Dermatology & Venereology 2008;
22(2):229-34.
Ferrandiz 2007
Ferrandiz L, Moreno RD, Nieto-Garcia A, Carrasco R, Moreno-Alvarez P, Galdeano R, et al. Teledermatology-based
presurgical management for nonmelanoma skin cancer: a pilot study. Dermatologic Surgery 2007;33(9):1092-8.
Ferrandiz 2012
Ferrandiz L, Ruiz-de-Casas A, Martin-Gutierrez FJ, Peral-Rubio F, Mendez-Abad C, Rios-Martin JJ, et al. Effect of
teledermatology on the prognosis of patients with cutaneous melanoma. Archives of Dermatology 2012;148(9):1025-8.
Gilmour 1998
Gilmour E, Campbell SM, Loane MA, Esmail A, Griffiths CE, Roland MO, et al. Comparison of teleconsultations and face-to-
face consultations: preliminary results of a United Kingdom multicentre teledermatology study. British Journal of Dermatology
1998;139(1):81-7.
Granlund 2003
Granlund H, Thoden CJ, Carlson C, Harno K. Realtime teleconsultations versus face-to-face consultations in dermatology:
immediate and six-month outcome. Journal of Telemedicine and Telecare 2003;9(4):204-9.
Griffiths 2010
Griffiths WA. Improving melanoma diagnosis in primary care--a tele-dermatoscopy project. Journal of Telemedicine and
#164f The use of teledermatology for the diagnosis of skin cancer in adults
103 / 167
Telecare 2010;16(4):185-6.
Harrison 1998
Harrison PV, Kirby B, Dickinson Y, Schofield R. Teledermatology--high technology or not? Journal of Telemedicine and
Telecare 1998;4(Suppl 1):31-2.
Heffner 2009
Heffner VA, Lyon VB, Brousseau DC, Holland KE, Yen K. Store-and-forward teledermatology versus in-person visits: A
comparison in pediatric teledermatology clinic. Journal of the American Academy of Dermatology 2009;60(6):956-61.
Hicks 2003
Hicks LL, Boles KE, Hudson S, Kling B, Tracy J, Mitchell J, et al. Patient satisfaction with teledermatology services. Journal
of Telemedicine and Telecare 2003;9(1):42-5.
High 2000
High WA, Houston MS, Calobrisi SD, Drage LA, McEvoy MT. Assessment of the accuracy of low-cost store-and-forward
teledermatology consultation. Journal of the American Academy of Dermatology 2000;42(5):776-83.
Hue 2016
Hue L, Makhloufi S, Sall N'Diaye P, Blanchet-Bardon C, Sulimovic L, Pomykala F, et al. Real-time mobile teledermoscopy for
skin cancer screening targeting an agricultural population: an experiment on 289 patients in France. Journal of the European
Academy of Dermatology & Venereology 2016;30(1):20-4.
Hwang 2014
Hwang JS, Lappan CM, Sperling LC, Meyerle JH. Utilization of Telemedicine in the U.S. Military in a Deployed Setting.
Military Medicine 2014;179(11):1347-53.
Ishioka 2009
Ishioka P, Tenorio JM, Lopes PR, Yamada S, Michalany NS, Amaral MB, et al. A comparative study of teledermatoscopy
and face-to-face examination of pigmented skin lesions. Journal of Telemedicine and Telecare 2009;15(5):221-5.
Kahn 2013
Kahn E, Sossong S, Goh A, Carpenter D, Goldstein S. Evaluation of skin cancer in Northern California Kaiser Permanente's
store-and-forward teledermatology referral program. Telemedicine Journal and E-health 2013;19(10):780-5.
Knol 2006
Knol A, van den Akker TW, Damstra RJ, de Haan J. Teledermatology reduces the number of patient referrals to a
dermatologist. Journal of Telemedicine and Telecare 2006;12(2):75-8.
Krupinski 1999
Krupinski EA, LeSueur B, Ellsworth L, Levine N, Hansen R, Silvis N, et al. Diagnostic accuracy and image quality using a
digital camera for teledermatology. Telemedicine Journal 1999;5(3):257-63.
Lamel 2012
Lamel SA, Haldeman KM, Ely H, Kovarik CL, Pak H, Armstrong AW. Application of mobile teledermatology for skin cancer
screening. Journal of the American Academy of Dermatology 2012;67(4):576-81.
Lamminen 2000
Lamminen H, Tuomi ML, Lamminen J, Uusitalo H. A feasibility study of realtime teledermatology in Finland. Journal of
Telemedicine and Telecare 2000;6(2):102-7.
Lesher 1998
Lesher JL Jr, Davis LS, Gourdin FW, English D, Thompson WO. Telemedicine evaluation of cutaneous diseases: A blinded
comparative study. Journal of the American Academy of Dermatology 1998;38(1):27-31.
Lewis 1999
Lewis K, Gilmour E, Harrison PV, Patefield S, Dickinson Y, Manning D, et al. Digital teledermatology for skin tumours: a
preliminary assessment using a receiver operating characteristics (ROC) analysis. Journal of Telemedicine and Telecare
1999;5(Suppl 1):S57-8.
Loane 1998
Loane MA, Bloomer SE, Corbett R, Eedy DJ, Gore HE, Mathews C, et al. Patient satisfaction with realtime teledermatology
in Northern Ireland. Journal of Telemedicine and Telecare 1998;4(1):36-40.
Loane 1998a
Loane MA, Corbett R, Bloomer SE, Eedy DJ, Gore HE, Mathews C, et al. Diagnostic accuracy and clinical management by
realtime teledermatology. Results from the Northern Ireland arms of the UK Multicentre Teledermatology Trial. Journal of
Telemedicine and Telecare 1998;4(2):95-100.
#164f The use of teledermatology for the diagnosis of skin cancer in adults
104 / 167
Loane 2000
Loane MA, Bloomer SE, Corbett R, Eedy DJ, Hicks N, Lotery HE, et al. A comparison of real-time and store-and-forward
teledermatology: a cost-benefit study. British Journal of Dermatology 2000;143(6):1241-7.
Loane 2001
Loane MA, Bloomer SE, Corbett R, Eedy DJ, Evans C, Hicks N, et al. A randomized controlled trial assessing the health
economics of realtime teledermatology compared with conventional care: an urban versus rural perspective. Journal of
Telemedicine and Telecare 2001;7(2):108-18.
Loane 2001a
Loane MA, Oakley A, Rademaker M, Bradford N, Fleischl P, Kerr P, et al. A cost-minimization analysis of the societal costs
of realtime teledermatology compared with conventional care: results from a randomized controlled trial in New Zealand.
Journal of Telemedicine and Telecare 2001;7(4):233-8.
Lowitt 1998
Lowitt MH, Kessler II, Kauffman C, Hooper FJ, Siegel E, Burnett JW. Teledermatology and in-person examinations: A
comparison of patient and physician perceptions and diagnostic agreement. Archives of Dermatology 1998;134(4):471-6.
Lyon 1997
Lyon CC, Harrison PV. A portable digital imaging system in dermatology: Diagnostic and educational applications. Journal of
Telemedicine and Telecare 1997;3(1_suppl):81-3.
Martinez-Garcia 2007
Martinez-Garcia S, del Boz-Gonzalez J, Martin-Gonzalez T, Samaniego-Gonzalez E, Crespo-Erchiga V. Teledermatology.
Review of 917 teleconsults. Actas Dermo-Sifiliograficas 2007;98(5):318-24.
Massone 2007
Massone C, Hofmann-Wellenhof R, Ahlgrimm-Siess V, Gabler G, Ebner C, Soyer HP. Melanoma screening with cellular
phones. PLoS ONE (Electronic Resource) 2007;2(5):e483.
May 2008
May C, Giles L, Gupta G. Prospective observational comparative study assessing the role of store and forward
teledermatology triage in skin cancer. Clinical and Experimental Dermatology 2008;33(6):736-9.
McGraw 2009
McGraw TA, Norton SA. Military aeromedical evacuations from central and southwest Asia for ill-defined dermatologic
diseases. Archives of Dermatology 2009;145(2):165-70.
McManus 2008
McManus J, Salinas J, Morton M, Lappan C, Poropatich R. Teleconsultation program for deployed soldiers and healthcare
professionals in remote and austere environments. Prehospital & Disaster Medicine 2008;23(3):210-6.
Moreno-Ramirez 2006
Moreno Ramirez D, Ferrandiz L, Galdeano R, Camacho FM. Teledermatoscopy as a triage system for pigmented lesions: a
pilot study. Clinical and Experimental Dermatology 2006;31(1):13-8.
Moreno-Ramirez 2007
Moreno Ramirez D, Ferrandiz L, Nieto-Garcia A, Carrasco R, Moreno-Alvarez P, Galdeano R, et al. Store-and-forward
teledermatology in skin cancer triage: experience and evaluation of 2009 teleconsultations. Archives of Dermatology 2007;
143(4):479-84.
Moreno-Ramirez 2009
Moreno Ramirez D, Ferrandiz L, Ruiz-de-Casas A, Nieto-Garcia A, Moreno-Alvarez P, Galdeano R, et al. Economic
evaluation of a store-and-forward teledermatology system for skin cancer patients. Journal of Telemedicine and Telecare
2009;15(1):40-5.
Ndegwa 2010
Ndegwa S, Prichett-Pejic W, McGill S, Murphy G, Severn M. Teledermatology services: rapid review of diagnostic, clinical
management, and economic outcomes. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH), 2010.
Nordal 2001
Nordal EJ, Moseng D, Kvammen B, Løchen ML. A comparative study of teleconsultations versus face-to-face consultations.
Journal of Telemedicine and Telecare 2001;7(5):257-65.
Oakley 1997
Oakley AM, Astwood DR, Loane M, Duffill MB, Rademaker M, Wootton R. Diagnostic accuracy of teledermatology: results of
a preliminary study in New Zealand. New Zealand Medical Journal 1997;110(1038):51-3.
#164f The use of teledermatology for the diagnosis of skin cancer in adults
105 / 167
Oakley 2006
Oakley AM, Reeves F, Bennett J, Holmes SH, Wickham H. Diagnostic value of written referral and/or images for skin lesions.
Journal of Telemedicine and Telecare 2006;12(3):151-8.
Oztas 2004
Oztas MO, Calikoglu E, Baz K, Birol A, Onder M, Calikoglu T, et al. Reliability of Web-based teledermatology consultations.
Journal of Telemedicine and Telecare 2004;10(1):25-8.
Pak 1999
Pak HS, Welch M, Poropatich R. Web-based teledermatology consult system: preliminary results from the first 100 cases.
Studies in Health Technology and Informatics 1999;64:179-84.
Pak 2002
Pak HS. Teledermoscopy: a specific application of teledermotology. SKINmed 2002;1(1):18-9.
Pak 2003a
Pak HS, Harden D, Cruess D, Welch ML, Poropatich R. Teledermatology: an intraobserver diagnostic correlation study, part
I. Cutis 2003;71(5):399-403.
Pak 2003b
Pak HS, Harden D, Cruess D, Welch ML, Poropatich R. Teledermatology: an intraobserver diagnostic correlation study, Part
II. Cutis 2003;71(6):476-80.
Pak 2007
Pak H, Triplett CA, Lindquist JH, Grambow SC, Whited JD. Store-and-forward teledermatology results in similar clinical
outcomes to conventional clinic-based care. Journal of Telemedicine and Telecare 2007;13(1):26-30.
Pak 2009
Pak HS, Datta SK, Triplett CA, Lindquist JH, Grambow SC, Whited JD. Cost minimization analysis of a store-and-forward
teledermatology consult system. Telemedicine Journal and E-health 2009;15(2):160-5.
Patro 2015
Patro B, Tripathy J, De D, Sinha S, Singh A, Kanwar AJ. Diagnostic agreement between a primary care physician and a
teledermatologist for common dermatological conditions in North India. Indian Dermatology Online Journal 2015;6(1):21-6.
Perednia 1998
Perednia DA, Wallace J, Morrisey M, Bartlett M, Marchionda L, Gibson A, et al. The effect of a teledermatology program on
rural referral patterns to dermatologists and the management of skin disease. Studies in health technology and informatics
1998;52(Pt 1):290-3.
Phillips 1997
Phillips CM, Burke WA, Shechter A, Stone D, Balch D, Gustke S. Reliability of dermatology teleconsultations with the use of
teleconferencing technology. Journal of the American Academy of Dermatology 1997;37(3):398-402.
Piccolo 1999
Piccolo D, Smolle J, Wolf IH, Peris K, Hofmann-Wellenhof R, Dell'Eva G, et al. Face-to-face diagnosis vs telediagnosis of
pigmented skin tumors: a teledermoscopic study. Archives of Dermatology 1999;135(12):1467-71.
Piccolo 2002
Piccolo D, Peris K, Chimenti S, Argenziano G, Soyer HP. Jumping into the future using teledermoscopy. SKINmed 2002;
1(1):20-4.
Rashid 2003
Rashid E, Ishtiaq O, Gilani S, Zafar A. Comparison of store and forward method of teledermatology with face-to-face
consultation. Journal of Ayub Medical College, Abbottabad 2003;15(2):34-6.
Ribas 2010
Ribas J, da Graça Souza Cunha M, Schettini AP, Barros da Rocha Ribas C. Concordância entre diagnósticos
dermatológicos obtidos por consulta presencial e por análise de imagens digitais. Anais Brasileiros de Dermatologia 2010;
85(4):441-7.
Romero 2010
Romero G, Sanchez P, Garcia M, Cortina P, Vera E, Garrido JA. Randomized controlled trial comparing store-and-forward
teledermatology alone and in combination with web-camera videoconferencing. Clinical and Experimental Dermatology 2010;
35(3):311-7.
Romero 2014
#164f The use of teledermatology for the diagnosis of skin cancer in adults
106 / 167
Romero Aguilera G, Cortina de la Calle P, Vera Iglesias E, Sánchez Caminero P, García Arpa M, Garrido Martín JA.
Interobserver reliability of store-and-forward teledermatology in a clinical practice setting. Actas Dermo-Sifiliográficas
(English Edition) 2014;105(6):605-13.
Seidenari 2004
Seidenari S, Pellacani G, Righi E, Di Nardo A. Is JPEG compression of videomicroscopic images compatible with
telediagnosis? Comparison between diagnostic performance and pattern recognition on uncompressed TIFF images and
JPEG compressed ones. Telemedicine Journal and E-health 2004;10(3):294-303.
Senel 2013
Senel E, Baba M, Durdu M. The contribution of teledermatoscopy to the diagnosis and management of non-melanocytic skin
tumours. Journal of Telemedicine and Telecare 2013;19(1):60-3.
Shin 2014
Shin H, Kim DH, Ryu HH, Yoon SY, Jo SJ. Teledermatology consultation using a smartphone multimedia messaging service
for common skin diseases in the Korean army: a clinical evaluation of its diagnostic accuracy. Journal of Telemedicine and
Telecare 2014;20(2):70-4.
Tait 1999
Tait CP, Clay CD. Pilot study of store and forward teledermatology services in Perth, Western Australia. Australasian Journal
of Dermatology 1999;40(4):190-3.
Tan 2010
Tan E, Oakley A, Soyer HP, Haskett M, Marghoob A, Jameson M, et al. Interobserver variability of teledermoscopy: an
international study. British Journal of Dermatology 2010;163(6):1276-81.
Tan 2010a
Tan E, Yung A, Jameson M, Oakley A, Rademaker M. Successful triage of patients referred to a skin lesion clinic using
teledermoscopy (IMAGE IT trial). British Journal of Dermatology 2010;162(4):803-11.
Tandjung 2015
Tandjung R, Badertscher N, Kleiner N, Wensing M, Rosemann T, Braun RP, et al. Feasibility and diagnostic accuracy of
teledermatology in Swiss primary care: process analysis of a randomized controlled trial. Journal of Evaluation in Clinical
Practice 2015;21(2):326-31.
Taylor 2001
Taylor P, Goldsmith P, Murray K, Harris D, Barkley A. Evaluating a telemedicine system to assist in the management of
dermatology referrals. British Journal of Dermatology 2001;144(2):328-33.
Tucker 2005
Tucker WF, Lewis FM. Digital imaging: a diagnostic screening tool? International Journal of Dermatology 2005;44(6):479-81.
van der Heijden 2013
van der Heijden JP, Thijssing L, Witkamp L, Spuls PI, de Keizer NF. Accuracy and reliability of teledermatoscopy with
images taken by general practitioners during everyday practice. Journal of Telemedicine and Telecare 2013;19(6):320-5.
Vano-Galvan 2011
Vano-Galvan S, Hidalgo A, Aguayo-Leiva I, Gil-Mosquera M, Rios-Buceta L, Plana MN, et al. (Store-and-forward
teledermatology: assessment of validity in a series of 2000 observations). Actas Dermo-Sifiliograficas 2011;102(4):277-83.
Warshaw 2009
Warshaw EM, Lederle FA, Grill JP, Gravely AA, Bangerter AK, Fortier LA, et al. Accuracy of teledermatology for pigmented
neoplasms. Journal of the American Academy of Dermatology 2009;61(5):753-65.
Warshaw 2009a
Warshaw EM, Lederle FA, Grill JP, Gravely AA, Bangerter AK, Fortier LA, et al. Accuracy of teledermatology for
nonpigmented neoplasms. Journal of the American Academy of Dermatology 2009;60(4):579-88.
Warshaw 2010a
Warshaw EM, Gravely AA, Bohjanen KA, Chen K, Lee PK, Rabinovitz HS, et al. Interobserver accuracy of store and forward
teledermatology for skin neoplasms. Journal of the American Academy of Dermatology 2010;62(3):513-6.
Warshaw 2015
Warshaw EM, Gravely AA, Nelson DB. Reliability of store and forward teledermatology for skin neoplasms. Journal of the
American Academy of Dermatology 2015;72(3):426-35.
Watson 2010
Watson AJ, Bergman H, Williams CM, Kvedar JC. A randomized trial to evaluate the efficacy of online follow-up visits in the
#164f The use of teledermatology for the diagnosis of skin cancer in adults
107 / 167
management of acne. Archives of Dermatology 2010;146(4):406-11.
Weingast 2013
Weingast J, Scheibböck C, Wurm EM, Ranharter E, Porkert S, Dreiseitl S, et al. A prospective study of mobile phones for
dermatology in a clinical setting. Journal of Telemedicine and Telecare 2013;19(4):213-8.
Weinstock 2002
Weinstock MA, Nguyen FQ, Risica PM. Patient and referring provider satisfaction with teledermatology. Journal of the
American Academy of Dermatology 2002;47(1):68-72.
Weinstock 2009
Weinstock MA. Evaluation of in-person dermatology versus teledermatology. Journal of the American Academy of
Dermatology 2009;61(5):902-3.
Whited 1999
Whited JD, Hall RP, Simel DL, Foy ME, Stechuchak KM, Drugge RJ, et al. Reliability and accuracy of dermatologists’ clinic-
based and digital image consultations. Journal of the American Academy of Dermatology 1999;41(5):693-702.
Whited 2002
Whited JD, Hall RP, Foy ME, Marbrey LE, Grambow SC, Dudley TK, et al. Teledermatology's impact on time to intervention
among referrals to a dermatology consult service. Telemedicine Journal and E-health 2002;8(3):313-21.
Whited 2003
Whited JD, Datta S, Hall RP, Foy ME, Marbrey LE, Grambow SC, et al. An economic analysis of a store and forward
teledermatology consult system. Telemedicine Journal and E-health 2003;9(4):351-60.
Whited 2004
Whited JD, Hall RP, Foy ME, Marbrey LE, Grambow SC, Dudley TK, et al. Patient and clinician satisfaction with a store-and-
forward teledermatology consult system. Telemedicine Journal and E-health 2004;10(4):422-31.
Whited 2006
Whited JD. Teledermatology research review. International Journal of Dermatology 2006;45(3):220-9.
Whited 2010
Whited JD. Economic analysis of telemedicine and the teledermatology paradigm. Telemedicine Journal and E-health 2010;
16(2):223-8.
Whited 2016
Whited JD. Diagnosis and management of pigmented skin lesions using teledermatology. Current Dermatology Reports
2016;5(2):90-5.
Williams 2001
Williams T, May C, Esmail A, Ellis N, Griffiths C, Stewart E, et al. Patient satisfaction with store-and-forward teledermatology.
Journal of Telemedicine and Telecare 2001;7(Suppl 1):45-6.
Williams 2007
Williams CM, Qureshi A, Geller A, Kvedar J. Skin cancer education program via teledermatology: Is it effective? Journal of
the American Academy of Dermatology 2007;56(2):AB100.
Wootton 2000
Wootton R, Bloomer SE, Corbett R, Eedy DJ, Hicks N, Lotery HE, et al. Multicentre randomised control trial comparing real
time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis. BMJ 2000;
320(7244):1252-6.
Zelickson 1997
Zelickson BD, Homan L. Teledermatology in the nursing home. Archives of Dermatology 1997;133(2):171-4.
Studies awaiting classification 
Ongoing studies 
Other references
Additional references 
ACIM 2014
Australian Cancer Database. Melanoma of the skin for Australia (ICD10 C43).. In: Australian Cancer Incidence and Mortality
(ACIM) Books (http://www.aihw.gov.au/acim-books/). Australian Institute of Health and Welfare, 2011.
Alam 2001
#164f The use of teledermatology for the diagnosis of skin cancer in adults
108 / 167
Alam M, Ratner D. Cutaneous squamous-cell carcinoma (Review). New England Journal of Medicine 2001;344(13):975-83. [
PubMed: 11274625]
Aldridge 2013
Aldridge RB, Naysmith L, Ooi ET, Murray CS, Rees JL. The importance of a full clinical examination: assessment of index
lesions referred to a skin cancer clinic without a total body skin examination would miss one in three melanomas. Acta
Dermato-Venereologica 2013;93(6):689-92. [ PubMed: 23695107]
Argenziano 2012
Argenziano G, Zalaudek I, Hofmann-Wellenhof R, Bakos RM, Bergman W, Blum A, et al. Total body skin examination for
skin cancer screening in patients with focused symptoms. Journal of the American Academy of Dermatology 2012;
66(2):212-19. [ PubMed: 21757257]
Arits 2013
Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical
imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority,
randomised controlled trial. Lancet Oncology 2013;14(7):647-54. [DOI: 10.1016/S1470-2045(13)70143-8]
Arnold 2014
Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten T, Pukkala E, et al. Trends in incidence and predictions of
cutaneous melanoma across Europe up to 2015. Journal of the European Academy of Dermatology & Venereology 2014;
28(9):1170-8. [ PubMed: 23962170]
Baldursson 1993
Baldursson B, Sigurgeirsson B, Lindelof B. Leg ulcers and squamous cell carcinoma. An epidemiological study and a review
of the literature. Acta Dermato-Venereologica 1993;73(3):171-4. [ PubMed: 8105611]
Bath-Hextall 2007
Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R. Trends in incidence of skin basal cell carcinoma. Additional
evidence from a UK primary care database study. International Journal of Cancer 2007;121(9):2105-8. [ PubMed: 17640064
]
Bath-Hextall 2007a
Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database of
Systematic Reviews 2007, Issue 1. Art. No.: CD003412 DOI: 10.1002/14651858.CD003412.pub2.
Bath-Hextall 2014
Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al. Surgical excision versus imiquimod 5%
cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Lancet Oncology 2014;15(1):96-105. [ PubMed: 24332516]
Batra 2002
Batra RS, Kelley LC. A risk scale for predicting extensive subclinical spread of nonmelanoma skin cancer. Dermatologic
Surgery 2002;28(2):107-12; discussion 112. [ PubMed: 11860418]
Belbasis 2016
Belbasis L, Stefanaki I, Stratigos AJ, Evangelou E. Non-genetic risk factorsfor cutaneous melanoma and keratinocyte skin
cancers: An umbrella review of meta-analyses.. Journal of Dermatological Science 2016;84(3):330-339.
Benelli 1999
Benelli C, Roscetti E, Pozzo VD, Gasparini G, Cavicchini S. The dermoscopic versus the clinical diagnosis of melanoma.
European Journal of Dermatology 1999;9(6):470-6. [ PubMed: 10491506]
Binder 1997
Binder M, Schwarz M, Steiner A, Kittler H, Muellner M, Wolff K, et al. Epiluminescence microscopy of small pigmented skin
lesions: short-term formal training improves the diagnostic performance of dermatologists. Journal of the American Academy
of Dermatology 1997;36(2 Pt 1):197-202. [ PubMed: 9039168]
Bono 2002
Bono A, Bartoli C, Cascinelli N, Lualdi M, Maurichi A, Moglia D, et al. Melanoma detection. A prospective study comparing
diagnosis with the naked eye, dermatoscopy and telespectrophotometry. Dermatology 2002;205(4):362-6. [ PubMed:
12444332]
Bono 2006
Bono A, Tolomio E, Trincone S, Bartoli C, Tomatis S, Carbone A, et al. Micro-melanoma detection: a clinical study on 206
consecutive cases of pigmented skin lesions with a diameter < or = 3 mm. British Journal of Dermatology 2006;155(3):570-3.
Boring 1994
#164f The use of teledermatology for the diagnosis of skin cancer in adults
109 / 167
Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA: a Cancer Journal for Clinicians 1994;
44(1):7-26. [ PubMed: 8281473]
Bossuyt 2015
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential
items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527. [DOI: 10.1136/bmj.h5527; PubMed: 26511519]
Cancer Research UK 2017
Cancer Research UK. Skin cancer statistics. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/skin-cancer#heading-One (accessed prior to 19 July 2017).
Carli 2002
Carli P, De Giorgi V, Argenziano G, Palli D, Giannotti B. Pre-operative diagnosis of pigmented skin lesions: in vivo
dermoscopy performs better than dermoscopy on photographic images. Journal of the European Academy of Dermatology &
Venereology 2002;16(4):339-46.
Carter 2013
Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with
perineural invasion: an 11-year cohort study. JAMA Dermatology 2013;149(1):35-41. [DOI: 10.1001/jamadermatol.2013.746; 
PubMed: 23324754]
CCAAC Network 2008
Cancer Council Australia & Australian Cancer Network. Basal Cell Carcinoma, Squamous Cell Carcinoma (and related
lesions) - a guide to clinical management in Australia.
www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-
Final_with_Corrigendums.pdf (accessed 19 May 2015).
Chao 2013
Chao D, London Cancer North and East. London Cancer, Guidelines for Cutaneous Malignant Melanoma Management
August 2014. www.londoncancer.org/media/76373/london-cancer-melanoma-guidelines-2013-v1.0.pdf (accessed 25
February 2015).
Chapman 2011
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. New England Journal of Medicine 2011;364(26):2507-16. [ PubMed: 21639808]
Chapman 2012
Chapman PB, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, et al. Updated overall survival (OS) results for
BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with
dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Journal of Clinical
Oncology 2012;30(15 Suppl 1):8502. [EMBASE: 71004853]
Cho 2014
Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival mean progress? The insight from
population incidence and mortality. Journal of the National Cancer Institute. Monographs 2014;2014(49):187-97. [ PubMed:
25417232]
Chowdri 1996
Chowdri NA, Darzi MA. Postburn scar carcinomas in Kashmiris. Burns 1996;22(6):477-82. [ PubMed: 8884010]
Chu 2006
Chu H, Cole SR. Bivariate meta-analysis for sensitivity and specificity with sparse data: a generalized linear mixed model
approach (comment). Journal of Clinical Epidemiology 2006;59(12):1331-2. [ PubMed: 17098577]
Chuchu 2018
Chuchu N, Takwoingi Y, Dinnes J, Matin RN, Bassett O, Moreau J, et al. Smartphone applications for triaging adults with
skin lesions that are suspicious for melanoma. Cochrane Database of Systematic Reviews (in press).
Dabski 1986
Dabski K, Stoll HL Jr, Milgrom H. Squamous cell carcinoma complicating late chronic discoid lupus erythematosus. Journal
of Surgical Oncology 1986;32(4):233-7. [ PubMed: 3736067]
Deeks 2005
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic
reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology 2005;58(9):882-93. [ PubMed:
16085191]
Dinnes 2018a
#164f The use of teledermatology for the diagnosis of skin cancer in adults
110 / 167
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, et al. Visual inspection for the diagnosis of
cutaneous melanoma in adults. Cochrane Database of Systematic Reviews (in press).
Dinnes 2018b
Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, et al. Dermoscopy, with and without visual
inspection, for the diagnosis of cutaneous melanoma in adults. Cochrane Database of Systematic Reviews (in press).
Dinnes 2018c
Dinnes J, Deeks JJ, Chuchu N, Matin RN, Thompson D, Wong KY, et al. Visual examination and dermoscopy, alone or in
combination, for the diagnosis of keratinocyte skin cancers in adults. Cochrane Database of Systematic Reviews (in press).
Dinnes 2018d
Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Takwoingi Y, et al. Reflectance confocal microscopy for the diagnosis
of cutaneous melanoma in adults. Cochrane Database of Systematic Reviews (in press).
Dinnes 2018e
Dinnes J, Deeks JJ, Saleh D, Chuchu N, Bayliss SE, Takwoingi Y, et al. Reflectance confocal microscopy for the diagnosis
of keratinocyte skin cancers in adults. Cochrane Database of Systematic Reviews (in press).
Dinnes 2018f
Dinnes J, Bamber J, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, et al. High frequency ultrasound for the diagnosis of
skin cancer in adults. Cochrane Database of Systematic Reviews (in press).
Drew 2017
Drew BA, Karia PS, Mora AN, Liang CA, Schmults CD. Treatment patterns, outcomes, and patient satisfaction of primary
epidermally limited nonmelanoma skin cancer. Dermatologic Surgery 2017;43(12):1423-30. [DOI:
10.1097/DSS.0000000000001225; PubMed: 28661992]
Drucker 2017
Drucker A, Adam GP, Langberg V, Gazula A, Smith B,Moustafa F, Weinstock MA, Trikalinos TA. Treatments for Basal Cell
and Squamous Cell Carcinoma of the Skin. Comparative Effectiveness Reviews, No. 199.. Rockville (MD): Agency for
Healthcare Research and Quality (US), 2017.
Dummer 2014
Dummer R, Arenberger P, Ascierto PA, De Groot JW, Hallmeyer S, Lotem M, et al. 1130TiP-NEMO: a phase 3 trial of
binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have
progressed after any number of immunotherapy regimens. Annals of Oncology 2014;25(suppl_4):iv392. [ PubMed:
28171154]
Erdmann 2013
Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of
malignant melanoma 1953-2008--are recent generations at higher or lower risk? International Journal of Cancer 2013;
132(2):385-400. [ PubMed: 22532371]
EUCAN 2012
EUCAN, International Agency for Research on Cancer. Malignant melanoma of skin: Estimated incidence, mortality &
prevalence for both sexes, 2012. eco.iarc.fr/eucan/Cancer.aspx?Cancer=20 (accessed 29 July 2015).
Fasching 1989
Fasching MC, Meland NB, Woods JE, Wolff BG. Recurrent squamous-cell carcinoma arising in pilonidal sinus tract--multiple
flap reconstructions. Report of a case.. Diseases of the Colon & Rectum 1989;32(2):153-8. [ PubMed: 2914529]
Ferlay 2015
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide:
Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136(5):E359-86. [
PubMed: 25220842]
Ferrante di Ruffano 2018a
Ferrante di Ruffano L, Dinnes J, Deeks JJ, Chuchu N, Bayliss SE, Davenport C, et al. Optical coherence tomography for the
diagnosis of skin cancer in adults. Cochrane Database of Systematic Reviews (in press).
Ferrante di Ruffano 2018b
Ferrante di Ruffano L, Takwoingi Y, Dinnes J, Chuchu N, Bayliss SE, Davenport C, et al. Computer assisted diagnosis
techniques (dermoscopy and spectroscopy-based) for the diagnosis of skin cancer in adults. Cochrane Database of
Systematic Reviews (in press).
Firnhaber 2012
Firnhaber JM. Diagnosis and treatment of basal cell and squamous cell carcinoma. American Family Physician 2012;
#164f The use of teledermatology for the diagnosis of skin cancer in adults
111 / 167
86(2):161-168.
Fitzpatrick 1975
Fitzpatrick TB. Soleil et peau. Journal de Médecine Esthétique 1975;2:33-4.
Friedman 1985
Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-
examination of the skin. CA: a Cancer Journal for Clinicians 1985;35(3):130-51. [ PubMed: 3921200]
Garbe 2016
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European
consensus-based interdisciplinary guideline - Update 2016. European Journal of Cancer 2016;63:201-17. [ PubMed:
27367293]
Garcia 2009
Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. Journal of the American Academy of Dermatology 2009;
60(1):137-43. [ PubMed: 19103364]
Gerbert 2000
Gerbert B, Bronstone A, Maurer T, Hofmann R, Berger T. Decision support software to help primary care physicians triage
skin cancer: a pilot study. Archives of Dermatology 2000;136(2):187-92. [ PubMed: 10677094]
Gershenwald 2017
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: Evidence-based changes
in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians 2017;
67(6):472-492. [DOI: 10.3322/caac.21409]
Gordon 2013
Gordon R. Skin cancer: an overview of epidemiology and risk factors. Seminars in Oncology Nursing 2013;29(3):160-9. [
PubMed: 23958214]
Gorlin 2004
Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genetics in Medicine 2004;6(6):530-9. [ PubMed: 15545751]
Grachtchouk 2011
Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, Wang A, et al. Basal cell carcinomas in mice arise from hair
follicle stem cells and multiple epithelial progenitor populations. Journal of Clinical Investigation 2011;121(5):1768-81. [
PubMed: 21519145]
Green 1988
Green A, Leslie D, Weedon D. Diagnosis of skin cancer in the general population: clinical accuracy in the Nambour survey.
Medical Journal of Australia 1988;148(9):447-50. [ PubMed: 3283506]
Griffin 2016
Griffin LL, Ali FR, Lear JT. Non-melanoma skin cancer. Clinical Medicine 2016;16(1):62-5. [ PubMed: 26833519]
Griffiths 2005
Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? British
Journal of Plastic Surgery 2005;58(6):795-805. [ PubMed: 16086990]
Grob 1998
Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis
for melanoma screening. Archives of Dermatology 1998;134(1):103-4. [ PubMed: 9449921]
Hamid 2013
Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and
biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic
melanoma (mM). Journal of Clinical Oncology 2013;31(15 Suppl 1):Abstract 9010. [EMBASE: 71099860]
Hanson 2016
Hanson JL, Kingsley-Loso JL, Grey KR, Raju SI, Parks PR, Bershow AL, Warshaw EM. Incidental melanomas detected in
veterans referred to dermatology. Journal of the American Academy of Dermatology 2016;74(3):462-9. [ PubMed: 26612677]
Hartevelt 1990
Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation
in The Netherlands. Transplantation 1990;49(3):506-9. [ PubMed: 2316011]
Hodi 2010
#164f The use of teledermatology for the diagnosis of skin cancer in adults
112 / 167
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients
with metastatic melanoma. New England Journal of Medicine 2010;363(8):711-23. [ PubMed: 20525992]
Hoorens 2016
Hoorens I, Vossaert K, Pil L, Boone B, De Schepper S, Ongenae K, et al. Total-body examination vs lesion-directed skin
cancer screening. JAMA Dermatology 2016;152(1):27-34. [ PubMed: 26466155]
HPA and MelNet NZ 2014
Health Promotion Agency and the Melanoma Network of New Zealand (MelNet). New Zealand Skin Cancer Primary
Prevention and Early Detection Strategy 2014 to 2017.
www.sunsmart.org.nz//sites/default/files/documents/NZ%20Skin%20Cancer%20PrimaryPrevention%20and%20EarlyDetection%20Strategy%202014%20to%202017%20FINAL%20VERSION%20%23406761.pdf
(accessed 29 May 2018).
Janda 2015
Janda M. Teledermatology: its use in the detection and management of actinic keratosis. Current Problems in Dermatology
2015;46:101-7. [ PubMed: 25561213]
Jansen 2018
Jansen MHE, Mosterd K, Arits AHMM, Roozeboom MH, Sommer A, Essers BAB, et al. Five-year results of a randomized
controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with
superficial basal cell carcinoma. Journal of Investigative Dermatology 2018;138(3):527-33. [DOI: 10.1016/j.jid.2017.09.033; 
PubMed: 29045820]
Jensen 1999
Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients
and different long-term immunosuppressive therapy regimens. Journal of the American Academy of Dermatology 1999;40(2
Pt 1):177-86. [ PubMed: 10025742]
Kao 1986
Kao GF. Carcinoma arising in Bowen's disease. Archives of Dermatology 1986;122(10):1124-6. [ PubMed: 3767398]
Kasprzak 2015
Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs in Context 2015;4:212281. [ PubMed:
26082796]
Kelleners-Smeets 2017
Kelleners-Smeets NW, Mosterd K, Nelemans PJ. Treatment of low-risk basal cell carcinoma. Journal of Investigative
Dermatology 2017;137(3):539-40. [ PubMed: 28235442]
Kim 2014
Kim DD, Tang JY, Ioannidis JP. Network geometry shows evidence sequestration for medical vs. surgical practices:
treatments for basal cell carcinoma. Journal of Clinical Epidemiology 2014;67(4):391-400. [ PubMed: 24491794]
Kittler 1999
Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Morphologic changes of pigmented skin lesions: a
useful extension of the ABCD rule for dermatoscopy. Journal of the American Academy of Dermatology 1999;40(4):558-62. [
PubMed: 10188673]
Kittler 2001
Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical
nevi. Archives of Dermatology 2001;137(12):1590-5. [ PubMed: 11735709]
Kittler 2002
Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy (Review). Lancet Oncology 2002;
3(3):159-65. [ PubMed: 11902502]
Kjome 2016
Kjome RLS, Wright DJ, Bjaaen AB, Garstad KW, Valeur M. Dermatological cancer screening: Evaluation of a new
communitypharmacy service. Research in Social & Administrative Pharmacy : RSAP 2017;13(6):1214-7. [DOI:
10.1016/j.sapharm.2016.12.001; PubMed: 27964893]
Lansbury 2010
Lansbury L, Leonardi-Bee J, Perkins W, Goodacre T, Tweed JA, Bath-Hextall FJ. Interventions for non-metastatic squamous
cell carcinoma of the skin. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD007869 DOI:
10.1002/14651858.CD007869.pub2.
Lansbury 2013
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell
#164f The use of teledermatology for the diagnosis of skin cancer in adults
113 / 167
carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013;347:f6153. [ PubMed:
24191270]
Larkin 2014
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined Vemurafenib and Cobimetinib in BRAF-
Mutated Melanoma. New England Journal of Medicine 2014;371(20):1867-76. [ PubMed: 25265494]
Lear 1997
Lear JT, Tan BB, Smith AG, Bowers W, Jones PW, Heagerty AH, et al. Risk factors for basal cell carcinoma in the UK: case-
control study in 806 patients. Journal of the Royal Society of Medicine 1997;90(7):371-4. [ PubMed: 9290417]
Lear 2012
Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. New England Journal of Medicine 2012;366(23):2225-6.
[ PubMed: 22670909]
Lear 2014
Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, et al. Challenges and new horizons in the management of
advanced basal cell carcinoma: a UK perspective. British Journal of Cancer 2014;111(8):1476-81. [DOI:
10.1038/bjc.2014.270; PubMed: 25211660]
Lederman 1985
Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma? Journal of the
American Academy of Dermatology 1985;13(6):983-7. [ PubMed: 4078105]
Leeflang 2013
Leeflang MM, Rutjes AW, Reitsma JB, Hooft L, Bossuyt PM. Variation of a test's sensitivity and specificity with disease
prevalence. CMAJ 2013;185(11):E537-44. [ PubMed: 23798453]
Lees 1991
Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in stage I invasive cutaneous malignant melanoma:
review of 1086 patients. British Journal of Surgery 1991;78(9):1108-10. [ PubMed: 1933198]
Leff 2008
Leff B, Finucane TE. Gizmo idolatry. JAMA 2008;299(15):1830-2. [ PubMed: 18413879]
Linos 2009
Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. Journal of
Investigative Dermatology 2009;129(7):1666-74. [ PubMed: 19131946]
Lister 1997
Lister RK, Black MM, Calonje E, Burnand KG. Squamous cell carcinoma arising in chronic lymphoedema. British Journal of
Dermatology 1997;136(3):384-7. [ PubMed: 9115922]
Lo 1991
Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a
review of the literature. Journal of the American Academy of Dermatology 1991;24(5 Pt 1):715-9. [ PubMed: 1869642]
Lomas 2012
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. British
Journal of Dermatology 2012;166(5):1069-80. [ PubMed: 22251204]
MacKie 1985
MacKie RM, English J, Aitchison TC, Fitzsimons CP, Wilson P. The number and distribution of benign pigmented moles
(melanocytic naevi) in a healthy British population. British Journal of Dermatology 1985;113(2):167-74. [ PubMed: 4027184]
MacKie 1990
MacKie RM. Clinical recognition of early invasive malignant melanoma. BMJ 1990;301(6759):1005-6. [ PubMed: 2249043]
Madan 2010
Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375(9715):673-85. [ PubMed: 20171403]
Maia 1995
Maia M, Proenca NG, de Moraes JC. Risk factors for basal cell carcinoma: a case-control study. Revista de Saude Publica
1995;29(1):27-37. [ PubMed: 8525311]
Maloney 1996
Maloney ME. Arsenic in Dermatology. Dermatologic Surgery 1996;22(3):301-4. [ PubMed: 8599743]
#164f The use of teledermatology for the diagnosis of skin cancer in adults
114 / 167
Marsden 2010
Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. BAD Guidelines: Revised UK guidelines for
the management of cutaneous melanoma 2010. British Journal of Dermatology 2010;163(2):238-56. [ PubMed: 20608932]
McCormack 1997
McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal
cell carcinoma. A possible indicator of differing causes. Archives of Dermatology 1997;133(5):593-6. [ PubMed: 9158412]
McCusker 2014
McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma:
Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer 2014;50(4):774-83. [ PubMed:
24412051]
Mistry 2011
Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. British
Journal of Cancer 2011;105(11):1795-803. [ PubMed: 22033277]
Moeckelmann 2018
Moeckelmann N, Ebrahimi A, Dirven R, Liu J, Low TH, Gupta R, et al. Analysis and comparison of the 8th edition American
Joint Committee on Cancer (AJCC) nodal staging system in cutaneous and oral squamous cell cancer of the head and neck.
Annals of Surgical Oncology 2018;25(6):1730-6. [DOI: 10.1245/s10434-018-6340-x; PubMed: 29352431]
Motley 2009
Motley RJ, Preston PW, Lawrence CM. Multi-professional Guidelines for the Management of the Patient with Primary
Cutaneous Squamous Cell Carcinoma. www.bsds.org.uk/uploads/pdfs/SCCguide2009.pdf (accessed 15/11/2017).
Murchie 2017
Murchie P, Amalraj Raja E, Brewster DH, Iversen L, Lee AJ. Is initial excision of cutaneous melanoma by General
Practitioners (GPs) dangerous? Comparing patient outcomes following excision of melanoma by GPs or in hospital using
national datasets and meta-analysis. European Journal of Cancer 2017;86:373-84. [ PubMed: 29100192]
Musah 2013
Musah A, Gibson JE, Leonardi-Bee J, Cave MR, Ander EL, Bath-Hextall F. Regional variations of basal cell carcinoma
incidence in the U.K. using The Health Improvement Network database (2004-10). British Journal of Dermatology 2013;
169(5):1093-9. [ PubMed: 23701520]
Nart 2015
Nart IF, Armayones SG, Medina FV, Orti MB, Orpinell XB. Basal cell carcinoma treated with ingenol mebutate. Journal of the
American Academy of Dermatology 2015;5(Suppl 1):AB180.
Newcombe 1998
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods.
Statistics in Medicine 1998;17(8):873-890.
NICE 2010
National Institute of Clinical Excellence. NICE Guidance on Cancer Services. Improving Outcomes for People with Skin
Tumours including Melanoma (update): The Management of Low-risk Basal Cell Carcinomas in the Community..
www.nice.org.uk/guidance/csg8/resources/improving-outcomes-for-people-with-skin-tumours-including-melanoma-2010-
partial-update-773380189 (accessed 27 November 2017).
NICE 2015a
National Collaborating Centre for Cancer. Melanoma: assessment and management. www.nice.org.uk/guidance/ng14
(accessed prior to 20 February 2018).
NICE 2015b
National Institute for Health and Clinical Excellence. Suspected cancer: recognition and referral.
www.nice.org.uk/guidance/ng12 (accessed prior to 20 February 2018).
NICE 2017
NICE. Vismodegib for treating basal cell carcinoma. www.nice.org.uk/guidance/ta489 (accessed prior to 28 March 2018).
Norman 2009
Norman G, Barraclough K, Dolovich L, Price D. Iterative diagnosis. BMJ 2009;339:b3490. [DOI: 10.1136/bmj.b3490]
O'Gorman 2014
O'Gorman SM, Murphy GM. Photosensitizing medications and photocarcinogenesis. Photodermatology, Photoimmunology &
Photomedicine 2014;30(1):8-14. [ PubMed: 24393207]
#164f The use of teledermatology for the diagnosis of skin cancer in adults
115 / 167
Offidani 2002
Offidani A, Simonetti O, Bernardini ML, Alpagut A, Cellini A, Bossi G. General practitioners' accuracy in diagnosing skin
cancers. Dermatology 2002;205(2):127-30. [ PubMed: 12218226]
Randle 1996
Randle HW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatologic Surgery 1996;
22(3):255-61. [ PubMed: 8599737]
Reitsma 2005
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity
produces informative summary measures in diagnostic reviews (Review). Journal of Clinical Epidemiology 2005;
58(10):982-90. [ PubMed: 16168343]
Roozeboom 2012
Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary
superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. British
Journal of Dermatology 2012;167(4):733-56. [ PubMed: 22612571]
Roozeboom 2016
Roozeboom MH, Arits AH, Mosterd K, Sommer A, Essers BA, de Rooij MJ, et al. Three-year follow-up results of
photodynamic therapy vs. Imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: A single-blind,
noninferiority, randomized controlled trial. Journal of Investigative Dermatology 2016;136(8):1568-74. [ PubMed: 27113429]
Rowe 1992
Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell
carcinoma of the skin, ear, and lip. Implications for treatment modality selection. Journal of the American Academy of
Dermatology 1992;26(6):976-90. [ PubMed: 1607418]
Rutjes 2005
Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic
accuracy studies (Review). Clinical Chemistry 2005;51(8):1335-41. [ PubMed: 15961549]
Sekulic 2012
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced
basal-cell carcinoma. New England Journal of Medicine 2012;366(23):2171-9. [ PubMed: 22670903]
Siegel 2015
Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA: a Cancer Journal for Clinicians 2014;65(1):5-29. [ PubMed:
25559415]
SIGN 2017
Scottish Intercollegiate Guidelines Network. Cutaneous Melanoma. www.sign.ac.uk/sign-146-melanoma.html (accessed prior
to 19 July 2017).
Sladden 2009
Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. Surgical excision margins for primary cutaneous
melanoma. Cochrane Database of Systematic Reviews 2009, Issue 10. Art. No.: CD004835 DOI:
10.1002/14651858.CD004835.pub2.
Slater 2014
Slater D, Walsh M. Standards and datasets for reporting cancers: Dataset for the histological reporting of primary cutaneous
malignant melanoma and regional lymph nodes, May 2014.
www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/G125_DatasetMaligMelanoma_May14.pdf
(accessed 29 July 2015).
Smeets 2004
Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs' micrographic
surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004;364(9447):1766-72. [ PubMed:
15541449]
Sober 1979
Sober AJ, Fitzpatrick TB, Mihm MC, Wise TG, Pearson BJ, Clark WH, et al. Early recognition of cutaneous melanoma. JAMA
1979;242(25):2795-9. [ PubMed: 501893]
Stanganelli 2000
Stanganelli I, Serafini M, Bucch L. A cancer-registry-assisted evaluation of the accuracy of digital epiluminescence
microscopy associated with clinical examination of pigmented skin lesions. Dermatology 2000;200(1):11-6. [ PubMed:
#164f The use of teledermatology for the diagnosis of skin cancer in adults
116 / 167
10681607]
Stata 2017
Stata [Computer program]. Version 15. College Station, TX, USA: StataCorp, 2017.Available at www.stata.com.
Stratigos 2015
Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive
squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European Journal of Cancer
2015;51(14):1989-2007. [ PubMed: 26219687]
Takwoingi 2017
Takwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few
studies or sparse data. Statistical Methods in Medical Research 2017;26(4):1896-911. [DOI: 10.1177/0962280215592269]
Thomas 1998
Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G. Semiological value of ABCDE criteria in the diagnosis of
cutaneous pigmented tumors. Dermatology 1998;197(1):11-7. [ PubMed: 9693179]
Usher-Smith 2016
Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016;
353:i3139. [DOI: 10.1136/bmj.i3139]
van Loo 2014
van Loo E, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs'
micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. European
Journal of Cancer 2014;50(17):3011-20. [ PubMed: 25262378]
Verkouteren 2017
Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. British
Journal of Dermatology 2017;177(2):359-372. [DOI: 10.1111/bjd.15321]
Villanueva 2010
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF
inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer
Cell 2010;18(6):683-95. [ PubMed: 21156289]
Walker 2006
Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment.
Australasian Journal of Dermatology 2006;47(1):1-12. [ PubMed: 16405477]
Warshaw 2011
Warshaw EM, Hillman YJ, Greer NL, Hagel EM, MacDonald R, Rutks IR, et al. Teledermatology for diagnosis and
management of skin conditions: A systematic review. J Am Acad Dermatol 2011;64(4):759-72. [ PubMed: 21036419]
Whiting 2011
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality
assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36. [ PubMed: 22007046]
WHO 2003
World Health Organisation. INTERSUN: The Global UV Project. A guide and compendium.
www.who.int/uv/publications/en/Intersunguide.pdf 2003 (accessed 20 May 2015).
Williams 2017
Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for
nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. Journal of Investigative
Dermatology 2017;137(3):614-619. [ PubMed: 27932240]
Wong 2017
Wong KY, Fife K, Lear JT, Price RD, Durrani AJ. Vismodegib for locally advanced periocular and orbital basal cell carcinoma:
A review of 15 consecutive cases. Plastic and Reconstructive Surgery Global Open 2017;5(7):e1424. [ PubMed: 28831360]
Zak-Prelich 2004
Zak-Prelich M, Narbutt J, Sysa-Jedrzejowska A. Environmental risk factors predisposing to the development of basal cell
carcinoma. Dermatologic Surgery 2004;30(2 Pt 2):248–52. [ PubMed: 14871217]
Other published versions of this review 
Dinnes 2015a
#164f The use of teledermatology for the diagnosis of skin cancer in adults
117 / 167
Dinnes J, Matin RN, Moreau JF, Patel L, Chan SA, Wong KY, et al. Tests to assist in the diagnosis of cutaneous melanoma
in adults: a generic protocol. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD011902 DOI:
10.1002/14651858.CD011902.
Dinnes 2015b
Dinnes J, Wong KY, Gulati A, Chuchu N, Leonardi-Bee J, Bayliss SE, et al. Tests to assist in the diagnosis of keratinocyte
skin cancers in adults: a generic protocol. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD011901
DOI: 10.1002/14651858.CD011901.
Classification pending references
Data and analyses 
Data tables by test
Test StudiesParticipants
1 Teledermatology - photographic image vs Histology (Any) 4 717
2 Teledermatology - dermoscopic image vs Histology (Any) 1 104
3 Teledermatology - photographic+dermoscopic image vs Histology (Any) 3 871
4 Expert Face to face (VI+Dermoscopy) vs Histology (Any) 2 248
5 Teledermatology - photographic image vs Histology (MM+MiS) 4 1834
6 Teledermatology - dermoscopic image vs Histology (MM+MiS) 2 116
7 Teledermatology photographic+dermoscopic image vs Histology (MM+MiS) 4 664
8 GP Face to face (Visual inspection only) vs Histology (MM+MiS) 1 235
9 GP Face to face (VI+Dermoscopy) vs Histology (MM+MiS) 1 235
10 Expert face to face (VI+Dermoscopy) (MM+MiS) 3 1663
11 Teledermatology - photographic+dermoscopic image vs Histology (MM) 1 43
12 Expert face to face (VI+Dermoscopy) vs Histology (MM) 1 43
13 Teledermatology - dermoscopic image vs Histology (Acral MM) 1 77
14 Teledermatology - photographic image vs Histology (BCC) 3 301
15 Teledermatology - dermoscopic image vs Histology (BCC) 1 104
16 Teledermatology - photographic+dermoscopic image vs Histology (BCC) 1 256
17 Expert face to face (VI+Dermoscopy) vs Histology (BCC) 2 248
18 Teledermatology - photographic image vs Histology (cSCC) 1 104
19 Teledermatology - dermoscopic image vs Histology (cSCC) 1 104
20 Expert face to face (VI+Dermoscopy) vs Histology (cSCC) 1 104
21 Teledermatology - photographic image vs face to face clinical diagnosis (Immediate action) 3 951
22 Teledermatology - photographic image vs face to face clinical diagnosis (Dx of malignancy) 1 90
23 Teledermatology - photographic image vs face to face clinical diagnosis (Immediate action or FU) 1 106
24 Teledermatology - photographic image vs face to face clinical diagnosis (Immediate action; Registrar
data) 1 796
25 Teledermatology - photographic/dermoscopic image vs face to face clinical diagnosis (Immediate
action) 1 301
26 Teledermatology - live link vs face to face clinical diagnosis (diagnosis of any skin cancer) 1 107
27 Teledermatology - live link vs face to face clinical diagnosis (definitely/probably malignant) 1 107
28 Teledermatology - live link vs face to face clinical diagnosis (biopsy decision) 1 107
Figures
Figure 1
Caption
Sample photograph of superficial spreading melanoma(left), BCC (centre) and SCC (right)
Figure 2
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Caption
Current clinical pathway for people with skin lesions
Figure 3
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Caption
PRISMA flow diagram.
Figure 4
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Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 5
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Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 6 (Analysis 1) 
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Caption
Forest plot of tests for the detection of any skin cancer (Any)
Figure 7 (Analysis 2) 
Caption
Summary ROC Plot of Teledermatology using photographic images vs histology for the detection of any skin cancer (Any).
Figure 8 (Analysis 3) 
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Caption
Forest plot of tests for the detection of invasive melanoma or atypical intraepidermal melanocytic variants (MM+MiS)
Figure 9 (Analysis 4) 
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Caption
Summary ROC Plot of Teledermatology using clinical and dermoscopic images for the detection of invasive melanoma or
atypical intraepidermal melanocytic variants (MM+MiS).
Figure 10 (Analysis 5) 
Caption
Forest plot of tests for the detection of invasive melanoma
Figure 11 (Analysis 6) 
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Caption
Forest plot of tests for the detection of BCC
Figure 12 (Analysis 11) 
Caption
ROC Plot Teledermatology using photographic images alone vs histology for the detection of BCC
Figure 13 (Analysis 7) 
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Caption
Forest plot of tests for the detection of cSCC.
Figure 14 (Analysis 9) 
Caption
Forest plot of tests for referral accuracy (expert in-person diagnosis as reference standard)
Figure 15 (Analysis 9) 
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Caption
ROC Plot of Teledermatology diagnosis or decision versus face-to-face expert diagnosis (reference standard) at any
threshold for action
Sources of support 
Internal sources
No sources of support provided
External sources
NIHR Systematic Review Programme, UK
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
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Appendices 
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Glossary of terms
Term Definition
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
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Term Definition
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, examination of
the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them
as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having
the disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes
malignant cells but with no invasive growth. May progress to an invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream or
the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis
The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either
at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an
evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin
lesions) who have that absence of disease correctly identified by the study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories.
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Term Definition
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination.
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area.
3 Content of algorithms used to assist melanoma diagnosis by visual inspection alone
 
ABCD (Friedman 1985; Rigel 1993;
Pehamberger 1993)
ABCDE (Carli 1994; Cristofolini 1994;
Thomas 1998; Benelli 1999; Benelli 2001;
Abbasi 2004)
BCD (McGovern 1992)
 
Seven-point checklist (
MacKie 1985; MacKie
1990; Keefe 1990)
 
Seven-point checklist (revised) (MacKie 1990;
Healsmith 1994)
 
A – asymmetry
variable centripetal growth of melanocytes
(Friedman 1985)
“geometrical asymmetry in two axes of the
tumour” (Thomas 1998; Benelli 1999;
Benelli 2001)
“one half does not match the other half”
(McGovern 1992); not separately scored in
study “because we believed that
asymmetry and border irregularity were
linked”
B - irregular borders
irregular shape with notching or scalloping
of border (Friedman 1985)
“edges are ragged, notched, or blurred
(McGovern 1992)
“irregular and notched” (Cristofolini 1994)
“unsharp or ill-defined or angular” (Thomas
1998)
“ragged or indented” (Benelli 1999, Benelli
2001)
C - colour
variable pigmentation, multiple colours;
various of hues of brown, also black, blue,
red and white (Friedman 1985 )
“pigmentation is not uniform; shades of
tan, brown and black are present with
dashes of red, white, or blue” (McGovern
1992)
“mottled-haphazard display” (Cristofolini
1994)
“presence of at least two different colours
within the lesion (with the exception of the
usual symmetrical darkening of the lesion
in its center)” (Thomas 1998; Benelli 2001)
“multiple colours” (Abbasi 2004)
D - diameter equal or superior to 6mm
all studies agree
E - evolution
“changes in pigmentation” (Cristofolini
1994)
“enlargement of the surface (and not in
height) of the lesion; anamnestic criterion
based on the patient’s description of the
 
sensory change,
(greater awareness of
the lesion or mild itch);
diameter of >=1 cm;
growth of the lesion;
an irregular edge;
irregular pigment with
different shades of
brown and black in the
lesion;
inflammation
crusting, oozing, or
bleeding.
Presence of 3 or more
suggestive of melanoma
 
MacKie 1990, Mackie 1991, and Healsmith 1994
describe the revised criteria as:
Major signs
Change in size
Change in shape
Change in colour
Minor signs
Inflammation
Crusting or bleeding
Sensory change
Diameter >=7 mm
“a patient with a pigmented lesion with any one of
the major signs should be considered for referral
and that the presence of any of the minor signs
should be a further stimulus to referral.” (MacKie
1990)
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natural history of the lesion” (Thomas
1998)
“elevation, enlargement or change in the
color of the lesion” (Benelli 1999; Benelli
2001)
“evolving (with respect to size, shape,
shades of colour, surface features, or
symptoms)” (Abbasi 2004)
McGovern 1992 describes 7 characteristics
as: “increasing size, variegation,
inflammation, irregular outline, greater than
1cm diameter, itch, bleeding”
These are expanded on in MacKie 1990, who
describes the original (1985) criteria as:
sensory change, often described as a
greater awareness of the lesion but also
as a mild itch;
diameter of 1 cm or greater;
growth of the lesion;
an irregular edge;
irregular pigment with different shades of
brown and black in the lesion;
inflammation (a reddish tinge within the
lesion); and
crusting, oozing, or bleeding.
>=3 criteria should prompt referral (MacKie
1990)
4 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
5 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
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3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
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47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
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93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
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21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
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67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
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10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
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56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
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102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
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#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
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or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
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#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
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S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
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S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
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sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
6 Full text inclusion criteria
Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
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Criterion Inclusion Exclusion
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
7 Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Participant selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible
to undergo a test should be included in a study, allowing for the intended use of that test within the context of the study. We
considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those that
supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion
sites, or that excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at
high risk of bias.
#164f The use of teledermatology for the diagnosis of skin cancer in adults
147 / 167
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion
populations, such as melanocytic, nodular, high risk or restrictions by size or to lesions that had been excised to be of high
concern for applicability. For teledermatology, lesions selected from referred populations rather than selected by GPs in a
primary care setting were also judged to be high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions
to contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We
considered studies that include a high number of lesions in relation to the number of participants in the study to be less
representative than studies conducted in a more general population of participants (i.e., if the difference between the number
of included lesions and number of included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to
the result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that
used the original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the
reference standard is known; however, studies using previously acquired images could be particularly susceptible to
information bias. For these studies to be at low risk of bias, we required a clear indication that observers were unaware of the
reference standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding
between interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was
not data driven, i.e., was not based on study results. Studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies
reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported
accuracy for the presence of independently significant lesion characteristics with no separate test set of lesions were
considered at high risk of bias.
In terms of applicability of the index test to the review question, we required images for teledermatology assessment to be
acquired in primary by GPs or other primary care staff rather than by expert dermatologists or medical photographers in a
specialist setting. We also required diagnosis to be made by a single observer as opposed to a consensus decision or
average across multiple observers.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion
characteristics that were considered to be indicative for melanoma, for BCC or for cSCC, particularly where established
algorithms or checklists were not used. Studies were considered of low concern if the threshold used was established in a
prior study or sufficient threshold details were presented to allow replication.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion
regardless of level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial
verification bias may occur where histology is the only reference standard used, and only those participants with a certain
degree of suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded
from the study or defined as being disease-negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of
suspicious lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with
benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy subsequently
develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-
positive individuals having a histological reference standard either at the time of application of the index test or after a period
of clinical follow-up; and at least 80% of disease-negative participants have received a histological diagnosis, with up to 20%
undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e., where the result of the index test is used to help determine the
reference standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to
be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of
incorporation bias, blinded interpretation of the histopathology reference standard is not normal practice, and enforcement of
such conditions would significantly limit the generalisability of the study results. For studies comparing teledermatology
against a histological reference standard, this item was therefore scored but did not contribute to the overall risk of bias. For
studies comparing teledermatology against a face-to-face expert diagnosis, however this item was scored and did contribute
to overall risk of bias.
In judging the applicability of the reference standard to our review question, scored studies as high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report
histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the acquisition of images for the teledermatology diagnosis and the reference standard diagnosis should
be made consecutively or as near to each other in time as possible to avoid changes in lesion over time. We have defined a
one-month period as an appropriate interval between application of the index test and the reference standard (either
histological or face-to-face). For studies using clinical follow-up, a minimum three-month follow-up period has been defined
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as at low risk of bias for detecting false-negatives. This interval was chosen based on a study showing that most false-
negative melanomas will be diagnosed within three months of the initial negative index test although a small number will be
diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were
excluded following recruitment.
Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes - if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
 
2) Was a case-control design avoided?
[Note: A diagnostic case-control study separately recruits
participants according to selected final diagnoses, e.g. those
with melanoma, with BCC, with severe dysplasia and with mild
dysplasia AND will usually deliberately sample certain numbers
from each group such that the overall case mix of included
participants and disease prevalence is not reflective of usual
care.]
 
Yes - if case-control design clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not clearly described or you have any concerns
that the authors have not selected a series of participants
 
3) Did the study avoid inappropriate exclusions, e.g.
‘difficult to diagnose’ lesions not excluded
lesions not excluded on basis of disagreement between
evaluators or histopathologists
Yes - if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g. 'difficult to diagnose' lesions, OR where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
Could the selection of participants have introduced bias? 
If answers to all of questions 1) AND 2) AND 3) ‘Yes’ :
If answers to any one of questions 1) OR 2) OR 3) ‘No’ :
If answers to any one of questions 1) OR 2) OR 3) ‘Unclear’: 
 
Risk is Low
Risk is High
Risk Unclear
 
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
1) Are the included patients and chosen study setting
appropriate to answer the review question, i.e. are the study
results generalisable?
This item is not asking whether exclusion of certain patient
groups might bias the study’s results (as in Risk of Bias above),
but is asking whether the chosen study participants and setting
are appropriate to answer our review question. Because we are
looking to establish test accuracy in both primary presentation
and referred participants, a study could be appropriate for one
setting and not for the other, or it could be unclear as to
whether the study can appropriately answer either question.
 
Yes – if patients included in the study appear to be
generally representative of those who might present in a
usual practice setting
No if study participants were restricted to those in lesion
subgroups, e.g. melanocytic only, or small lesions only, if
only excised lesions were included, or lesions were
selected from referred populations rather than selected by
GPs in a primary care setting
Unclear – if insufficient details are provided to determine
the generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
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Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
Is there concern that the included participants do not match the
review question?
If the answer to question 1) and 2) ‘Yes’: 
If the answer to question 1) or 2) ‘No’:
If the answer to question 1) or 2) ‘Unclear’:
 
Concern is Low
Concern is High
Concern is Unclear
 
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes - if index test described as interpreted without
knowledge of the reference standard result or, for
prospective studies, if index test is always conducted and
interpreted prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
2) Was the diagnostic threshold at which the test was
considered positive (i.e. melanoma, BCC or cSCC present) pre-
specified?
Yes - if threshold was pre-specified (i.e. prior to analysing
study results), ie results were not data driven
No - if threshold was not pre-specified but was selected
after analysis of results usually to maximise sensitivity
and/or specificity, or multiple thresholds were tested
Unclear - if not possible to tell whether or not diagnostic
threshold was pre-specified
Could the conduct or interpretation of the index test have
introduced bias?
v FOR NC and BPC STUDIES
If answers to questions 1) and 2) ‘Yes’
If answers to either questions 1) or 2) ‘No’ 
If answers to either questions 1) or 2) ‘Unclear’ 
v FOR WPC STUDIES
If answers to all questions ‘Yes’: 
If answers to any one question ‘No’ : 
If answers to any one of questions is ‘Unclear’: 
 
Risk is Low
Risk is High
Risk is Unclear
Risk is Low
Risk is High
Risk is Unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Was the test applied and interpreted in a clinically applicable
manner?
Yes – in-person evaluation and single observer result
present
No - either image based and/or average or consensus
result presented
Unclear – if can’t tell
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Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis of the target disorder were
reported in sufficient detail to allow replication. If the study
does not describe the threshold in detail BUT evaluates an
established test/algorithm AND provides a citation to a
previous study of the test in the Methods or Results, then
respond Yes.
No – if the criteria for diagnosis of the target disorder were
not reported in sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria
for diagnosis to allow replication were provided. If the study
does not describe the threshold in detail BUT evaluates an
established test/algorithm but with NO citation to a previous
study of the test in the methods, then respond Unclear.
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by one or more speciality
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge OR if examiners
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e. no observer
interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1),2) AND 3) ‘Yes’
If answers to questions 1),2) OR 3) ‘No’ 
If answers to questions 1),2) OR 3) ‘Unclear’
 
Concern is Low
Concern is High
Concern is Unclear
REFERENCE STANDARD (3) - RISK OF BIAS
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Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
a) DISEASE POSITIVE - One or more of:
-Histological confirmation of the target disorder following biopsy
or lesion excision
-Clinical follow up of benign appearing lesions following the
application of the index test, leading to a histological diagnosis
of the target disorder of interest:
at least 3 months for melanoma or cSCC
at least 6 months for BCC
b) DISEASE NEGATIVE - One or more of:
-Histological confirmation of absence of the target disorder
following biopsy or lesion excision in at least 80% of disease
negative participants
-Clinical follow up of benign appearing lesions following the
index test in up to 20% of disease negative participants of
at least 3 months for melanoma or cSCC
at least 6 months for BCC
 
Yes – if all disease positive participants underwent one of
the listed reference standards
No – If a final diagnosis for any disease positive participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any disease positive participant OR if the length of
clinical follow-up used was not clear OR if a clinical follow-
up reference standard was reported in combination with a
participant-based analysis and it was not possible to
determine whether the detection of a malignant lesion
during follow-up is the same lesion that originally tested
negative on the index test
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow up
of for a minimum of 3 (or 6) months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow up of a minimum of 3 (or 6) months
following the index test OR if clinical follow-up period was
less than 3 (or 6) months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or disease negative
diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies. Response to the item will
not be incorporated into the overall risk of bias assessment for
comparisons against a histological reference standard as
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection
and/or dermoscopy). Response to the item will be incorporated
into the overall risk of bias assessment for comparisons against
a face-to-face reference standard
 
For studies comparing teledermatology against a
histological reference standard 
Yes – if the histological reference standard diagnosis was
reached blinded to the index test result
No – if the histological reference standard diagnosis was
reached with knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
If the histopathologist is described as 'blinded' with no
further detail as to whether the blinding applies to both
index test or to clinical information (prior testing), we will
assume that blinding is to the index test result only, unless
further detail is provided
For studies comparing teledermatology against a face-to-
face expert diagnosis
Yes - if the face-to-face reference standard diagnosis was
described as interpreted without knowledge of the
teledermatology diagnosis (e.g. the remote and face to face
diagnosis was made by two different dermatologists)
No - if the face-to-face reference standard diagnosis was
made with knowledge of the teledermatology diagnosis or
was made by the same dermatologist within a month of the
remote image-based diagnosis
Unclear – if it is not possible to tell whether knowledge of
the teledermatology diagnosis could have influenced the
reference standard diagnosis
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Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For comparisons against a histological reference standard:
If answer to question 1) ‘Yes’ 
If answer to question 1) ‘No’: 
If answer to question 1) ‘Unclear’:
For comparisons against a face-to-face reference standard:
If answers to questions 1) AND 2 ‘Yes’ 
If answers to questions 1) OR 2) ‘No’: 
If answers to questions 1) OR 2) ‘Unclear’:
 
Risk is Low
Risk is High
Risk is Unclear
Risk is Low
Risk is High
Risk is Unclear
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) For studies comparing teledermatology/face-to-face clinical
diagnosis to histology, was histology interpretation carried out
by an experienced histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
2) For studies comparing teledermatology to face-to-face
diagnosis, was the clinical diagnosis carried out by an
experienced observer?
Yes – if face-to-face interpretation was reported to be
carried out by an experienced dermatologist
No – if face-to-face interpretation was reported to be carried
out by a less experienced dermatologist
Unclear – if the experience/qualifications of the face-to-face
clinician were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answer to either questions 1) or 2), ‘Yes’:
If answer to either questions 1) OR 2), ‘No’:
If answer to either questions 1) OR 2), ‘Unclear’:
 
Concern is Low
Concern is High
Concern is Unclear
 
FLOW AND TIMING (4): RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
a) For histopathological reference standard, was the interval
between index test and reference standard <= 1month?
b) If the reference standard includes clinical follow-up of
borderline/benign appearing lesions, was there a minimum
follow-up following application of index test(s) of at least:
3 months for melanoma or cSCC
6 months for BCC?
 
Yes – if study reports <=1 month between index and
reference standard
No – if study reports >1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
Yes – if study reports >=3 (or 6) months follow-up
No – if study reports <3 (or 6) months follow-up
Unclear – if study does not report length of clinical follow-up
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Item Response (delete as required)
 
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than one reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
Could the participant flow have introduced bias?
v FOR NON COMPARATIVE and BPC STUDIES
-If answers to questions 1)AND 2) AND 3) : ‘Yes’:
-If answers to any one of questions 1) OR 2)OR 3) ‘No’ : If
answers to any one of questions 1) OR 2)OR 3) ‘Unclear’ :
 
Risk is Low
Risk is High
Risk is Unclear
Comparative domain: For (BPC) and/or within-person comparisons (WPC) of index tests or testing strategies (i.e. >1 index
test applied per participant):
Index tests  
1) was each index test result interpreted without knowledge of
the results of other index tests or testing strategies?
Yes - if all index tests were described as interpreted without
knowledge of the results of the others
No - if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only one index test was evaluated
Not applicable
 
2) Was the interval between application of index tests <= 1
month?
 
Yes – if study reports <=1 month between index tests
No – if study reports >1 month between index tests
Unclear – if study does not report interval between index
tests
   
Clinical applicability of comparison
1) Were both tests applied and interpreted in a clinically
applicable manner?
 
8 Summary study details
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Author & year
Outcome
 
Study type
Country
Setting
Patients
(lesions) 
Inclusion
criteria
 
Store and forward
teledermatology
Image acquisition
Image
interpretation
Diagnostic decision
 
Face to face
diagnosis
Method of
diagnosis
Diagnostic
decision
 
Reference standard
Final diagnoses
Prevalence (Malignant)
Excluded
participants (from
final analysis)
Studies of diagnostic accuracy (TD vs Histology) Arzberger 2016
ANY
 
NC
P-CS
Secondary
Austria
20 (23)
Study
participants
were required
to have
moderate-to-
high risk of
melanoma
based on: (i)
personal or
first-degree
relative
history of
melanoma;
(ii) history of
dysplastic
naevi; (iii) > 5
atypical
naevi; (iv) >
100 naevi; (v)
lesion
suspicious for
melanoma.
 
Clinical and
dermoscopic
images acquired
in secondary
care with digital
camera coupled
with
dermoscope
(equipment
described).
Four remote
teledermoscopy
experts
(dermatologists)
evaluated the
total body
images and
dermoscopic
images, and
gave a
recommendation
for each lesion
Decision
recorded:
“self-
monitoring”,
“short-term
monitoring” and
“excision”
Not evaluated Histology
Malignant
MM 8 ; MiS1;
BCC 2
BN 12
0.478
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Of 70 eligible patients only
20 were excised no
information reported on the
50 patients who had expert
diagnosis
Borve 2015
Any
 
BPC
P-CS
Primary and
Secondary
Sweden
772
(816)
 
Patients with one
or more skin
lesions of concern
requiring referral to
a dermatologist.
(Accuracy was
compared to a
control group of an
equal number of
consecutive
patients referred
from other PHCs
via the traditional
paper-based
referral system
during the same
period; data
included in this
review)
Primary healthcare
centres (PHCs)
that regularly
referred patients
with skin
lesions of concern
were invited to
participate.
 
Clinical and
dermoscopic
images
acquired in
primary care by
GPs using
smartphone
digital camera
and portable
dermoscope
using an
iPhone 4 with a
FotoFinder
Handyscope
app
Remote
dermatologists
(n=4) reviewed
images along
with clinical
information on
an online
platform and
selected from
standardised
triage
responses
Decision
recorded:
benign,
malignant or
unclear
malignancy
as possible
diagnosis
priority given
(high, <2
weeks;
medium, <4
weeks or
low, 8–12
weeks),
management
(none,
medical
therapy,
destructive
therapy or
surgery)
dermoscopic
description.
Not evaluated  
Histology plus
Expert
Malignant:
MM 19; MiS 16;
cSCC 17; BCC 109
Benign:
Dysplastic 89 BN
236 SK 125
Other benign: 137
*Actinic keratosis:
61
*cSCC (in situ): 7
0.281
 
86 excluded
from TDS
group (incl 4
with poor
image quality,
21 under 18
years old, 50
‘no shows’;
other reasons
also provided)
*Authors
include in situ
cSCC and AK
as D+; can
only be
disaggregated
for threshold
of malignancy
as any
differential
diagnosis
Bowns 2006
MM+MIS
BCC
 
WPC-tests
P-CS
Specialist unit
UK
NR (256)
Patients (with
skin lesions)
who were either
referred to the
2-week wait or
‘target’ clinics,
or those initially
referred to the
normal
outpatient
service but who
were diverted by
the consultant
on the basis of
the referral
form.
 
Clinical and
dermoscopic
images acquired in
secondary care at
a Medical
Photography
Department using
a digital camera
(equipment not
described).
An independent
dermatologist (n=3)
assessed the
images along with
clinical information
Decision recorded:
most likely
diagnosis
level of
confidence in
diagnosis.
malignant vs
benign
recommendation
on whether they
would wish to
see the patient.
Not evaluated Histology plus
Expert diagnosis
Malignant:
MM 19; MiS 5
BCC: 29; cSCC:
16; Other
malignant: 1
*Severely
dysplastic naevi
3; BN 64; *BD/in
situ SCC 9; SK 70;
solar keratosis 12;
*severely
dysplastic solar
keratosis 3; other
benign 25
0.332
 
11 excluded -
Wrong lesion
imaged (n=7),
Histology
already
undertaken
(n=3), Image file
lost (n=3)
*Authors include
these as D+ for
malignancy; data
excluded from
our ‘Any’ skin
cancer analyse
(author
contacted)
Congalton 2015
MM+MIS
 
NC
P-CS
Secondary
and Private
New Zealand
99 (129)
excised
Full sample:
310 pts (613
lesions)
All patients
referred with
skin lesions
suspicious for
melanoma
assessed at a
Virtual Lesion
Clinic for triage,
instead of being
seen face-to-
face at a
hospital clinic.
Only those
excised can be
included
 
Clinical and
dermoscopic
images acquired
in secondary care
using a digital
camera coupled
with dermoscope
Experienced
dermatologists
(n=2) reviewed
patient details and
images remotely
using the
MoleMapDiagnose
software,
Decision recorded:
management
decision; i)
specialist
assessment or
excision of the
lesion needed; ii)
re-image in 3-
months’; (iii)
discharge to GP
e.g., for
cryotherapy or
topical therapy;
(iv) self-monitoring
and (v) lesion of
no concern.
Not evaluated
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Histology plus Expert
diagnosis
MM 47; Mel Mets 1*; 40
BCC; 9 cSCC (incl in situ*)
Benign 32
0.403
 
One patient
was excluded
from further
analysis
because he
attended the
VLC after the
referred lesion
had been
excised
*one MM Mets
incl as D+;
cannot
disaggregate
in situ SCC;
data excluded
from our ‘Any’
skin cancer
analysis
Coras 2003
MM
 
WPC-tests
P-CS
Secondary and
Private
Germany
NR (46)
Pigmented skin
lesions
undergoing
excision due to
diagnosis of
melanoma or
atypical nevus,
to rule out
melanoma or at
the patient's
request
 
Clinical and
dermoscopic images
acquired at private
clinic using digital
camera coupled with
dermoscope.
A dermatologist (n=1)
evaluated the images
and made a diagnosis
based on the images
and history of the
patient
Decision recorded:
lesion diagnosis
Participating
dermatologists
(n=3) with
experience in
dermatoscopy
established a
clinical diagnosis
based on pattern
analysis after
personal
consultation with
the patient in their
private practice
clinics.
Histology
MM 16
Benign 29
0.356
They
reported that
many images
were of poor
quality (10)
and that only
45 biopsies
were done
50 patients
who did not
have
histology
excluded
Ferrara 2004
MM+MIS
 
NC
CCS
Unspecified
NR; likely Italy
NR (12)
Twelve
melanocytic lesions
with dermoscopic
images (a single
image per case)
and accompanying
histological
material were
retrieved from our
consultation files
 
Dermoscopic images
acquired using a film or
digital camera coupled
with dermoscope; setting
for lesion acquisition
unclear.
Stored images were
viewed on a standard-
resolution colour monitor
by remote consultants in a
single session (n=3).
Dermoscopic images
presented first (dx
recorded by single
observer), followed by
histological image (for
teledermatopathology
diagnosis), the original
histological diagnosis from
the consultation file was
then presented (apparently
along with the original
clinical diagnosis).
“Dermoscopic–pathological
remarks” were made and
finally a consensus
diagnosis was reached by
two consultants (LC and
HPS); the latter was taken
as a second ‘gold
standard’ for the study
Decision recorded:
lesion diagnosis
Not evaluated Histology
MM 4; MiS 3
'Benign' 5 (incl
junctional nevus
1; reed naevus
1; blue naevus 1;
actinic lentigo 1;
SN 1)
0.583
not reported Grimaldi
2009
MM
 
Case series
WPC-tests
P-CS
Primary and
Secondary
Italy
197 (235)
Cutaneous
pigmented lesions
with digital images
forwarded by
primary care
physicians to a
referral centre for
confirmation of
diagnosis.
 
Clinical and
dermoscopic
images acquired
in primary care
using a digital
camera coupled
with
dermoscope. All
photographed
lesions uploaded
from the
peripheral units
to the central
research unit for
telediagnosis.
Images
appraised at the
reference unit by
dermatologist
and plastic
surgeons
N=NR)
Decision
recorded:
‘needing
control’ (i.e.
periodic
observation
programme)
vs ‘needing
surgery’ (e.g.
radical
removal,
sentinel
lymph node
biopsy,
reconstructive
surgery, other
therapies)
#164f The use of teledermatology for the diagnosis of skin cancer in adults
157 / 167
 
Each GP (n=13) was asked
to formulate a written first
judgment of every lesion
before digital acquisition
using visual inspection
alone and then following
dermoscopy. The
evaluation method followed
the ABCD rule of
dermoscopy according to
Nachbar et al"
Decision recorded:
benign vs suspicious for
malignancy
Histology plus
follow up (FU)
(208
diagnosed as
benign after 6
months FU)
MM 5
Benign 230
0.021
not reported Jolliffe 2001a
ANY
BCC
 
WPC-tests
P-CS
Specialist unit
UK
138 (144)
 
Patients referred by
their GP for
dermatological
assessment of a
pigmented lesion at the
Pigmented Lesion
Clinic
 
Images acquired at
PLC using a single
chip video camera.
The image was
archived using
proprietary software
and images were
transmitted through
a Fast Screen
Machine2 video
overlay card and
viewed alongside
clinical information
on a 15 inch
monitor (observer
qualifications and
expertise NR).
Decision recorded:
Clinical diagnosis
Dermatologist
at the PLC
(n=1) made a
clinical
diagnosis (+/-
the use of
dermoscopy)
based upon
information in
the referral
letter and
examination
findings
Histology
MM 2; LM: 2;
BCC: 9
Atypical: 5;
BN: 89; SK
9; Solar
lentigo: 7;
Blue naevus:
4; SN: 2;
Other 15
0.090
In four cases
(2.7%) it was
impossible to
make a diagnosis
from the image,
due to poor
image quality.
Kroemer 2011
MM+MIS
BCC
cSCC
ANY
 
WPC-tests
P-CS
Secondary
Austria
88 (113)
Patients self-referred or
referred to general
outpatient clinic at the
Department of
Dermatology, Medical
University of Graz, Graz,
Austria by a local doctor
for evaluation of a skin
tumour.
 
Clinical and
dermoscopic
images (up to 3
each per patient)
acquired by
dermatologist in
secondary care
using a mobile
phone camera
(Nokia N73 with
Dermlite II Pro).
Images reviewed
by board-certified
dermatologist
(n=1) with clinical
expertise in
teledermatology
and dermoscopy;
images reviewed
blinded to each
other
Decision recorded:
Lesion
diagnosis
(benign
melanocytic,
benign
nonmelanocytic,
malignant
melanocytic and
malignant non-
melanocytic
skin tumours).
recorded one
primary and one
differential
diagnosis
Face to face
clinical diagnosis
at general
dermatology
outpatient clinic
by a single
dermatologist.
Not clearly
reported; most
likely visual
inspection of the
skin (+/- use of
dermoscopy). No
algorithm
described
Histology
MM 1; MiS 1; BCC 30;
cSCC:10, LM 3; Mel mets
1
SK 6, AK 17, BD 1, BN 15,
Other: 19
0.058
 
N=9 lesions
(8 patients); 3
patients
declined
participation.
Of 322
clinical and
278
dermoscopic
images, 2
clinical and
18
dermoscopic
images
Massone 2014
ANY
 
NC
P-CS
Private care
Austria
112 (121)
Full sample:
690 (962)
Patients
undergoing a 2
day ‘health
screening
holiday’ as part
of a preventative
medical
screening
programme;
images acquired
by GPs for any
suspicious skin
lesions. Only
those
recommended
for excision or
FtF assessment
by
teledermatology
were included
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Clinical and dermoscopic
images acquired in primary
care using a digital camera
coupled with a dermoscope.
Images were reviewed
blinded to other information
by dermatologist (n=2)
within 48hrs (“No personal
patients’ data were
transmitted; patients were
identified only by a
progressive number”.
Decision recorded:
correct diagnosis of
malignancy
TD decisions for full
sample included
Image quality
Lesion group: benign
melanocytic or
nonmelanocytic;
malignant melanocytic or
non-melanocytic
diagnosis
management decision -
(i) no further treatment or
follow-up in 3, 6 or 12
months interval (ii)
referral to a local
dermatologist for FTF
examination (iii) excision
in case of suspected
malignancy.
Not evaluated
Histology plus
Expert clinical
diagnosis
Malignant:
MM 2; BCC: 5
Dysplastic 11,
SK 4, *AK 1,
Other: 3
0.25
 
82/121 pts
were lost to FU
) i.e no histo
diagnosis,
including 4
considered to
have
melanoma and
8 with BCC
*authors
consider AK as
D+; can be
disaggregated
and
considered D-
Moreno Ramirez
2005
MM+MIS
BCC
ANY
 
NC
R-CS
Specialist unit
Spain
57 patients
included in the
final analysis
(NR)
Patients with
pigmented,
circumscribed lesions
fulfilling at least one of
the
following criteria: a
changing lesion
(‘ABCD changes’),
recent lesion (less than
three-year history),
multiple lesions (more
than 20 melanocytic
naevi counted by the
GP), symptomatic
lesion (pain, itching,
bleeding), or patient
concern about moles.
 
photographic
images acquired in
primary care using
a digital camera.
Images evaluated
at PLC by a
dermatologist
alongside clinical
information
Decision recorded:
Lesion diagnosis
(incl MM, BCC,
BN, multiple
melanocytic
naevi (>20 naevi
as seen on
teleconsultation),
atypical naevus,
lentigo maligna
etc etc)
Suggested
management
(‘referral’ or
‘non-referral’* to
the face-to-face
clinic)
Not evaluated Histology
plus follow-
up (FU
period not
reported)
Malignant:
MiS 1, BCC
23, LM 3
Dysplastic
16; BN 8;
Blue nevi 4
0.105
 
Difficult to
diagnosis cases
excluded
(number not
reported)
* obviously
benign were not
referred; all other
categories were
routinely referred
to the PLC for
face to face
assessment.
Piccolo 2000
MM
 
WPC-tests
P-CS
Unspecified
Austria (Graz)
40 (43)
Patients with pigmented
skin lesions selected
because of their diagnostic
difficulty and subsequently
excised for a
histopathological
evaluation.
 
Clinical and
dermoscopic
images acquired in
secondary care
using a
dermoscopic
digital camera.
Images stored on
a prototype
teledermatology
workstation and
distributed to
remote centres via
email together with
basic patient data
(initials, age, sex
and site of the
lesion). Observers
included
dermatologists (6),
residents in
dermatology (2),
internist (1), GP(1),
oncologist(1)
Decision recorded:
Not reported
All lesions were
examined with a
dermatoscope
by an expert
dermatologist
(n=1) during the
face to face
clinical diagnosis
(most likely in a
secondary care
setting). No
specific
algorithm used.
Histology
MM 11
SK 3, BN 25;
Angiokeratoma 1,
lentigines 3
0.259
Poor quality
index test
image (all
images
scoring 4
were
excluded
from the
study)
Piccolo 2004
MM+MIS
 
NC
R-CS
Unspecified
Images selected
from University of
Graz Austria and
University of
L'Aquila Italy
73 (77)
Patients with
melanocytic
acral lesions
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Dermoscopic images
acquired in secondary care
using a dermoscopic digital
camera. Images analysed
along with information on
age, sex and lesion site on
a PC monitor by each
dermatologist (n=11; 5
rated highly
experienced in
dermoscopy, 2 medium
experience and 4 low level
of experience.)
Decision recorded:
acral melanoma vs
atypical lesions
(considered atypical
when at least 6 of the 11
observers made this
diagnosis.)
categorized according to
the ‘Saida’ classification.
management
recommendation (digital
dermoscopy follow-up or
surgical excision)
  Histology
Malignant:
MM (Acral) 6
Acral
melanocytic
naevi 71
0.078
None reported Silveira 2014
ANY
 
Non-comparative
P-CS
Community
Brazil
NR (416)
The present study
included individuals
with skin lesions
that were
determined to be
suspicious after a
direct visual
inspection by a
physician at a
Community Mobile
Prevention Unit
(MPU) (providing
screening the local
people for prostate,
cervical and skin
cancers.
 
photographic
images
acquired in a
community
setting using
a digital
camera.
Images were
coded, stored
and submitted
at random to
two
oncologists at
Barretos
Cancer
Hospital
(BCH),
blinded to the
MPU
physician’s
diagnosis and
pathology
report but with
age, skin type
and lesion
site provided
Decision
recorded:
Management
decision - 1) a
malignant
lesion,
oncological
treatment is
indicated; 2) a
benign lesion,
no treatment
required; 3)
unknown; or
4) a low-
quality image
  Histology plus
Expert (52 were
diagnosed by
expert opinion)
Malignant:
MM 5; BCC: 286,
cSCC: 59,
Malignant
other:14
Benign diagnosis:
52
0.875
21 were
excluded from
the study
because of poor
quality photos,
23 were
excluded
because of
incomplete data
preventing the
identification of
the patient,
 
Warshaw 2010
MM+MiS
Full methods
reported in
Warshaw 2009 and
Warshaw 2009a
which reported
data for primary
lesions only)
 
WPC
P-CS
Secondary
US
NR / 1514
(2152 pts w 3021 lesions
enrolled in full trial; 1685
lesions were biopsied)
Patients with
pigmented and
non-pigmented
lesions enrolled at
the Dept of
Veteran Affairs
dermatology clinic
who required (or
requested)
removal of one or
more skin
neoplasms ('high-
risk group') and
participants who
were referred to
general
dermatology clinic
by non-
dermatology
healthcare
providers for
evaluation of a
skin neoplasm
(lower risk group).
Biopsied lesions
only were
included; and for
the 2010 paper,
only lesion
categories with >=
25 lesions
 
Macro images*
and polarised
light dermoscopy
(PLD) images
were obtained
for each lesion
by research staff
on attendance at
Dermatology
clinic. Contact
immersion
dermatoscopy
images also
obtained for a
sample of
pigmented
lesions.
1 of 3 board-
certified
dermatologists
with clinical
expertise in
dermatoscopy
were randomly
assigned to
review a macro
package alone
or with a PLD
image along with
standardised
patient and
lesion history.
Images of all
lesions for a
single participant
visit (i.e. >=1
lesion per
patient) were
evaluated by the
teledermatologist
in a single
session
Recorded:
one primary
diagnosis
(2x2 extracted
for MM/MiS),
<=2
differential
diagnoses
management
plan
 
Clinical assessment by 1
of 11 staff dermatologists;
history obtained history in
the usual manner and
clinical examination could
include all options
normally available in the
clinical
setting (eg, palpation,
diascopy, dermatoscopy)
Recorded:
one primary diagnosis
from a choice of 17
common diagnoses
(2x2 extracted for
MM/MiS),
<=2 differential
diagnoses
management plan
(remove/biopsy/destroy,
observe/reassure,
antifungal Rx, antibiotic
Rx, anti-inflammatory
Rx)
Histology
(board-
certified
dermato-
pathologist)
MM 41, BCC:
410,
cSCC: 240
Benign
keratoses
223; DN 154;
AK 145; BN
138; cysts 73;
benign
appendageal
tumours 35;
lentigines 29;
benign
vascular
neoplasms
26
0.042
 
171 lesions in
histopathologic
categories with
<25 lesions
*Paper presents
accuracy data
for each image
type; underlying
data to allow
construction of
2x2 tables
obtained from
author only for
Macro images
for primary
diagnosis of
MM/MiS.
 
Wolf 2013
MM+MIS
 
WPC
CCS
Secondary
US
NR (159)
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Patients with pigmented
lesions that were
considered atypical in
clinical appearance by at
least one dermatologist and
for which a clear histologic
diagnosis had been
rendered by a board-
certified
dermatopathologist(invasive
melanoma, melanoma in
situ, lentigo, benign nevus
dermatofibroma, seborrheic
keratosis, and
hemangioma). Excluded
equivocal diagnoses and
specific lesion types.
 
photographic
images
acquired in
routine
secondary
care prior to
skin lesion
removal). Four
applications
for
smartphone
devices were
evaluated
including one
store and
forward
application
(app 4) which
can be run on
a smartphone
or from a
website.
Images sent to
a board-
certified
dermatologist
(n=NR) for
evaluation
within 24
hours.
Decision
recorded:
“atypical”
(test
positive) or
“typical”
(test
negative)
Other
options
included
“send
another
photograph”
or “unable
to
categorize”
   
Histology
Melanoma 44
Mel in-situ 16
Benign diagnosis
34
SK 20
lentigo 8
Hemangiona 2
Dermatofibroma 4
0.34
 
29 not
evaluable
excluded from
analysis
“send another
photograph” or
“unable to
categorize,”
considered
these images to
be unevaluable
in our analysis.
(390 images for
possible
inclusion in this
study. We
excluded 202
as being of
poor image
quality,
containing
identifiable
patient
information or
features, or
lacking
sufficient
clinical or
histological
information.
)
Studies of referral accuracy (TD vs FtF diagnosis) Jolliffe 2001b
refer/no referral
 
NC
P-CS
Secondary
UK
611 (819)
All patients
referred to the
dermatology
departments of
the Royal Free
Hospital or the
Whittington
Hospital during
the study period
by their GPs for
assessment of a
pigmented lesion
were seen in
clinic
photographic images
acquired in secondary
care using a single chip
video camera
Images were viewed
alongside GP referral
information independently
by 2 dermatologists and a
registrar several months
following the FTF
encounter.
Decision recorded:
· Refer or not (Action); "On
the basis of the image and
the referral information
each doctor made a
decision as to whether the
particular lesion warranted
a referral or not"
Not evaluated
as an index
test
Expert opinion
(in clinic
diagnosis by the
registrar and
one of either of
the two
consultants)
Clinical
diagnoses:
MM 9; BCC 19;
LM 1
SK 152; BN 361;
atypical 112;
congenital 27;
DF 25; Solar
lentigo 23; KA 1;
angioma 18; AK
13; SN 1; Blue
2; Other 56
Clinical dx: 3.6%
Action needed:
17.5%
23 poor quality
images (lesion
referred on the
basis of poor
picture quality
rather than known
clinical need)
Mahendran
2005
action/no action
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WPC-tests
P-CS
Primary and secondary
UK
163 (163)
GPs recruited
consecutive
unselected
patients with
suspicious
skin lesions
whom they
refer to the
dermatology
department in
their normal
practice
 
photographic
images
acquired in
primary care
by the GP
using a digital
camera (Nikon
Coolpix 950
digital camera
(1200 x 1600
pixel
resolution).
Images
reviewed by
one of two
consultant
dermatologists
along with
clinical
information.
Decision
recorded:
1. diagnosis or
differential
diagnosis (2x2
cannot be
extracted)
2. hypothetical
management
plan
(reassurance;
minor
operation, no
action but
further review
appointment
required); 2x2
extracted for 2
thresholds
book for
minor
operation
(immediate
Action) vs
not
book for
minor
operation or
book further
review
appointment
(immediate
Action or
FU) vs
Not evaluated as
an index test
Expert clinical
diagnosis
(unclear but
appears to be
by the same TD
consultants
within 2 weeks)
Consultant
diagnoses (not
histo
confirmed)
MM 4, BCC:
37, cSCC 4; AK
10, BD 7, SC 4;
LM 1; Atypical
6; SK 27; BN
20; DF 11;
Other: 36
Malignant:
27.6%
Action required
(FTF): 65.1%
57 (35%) excluded as
no TD decision could
be made; 24 (15%)
poor quality images; 33
(20%) needed to be
seen FTF.
 
Manahan 2015
Action (see face-to-
face or not)
 
NC
P-CS
Community
Australia
49 / 340
 
Participants
aged 50–64
years at high
risk of
melanoma
(fair skin
type,
previous skin
excisions,
personal or
family
history)
recruited via
the 'QSkin'
study or
volunteers
who
completed
questionnaire
and who had
a suitable
smartphone.
Participants
instructed to
submit
"photos of
moles or
spots that
they ‘did not
like the look
of’", and
were given
instructions
about how to
select lesions
based on
asymmetry
and colour.
 
Study participants
used
Handyscope
FotoFinder
dermoscope
smartphone
attachment
(FotoFinder
Systems
GmbH, Bad
Birnbach,
Germany) and
Handyscope app,
to obtain and
send magnified
lesion image
along with a
second clinical
(macro) image to
verify the
anatomical site of
each skin lesion.
Teledermatologist
(n=1) recorded:
a primary
diagnosis, with
up to two
differential
diagnoses
(cannot extract
2x2), and
whether
clinical skin
examination
(FtF) was
required
(Action).
Not evaluated
as an index test
Clinical skin
examination by a
dermatology
registrar under
supervision of the
dermatologist who
undertook the
telediagnosis. The
same management
options were
recommended in
the FtF
consultation
FtF diagnoses (not
histo confirmed):
BCC 13; SCC/IEC
1
Atypical naevus 4;
BN 165; SL 22; SK
81. Non-
pigmented: AK 34;
DF 2; other 18
 
8 /58 participants did not
attend for FtF examination;
1/58 outwith age
restriction; 32/341 lesions
did not appear to have a
primary teledermatology
diagnosis
 
Oliveira 2002
Diagnosis
(Malignant vs not)
 
NC
P?-CS
Primary
Brazil
90 / 90/
Participants with suspect
dermatological conditions
identified by an assistant
nurse who had undergone
training to identify
potentially malignant skin
lesions. Only those who
attended for face-to-face
assessment were
included.
 
Lesions
photographed
by the nurse
using a
Kodak
DC265 Zoom
digital
camera.
2 hr training
in the use of
the camera
was provided
and included
instruction
on the
installation of
the camera’s
software and
transferring
the images to
the PC.
Images were
sent by nurse
with an
electronic
case report
form and
included her
diagnostic
impression
whether the
lesion was
non-
malignant or
malignant
All cases
were
assessed the
cases
remotely by a
dermatologist
prior to the in-
person
evaluation
and assessed
as malignant
or benign.
Not evaluated
as an index test
 
Within a week the
same
dermatologist saw
the patient in-
person. Patients
were referred for
biopsy when skin
cancer was the
suspected
diagnosis. The in
person
assessments by
the dermatologist
(and the biopsy
results in a few
cases)
were used as
reference.
Malignant: 8
Benign: 84
9 were referred for
biopsy of whom 5
attended, incl 1
SCC and 3 BCC
2 lesions without
a tele-dx
#164f The use of teledermatology for the diagnosis of skin cancer in adults
162 / 167
 
Phillips 1998
Dx SC
Malignant/probably
malignant
Excise
 
NC
P-CS
Community
US
51 / 107
 
Participants
attending four
skin cancer
screenings at
community
hospitals in
rural eastern
North Carolina.
Patients were
given a choice
of having a
total body
examination,
only the sun-
exposed skin,
or a specific
lesion(s)
evaluated by
the on-site
physician.
 
Live link
teledermatology
using: a full-body
camera, a lens for
viewing the lesions
close up, and a
magnifying lens
that allowed even
closer views as
well as
examination with
polarized light. It is
not clear who
operated the
cameras during the
teleconsultations. If
a complete patient
skin examination
was performed in-
person,
representative
lesions were
selected by the on-
site physician for
evaluation by the
remote physician.
Decision recorded:
Most likely
diagnosis for a
given lesion;
the degree of
concern that a
specific lesion
was malignant;
and
recommendation
as to whether to
do a biopsy of
the lesion.
Not evaluated
as an index test
 
All patients were first
evaluated by the on-
site physician who
recorded specific
lesions on an image of
the human body and
diagnosis/management
decisions as per
remote observer.
Target condition (FtF
diagnoses)
Malignant: BCC 2;
SCC 3; lentigo maligna
1
Benign: SK 27; BN 32;
AK 14; lentigo 10;
Other 30
None reported Shapiro 2004
Biopsy
 
NC
P-CS
Secondary
US
49 (NR)
Only those
patients with skin
growths that
posed a true
diagnostic
challenge
selected by PCP
(board certified in
internal medicine
since 1984)
 
photographic
images acquired
in primary care
by network
community
primary care
physician (PCP)
using a digital
camera.
Reviewed by a
board certified
academic
dermatologist
for
teledermatologic
consultation
alongside
clinical
information.
Decision
recorded:
· diagnosis or
differential
diagnosis
(cannot extract
2x2)
· indication for
sampling biopsy
(Action: Excise
or not)
· reason for
biopsy
(management
plan included 15
options
including 3
biopsy plans
(rule out
malignancy,
establish a
diagnosis, or
cosmetic
purposes)
Not evaluated as
an index test
Expert (local dermatologist
in private practice)
23 underwent biopsy:
5 BCC, 4 cSCC
17 benign
Assumed benign (no
biopsy): 23 (incl. one
patient who refused
biopsy)
Malignancy: 18%
Action recommended: 49%
N=11 (4 failed to
present for FTF
assessment, 4 saw
a different FTF
derm-atologist, 1
died, and 2
underwent
evaluation of
different lesions by
the SAF
teledermatologist
and FTF derm-
atologist)
ABCD(E) - asymmetry, border, colour, differential structures (enlargement); AK - actinic keratosis; AMN –
atypical melanocytic naevi; BCC - basal cell carcinoma; BD – Bowen’s disease; BN – benign naevi; BPC –
between person comparison (of tests); CAD – computer assisted diagnosis; CCS – case control study; CD –
compact disc; CM – cutaneous melanoma; CMM - cutaneous malignant melanoma; CS – case series; CSCC –
cutaneous squamous cell carcinoma; Derm – dermoscopy; DF – dermatofibroma; Dx – diagnosis; ELM –
epiluminescence microscopy; FPs - false positives; FtF - face-to-face; FU – follow-up ; GP – general practitioner;
H&E – haematoxylin and eosin stain; LPLK – lichen planus-like keratosis; LS – lentigo simplex; MM – malignant
melanoma; MiS – melanoma in situ (or lentigo maligna); MN – melanocytic naevi; MPU - Mobile Prevention Unit;
N/A – not applicable; NC – non comparative; NMLs – non melanocytic lesions; NR – not reported; P –
prospective; PCPs – primary care providers; PLC – pigmented lesion clinic; PSL – pigmented skin lesion; R
–retrospective; RCM – reflectance confocal microscopy; RCT – randomised controlled trial; SCC - squamous cell
carcinoma; SD – standard deviation; SDDI - short-term sequential digital dermoscopy imaging; SK – seborrhoeic
keratosis; SN – Spitz nevi; SSM – superficial spreading melanoma; SVS – support vector system; VI – visual
inspection; WPC – within person comparison (of tests)
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